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Arterial Stiffness and Endothelial Function in Obstructive Sleep 
Apnoea: The Effect of Continuous Positive Airway Pressure (CPAP) 
Therapy 
Introduction: Obstructive sleep apnoea (OSA) is common and is caused by 
repetitive obstruction of the upper airway during sleep. OSA is associated with 
increased cardiovascular morbidity and mortality and is an independent risk factor 
for hypertension. The immediate physiological effects of OSA include intermittent 
hypoxia, repeated arousal from sleep and intra-thoracic pressure swings. The 
resulting activation of the sympathetic nervous system, systemic inflammation and 
oxidative stress may result in increased arterial stiffness and endothelial dysfunction, 
potentially explaining any causal link between OSA and cardiovascular disease 
(CVD). Continuous positive airway pressure (CPAP) therapy improves excessive 
daytime sleepiness (EDS) and in non-randomised studies, reduces cardiovascular 
mortality. Prior to starting this study, there was a limited amount of evidence 
suggesting that CPAP therapy improved arterial stiffness and endothelial function, 
but the effects in subjects without pre-existing CVD were unclear. 
 
Aims: i) to determine whether CPAP therapy has an effect upon measures of arterial 
stiffness and endothelial function in patients with OSA, in the absence of known 
CVD. ii) To compare arterial stiffness and endothelial function in a subset of patients 
with OSAHS (defined as OSA and EDS), with a group of well-matched control 
subjects. 
 
Methods: Fifty three patients with OSA, defined as an apnoea/hypopnoea index of 
≥15, and without known CVD, entered a double-blind placebo-controlled crossover 
trial of 12 weeks CPAP therapy, of whom forty three completed the study protocol. 
Sham CPAP was used in the placebo arm of the study and vascular assessments were 
made at baseline and after each arm of the study. Arterial stiffness was determined 
by measuring aortic distensibility using cardiovascular magnetic resonance imaging 
and by measuring the augmentation index (AIx) and aortic pulse wave velocity 
(PWV) by applanation tonometry. Endothelial function was assessed non-invasively 
by measuring vascular reactivity after administration of salbutamol and glyceryl 
trinitrate. In a subset of twenty patients with OSAHS, arterial stiffness and 
endothelial function at baseline were compared to readings obtained from healthy 
control subjects, matched on a one-to-one basis for age, sex and BMI. 
 
Results: Patients with OSAHS (n=20) had increased arterial stiffness [AIx 
19.3(10.9) vs. 12.6(10.2) %; p=0.017] and impaired endothelial function, measured 
as the change in AIx following salbutamol [-4.3(3.2) vs. -8.0(4.9) %; p=0.02] 
compared to controls. Twelve weeks of CPAP therapy had no significant effect upon 
any measure of arterial stiffness or endothelial function in patients with OSA (n=43). 
A trend towards a reduction in AIx following CPAP therapy was seen, but this was 
non-significant. There was a reduction in systolic blood pressure following CPAP 
therapy [126(12) vs. 129(14) mmHg]. Sub group analysis showed CPAP to have no 
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effect on arterial stiffness or endothelial function in patients with EDS or in patients 
using CPAP for ≥4 hours per night. 
 
Conclusions: This study demonstrates that even in the absence of known CVD, 
patients with OSAHS have evidence of increased arterial stiffness and impaired 
endothelial function. However, in patients with OSA, free from CVD, CPAP therapy 
did not lead to an improvement in any measure of arterial stiffness or endothelial 






Obstructive sleep apnoea (OSA) is a common condition in which the upper airway 
intermittently becomes obstructed during sleep. This leads to disturbed sleep, 
snoring, breathing pauses and can cause patients with OSA to be excessively sleepy 
during the daytime. Studies have shown that OSA is associated with high blood 
pressure and cardiovascular disease. The breathing pauses seen in OSA can lead to a 
reduction in blood oxygen levels, frequent awakenings from sleep and changes in 
pressure within the chest. These immediate consequences of OSA in turn are thought 
to lead to other changes within the body which may result in stiffening of the blood 
vessels (arterial stiffening) and an impairment of the way that blood vessels work, 
called endothelial dysfunction. Arterial stiffening and endothelial dysfunction may 
explain why OSA is associated with cardiovascular disease. 
Continuous positive airway pressure (CPAP) therapy is the treatment for OSA and 
this involves the delivery of a high pressure of air via a tight fitting face mask. This 
keeps the upper airway open during sleep. This treatment is highly effective in 
treating the symptoms of OSA, namely snoring, breathing pauses and excessive 
daytime sleepiness. Some studies have also suggested that CPAP therapy reduces the 
risk of cardiovascular disease in patients with OSA, but this is less certain and more 
high quality evidence is needed. Before this study started there were some small 
studies showing that CPAP therapy improved arterial stiffness and endothelial 
dysfunction. Many patients in these previous studies however already had evidence 
of cardiovascular disease. 
 
Aims 
The aim of this study was to look at whether CPAP therapy could improve arterial 
stiffness and endothelial dysfunction in patients who had OSA but who did not have 
a history of cardiovascular disease. In addition, arterial stiffness and endothelial 
function were examined in 20 patients with the most symptomatic OSA (i.e. patients 
with OSA who also had evidence of excessive daytime sleepiness) and compared to a 
control group of well-matched volunteers who did not have OSA. 
 
Methods 
Measurements of arterial stiffness and endothelial function were taken from 53 
patients with OSA at the start of the study. Patients were then randomly allocated to 
receive either standard CPAP therapy or a placebo CPAP in which the pressure of air 
applied through the mask was lower than would be needed to hold the upper airway 
open. After 12 weeks the measurements were repeated and patients switched over to 
receive the other form of CPAP for a further 12 weeks, after which the measurements 
were again repeated. Neither the patients, nor the researcher performing the 
measurements knew the order in which the patients received each treatment. 
Measurements were also performed once in a group of 20 healthy volunteers without 






Patients with OSA and excessive daytime sleepiness had increased arterial stiffness 
and impaired endothelial function compared to the 20 volunteers without OSA. 
Despite this, 12 weeks of CPAP therapy did not lead to an improvement in either 
arterial stiffness or endothelial function in the 43 patients with OSA who completed 
the study. In keeping with previous studies, a small reduction in blood pressure 
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Chapter 1: General Introduction 
 
1.1 Introduction 
Obstructive sleep apnoea (OSA) is caused by repetitive partial or complete 
obstruction of the upper airway during sleep. When it leads to excessive daytime 
sleepiness (EDS) then it is termed obstructive sleep apnoea/hypopnoea syndrome 
(OSAHS). OSAHS is common, affecting 2-4% of the middle aged population 
(Young 1993), with at least 20% of the population having frequent apnoeas and 
hypopnoeas in the absence of EDS (Young 2002a). Given the association with 
obesity in more than 40% of cases (Young 2005), then the prevalence of OSA is 
likely to increase. 
The repetitive airway obstruction seen in OSA leads to sleep fragmentation and 
subsequently may cause EDS, the consequences of which are well documented and 
include cognitive dysfunction (Engleman 2004) along with a significant increase in 
road traffic accidents (George 2004). However, it is becoming increasingly apparent 
that patients with OSA are also at increased risk of a variety of cardiovascular 
diseases including ischaemic heart disease (IHD) (Kiely 2000, Peker 2006), 
cerebrovascular disease (Shahar 2001, Yaggi 2005) and the metabolic syndrome 
(Coughlin 2004). To date, OSA has been shown to be an independent risk factor for 
hypertension (Stradling 2001, McNicholas 2007). 
OSA can be successfully treated, most commonly with continuous positive airway 
pressure (CPAP) therapy which acts as a pneumatic splint holding the airway open 
during sleep. Observational studies suggest that the increased risk of cardiovascular 
disease (CVD) is reduced in patients treated with CPAP therapy (Marti 2002, Marin 
2005) and numerous studies have shown a small but significant reduction in blood 
pressure in CPAP-treated patients (Bazzano 2007). 
The mechanisms for the association of OSA and CVD are incompletely understood, 
but are likely to be multifactorial (McNicholas 2007). Evidence suggests that arterial 
stiffness and endothelial dysfunction may play a role in this and prior to starting this 
study there was limited evidence to suggest that CPAP therapy improved arterial 
stiffness and endothelial function. Those studies that did exist were however largely 
small and with one exception, non-randomised. In particular, the effect of CPAP on 
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arterial stiffness and endothelial function in OSA patients, without concomitant CVD 
or hypertension was unknown.  
The data contained within this thesis were obtained from conducting a double-blind 
randomised placebo-controlled crossover trial of the effect of CPAP on arterial 
stiffness and endothelial function in patients with OSA. Additionally, a case-control 
study was undertaken examining vascular function in a subset of patients with 
OSAHS compared to well-matched controls. 
Chapter 1 provides a comprehensive overview of OSA and its treatment. Chapter 2 
outlines the existing evidence for, and potential mechanisms underlying the link 
between OSA and CVD in general, with particular focus on arterial stiffness and 
endothelial function. The methods employed in this study are described in Chapter 3. 
The results of the randomised controlled trial, case-control study and a comparison of 
the different methods of measuring arterial stiffness are presented in Chapters 4, 5 
and 6. The discussion of the results of this study and conclusions are found in 
Chapter 7. 
 
1.2 Historical perspectives on obstructive sleep apnoea (OSA) 
OSA as we now know it to be, was first described from a pathophysiological point of 
view in the 1960s. However, there are case reports of the clinical syndrome dating 
back to the 19th Century (Lavie 1984a). Charles Dickens is often credited with the 
first description of a person with OSA in the character of Joe; an obese excessively 
sleepy boy in ‘The Posthumous Papers of the Pickwick Club’ in 1837. In 1918 Dr 
William Osler used the word ‘Pickwickian’ to describe overweight patients with 
obesity and hypersomnolence. This was expanded upon by Burwell in 1956, who 
described the association of obesity and alveolar hypoventilation leading to 
hypersomnolence and polycythaemia (Burwell 1956). However this condition was 
probably what we would now more correctly term obesity hypoventilation, with 
alveolar hypoventilation occurring during wakefulness and sleep, rather than upper 
airway collapse during sleep alone, leading to OSA (although, of course, the two can 
co-exist). It was not until 1965 that the link between nocturnal events and daytime 
symptoms were recognised initially by Gastaut (Gastaut 1965) and subsequently by 
Jung and Kuhlo (Jung 1965) who performed polysomnographic studies on so-called 
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‘Pickwickian’ patients. It was later appreciated that non-obese patients could also 
suffer nocturnal apnoeas and EDS and the term obstructive sleep apnoea syndrome 
was used in 1976 to describe this (Guilleminault 1976). Following the appreciation 
that hypopnoeas were also important (Gould 1988), the syndrome became known as 
the obstructive sleep apnoea/hypopnoea syndrome (OSAHS). 
 
1.3 Definition of obstructive sleep apnoea (OSA) 
OSA refers to the physical condition whereby there is repetitive obstruction of the 
upper airway during sleep which may or may not result in EDS. If EDS is present, 
the condition is known as the obstructive sleep apnoea/hypopnoea syndrome 
(OSAHS). 
Most people, if their sleep is studied, will have evidence of some respiratory events 
during sleep and the degree of respiratory disturbance is quantified using the 
apnoea/hypopnoea index (AHI). The AHI varies with age and gender (Riha 2009), 
and the level at which this is deemed to require treatment varies throughout the 
world. In a survey of European centres, an AHI of ≥15 was commonly used as the 
cut off for offering treatment with CPAP, with some centres using a lower cut off if 
there were associated co-morbidities or significant EDS and some using a higher cut 
off (Fietze 2011). The degree of respiratory disturbance is quantified using the 
apnoea/hypopnoea index (AHI). An apnoea is generally defined as a reduction in 
airflow of  ≥90% from baseline for at least 10 seconds. The definition of a 
hypopnoea is less uniformly applied, but the then current 2007 American Academy 
of Sleep Medicine (AASM) manual defined it as a reduction in airflow of ≥30% for 
at least 10 seconds with an oxygen desaturation of ≥4% from baseline or a ≥50% 
reduction in airflow for at least 10 seconds with a ≥3% oxygen desaturation or 
associated arousal (Iber 2007). In the 2012 update of the AASM guidelines, the 
criteria for scoring a hypopnoea has been relaxed and is now defined as a reduction 
in airflow of ≥30% for at least 10 seconds associated with either a 3% desaturation or 
an arousal (Berry 2012). It is recognised that the degree of oxygen desaturation for 
any given reduction in airflow may vary from person to person, with greater 
desaturation seen in obese patients (Peppard 2009) or in those with underlying lung 
disease (Bradley 1985). Therefore, in lean patients without underlying lung disease, 
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the requirement for an oxygen desaturation may result in many arousals not being 
scored or included in the AHI, and the 2012 AASM update reflects this concern 
(Berry 2012). It is likely that the use of the new 2012 definition will result in a 
greater number of hypopnoeas being scored and hence an increase in the calculated 
AHI (BaHammam 2012). 
Based upon the 1999 recommendations of the American Academy of Sleep Medicine 
(Sleep Medicine Task Force 1999), the severity of OSA, based upon the results of 
polysomnography (PSG), is often classified as follows (SIGN 2003): 
 
AHI  Disease severity 
5-15  Mild 
15-30  Moderate 
>30  Severe 
 
The AHI increases with age (Bixler 1998, Young 2002b) and any cut-off point in 
making a diagnosis or grading severity is essentially arbitrary. However an AHI of 
15 or greater is usually deemed in the UK (SIGN 2003) and Europe (Fietze 2011) to 
represent clinically significant disease.  
Evidence of sleep disordered breathing in the absence of EDS is more common than 
the syndrome of OSAHS (Young 2002a) and is variably termed obstructive sleep 
apnoea (OSA), minimally symptomatic OSA or sleep disordered breathing in the 
literature. Confusingly, OSA and sleep disordered breathing can also be used to 
describe all patients with a predefined AHI, irrespective of daytime symptoms. 
For clarity, within this thesis, the term obstructive sleep apnoea (OSA) refers to 
any patient with an AHI of ≥ 15 or greater, with obstructive sleep 
apnoea/hypopnoea syndrome (OSAHS) used to describe the subset of patients 
with an AHI ≥15 and evidence of EDS. 
 
1.4 Normal sleep physiology 
Normal sleep is a reversible physiological process which can be divided into two 
broad categories; rapid eye movement (REM) sleep and non-REM sleep. During this 
study, sleep staging at our centre followed the then standard Rechtschaffen and Kales 
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criteria (Rechtschaffen 1968). According to Rechtschaffen and Kales, non-REM 
sleep can be further subdivided (by electroencephalographic (EEG), electro-
oculographic (EOG) and electromyographic (EMG) appearance during 
polysomnography) into stages I-IV with stages III and IV often referred to as slow 
wave sleep. REM sleep takes its name from the bursts of rapid eye movements that 
occur. These are associated with a general loss of skeletal muscle tone and it is 
during REM sleep that episodic dreaming occurs. Humans generally enter sleep 
through stage I or II and progress through the stages in a cyclical fashion, eventually 
entering REM after approximately 90 minutes of sleep. This process continues 
through the night with periods of REM occurring more frequently and lasting for 
longer as the night progresses. Sleep, recorded at polysomnography, can be 
represented as a hypnogram (shown below in Figure 1.1) with the sum of the 
component parts described as the sleep architecture. 
 




Figure 1.1 An example of a normal hypnogram, based upon the Rechtschaffen and Kales criteria used 
during this study (Rechtschaffen 1968). Hours in bed are represented by the black horizontal line at 
the top of the image. Periods of REM sleep are represented in red above the lower horizontal line and 
below this line are periods of non-REM sleep. Sleep stage I is represented in yellow, stage II in green, 
stage III in light blue and stage IV in dark blue. Any blank regions below the lower horizontal line 
represent periods of wakefulness.  
 
Whilst similar in principle, the 2007 AASM guidelines recommended a change in the 
terminology used in sleep stage scoring (Iber 2007). REM sleep was renamed as 
Stage R and stages I and II renamed as Stages N1 and N2 respectively. Stage N3 now 
represents slow wave sleep and replaces stages III and IV in the Rechtschaffen and 
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Kales classification (Rechtschaffen 1968). In the 2007 classification, wakefulness is 
termed Stage W. 
 
1.5 Pathophysiology of breathing during sleep 
OSA is caused by repetitive obstruction of the upper airway during sleep, leading to 
the cessation or reduction of airflow despite continued respiratory efforts. Cessation 
of airflow due to this is known as an obstructive apnoea, with a reduction in airflow 
termed a hypopnoea.  In contrast, a central apnoea represents a cessation in airflow 
without on-going respiratory effort. Central sleep apnoea (CSA) is associated with a 
diverse range of conditions including cardiac failure (where it is often termed 
Cheyne-Stokes Respiration) (Naughton 2012), cerebrovascular disease (Javaheri 
2010) and less commonly may be idiopathic (Eckert 2007a). It can also be caused by 
high altitude (known as high–altitude periodic breathing) (Eckert 2007a) and by 
drugs, particularly opiates (Malhotra 2010). Whilst CSA may co-exist with OSA, 
they are separate entities and as such CSA will not be discussed further in this thesis. 
The site of the obstruction in OSA is the pharyngeal airway and this area is shown in 















Figure 1.2 Sites of obstruction in the upper airway in OSA  
 
 
Figure 1.2 The shaded area in the figure denotes the sites where obstruction occurs. (Figure 
reproduced with kind permission of Dr RL Riha) 
 
Obstruction may occur at multiple levels within the same airway (Bachar 2008), with 
the retropalatal and retroglossal regions most frequently implicated (Schellenberg 
2000, Schwab 2003). Airway collapse occurs when negative pressure within the 
pharynx during inspiration exceeds the ability of the pharynx to remain patent 
(Remmers 1978).  
Anatomical considerations affecting the upper airway clearly play a role, however 
the airway obstructions only occur during sleep and not when the patient is awake. 
This coupled with the often intermittent nature of respiratory events during sleep 
means that other factors including upper airway dilator muscle activity, lung volume, 




1.5.1 Anatomical considerations in obstructive sleep apnoea (OSA) 
The size of the upper airway during wakefulness is smaller in patients with OSA 
(Eckert 2009) and many factors are known to affect this. Bony craniofacial 
abnormalities such as micrognathia, retrognathia or abnormalities of the mandible 
can all lead to a reduction in upper airway size. Airway length is also important, with 
longer airways more susceptible to collapse (Owens 2008) and airway length 
correlating with OSA severity (Segal 2008). The risk of developing OSA increases 
with the size of surrounding soft tissue structures, principally the lateral pharyngeal 
walls, tongue, uvula and tonsils (Schellenberg 2000, Schwab2003). Tonsillar and 
adenoidal hypertrophy is a leading cause of OSA in children (Marcus 2012). Airway 
trauma and subsequent inflammation due to snoring or recurrent obstructions may 
lead to further expansion of soft tissues (Paulson 2002). Increased inflammatory cell 
infiltrate has been reported in both the mucosa and musculature of the upper airway 
in patients with OSA compared to control subjects (Boyd 2004).  
Fixed anatomical problems with the airway are common contributory factors in the 
non-obese patient with OSA (Nelson 1997). However, the commonest anatomical 
factor is probably obesity. Fat deposition in the anterior neck and surrounding soft 
tissues can compromise the airway and neck circumference has been correlated with 
disease severity (Davies 1990, Davies 1992). Even non-obese patients have been 
shown to have excess adipose tissue in the anterolateral region of the neck 
(Mortimore 1998). 
Early cephalometric studies showed that only a relatively small proportion of the 
variance seen in AHI could be explained by upper airway anatomical variables, 
although this may be more important in younger, non-obese patients (Mayer 1996). 
 
1.5.2 Upper airway dilator muscle activity in obstructive sleep apnoea 
(OSA) 
During wakefulness, the upper airway dilator muscles counteract the effect of 
inspiration on the pharynx, keeping it patent. Dilator muscle activity is state 
dependent with reductions in both genioglossus (the largest of the dilator muscles) 
and tensor palatini activity during sleep in healthy subjects (Lo 2007, Mezzanotte 
1996). As well as being state dependent, genioglossus activity can be modulated by 
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mechanoreceptors within the airway and chemoreceptors to protect against airway 
collapse (Stanchina 2002), with activity increasing following an obstructive breath 
(Jordan 2007). This protective reflex may however be diminished in patients with 
OSA (McGinlay 2008). The mechanisms leading to impaired dilator muscle activity 
during sleep in OSA are not clear, with congenital and acquired defects proposed. 
Evidence of disease progression has led to speculation that mechanical trauma to the 
upper airway due to snoring and repeated obstructive events may directly affect 
either the dilator muscles (Petrof 1996) or their innervation, however the importance 
of this in the pathogenesis of OSA is unclear (Eckert 2007b) and it may purely 
represent an epiphenomenon. 
During the awake state, patients with OSA have higher genioglossus activity than 
control subjects (Mezzanotte 1992), and this may be a compensatory mechanism for 
an anatomically compromised airway (Owens 2008). 
 
1.5.3 Lung volumes in obstructive sleep apnoea (OSA) 
Upper airway size increases with increases in lung volume across the respiratory 
cycle (Eckert 2009) and animal work suggests that this is probably due to caudal 
traction on the upper airway, independent of upper airway dilator muscle activity 
(Van de Graaff 1988). A modest reduction in functional residual capacity (FRC) is 
seen during sleep (Hudgel  1984, Ballard 1990) and by experimentally increasing 
lung volumes in patients with OSA, Heinzer et al showed a reduction in the AHI 
(Heinzer 2006). Similarly, experimental increases and decreases in lung volume led 
respectively to decreases and increases in CPAP pressure requirements (Heinzer 
2005). It is not yet clear what the relative contribution of lung volume is to the 
pathophysiology of OSA, but it is may be more important in patients who already 
have a compromised upper airway due to the factors outlined above.  Lung volumes 
are reduced in obesity (Piper 2010) and this could be a further contributory factor in 
obese patients.  A reduction in lung volume may be a sign of pre-existing lung 





1.5.4 Ventilatory control in obstructive sleep apnoea (OSA) 
During sleep, ventilation is largely controlled by negative feedback control, acting 
upon information from peripheral and central chemoreceptors. Sleep stage itself can 
also affect the depth and rate of respiration (Lydic 1987). The stability (or otherwise) 
of ventilation can be quantified as loop gain, i.e. the degree of ventilatory disturbance 
in relation to the degree of the provoking stimulus, with high loop gain indicating 
greater instability.  
Evidence suggests that patients with OSA have ventilatory instability (Hudgel 1998, 
Younes 2001), with early observational studies demonstrating central apnoeas in 
patients with severe disease who had undergone a tracheostomy (thus removing any 
physical obstruction) (Eckert 2009). During a central apnoea, pharyngeal narrowing 
occurs, predisposing the airway to collapse and a subsequent obstructive event (Badr 
1995). Furthermore a central apnoea may occur as the result of high loop gain 
following an obstructive event, hence predisposing to further obstruction and 
instability. Recent work has shown acetazolamide, a carbonic anhydrase inhibitor, to 
reduce both loop gain and the severity of OSA (Edwards 2012). However, the impact 
of ventilatory instability on disease pathophysiology and severity remains unclear 
and may be a result of the disease rather than a causative factor.  
 
1.5.5 Sleep–state stability and obstructive sleep apnoea (OSA) 
Arousal from sleep is a critical mechanism in preventing asphyxia following an 
obstructive event. However, this inevitably leads to disruption of normal sleep.  
Arousals can also contribute to ventilatory instability with hyperventilation 
commonly seen on awakening (Jordan 2004). However, not all obstructive events are 
terminated by an arousal (Younes 2004) and therefore, other mechanisms must exist 
to reopen the pharynx. In healthy subjects, dilator muscle activity has been shown to 
be responsive to a combination of changes in the partial pressures of carbon dioxide 
and upper airway resistance (Stanchina 2002). This is likely to also occur in patients 
with OSA (Berry 1997) and if the airway is re-opened in this way then arousal may 
be averted. Thus, the threshold at which arousal occurs may be important and this 
has been shown to vary from patient to patient (Younes 2007). This leads to the 
hypothesis that subjects with a lower arousal threshold may suffer more sleep 
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disruption and perpetuation of obstructive events than those in whom arousal occurs 
only if other mechanisms of airway re-opening are unsuccessful. 
 
1.6 Natural history of obstructive sleep apnoea (OSA) 
The natural history of OSA is unclear, with studies producing conflicting results. In a 
study of initially untreated patients, over half showed a subsequent increase in the 
AHI, independently of any weight gain (Pendlebury 1997). More recently, an 
increase in AHI over time was found largely to be due to concomitant weight gain 
(Berger 2009). Others have shown no change in AHI over at least five years, in the 
absence of significant weight gain (Sforza 1994). It is clear that weight gain leads to 
an increase in AHI (Peppard 2000a), and given the weight gain that often occurs with 
advancing years, OSA will inevitably progress in a proportion of patients. 
 
1.7 Epidemiology of obstructive sleep apnoea (OSA) 
 
1.7.1 Prevalence of obstructive sleep apnoea (OSA) 
Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is usually quoted as 
affecting 2-4% of the middle aged population. This is based on information from the 
Wisconsin Sleep Cohort Study, published in the early 1990s. If symptoms of EDS 
are ignored, approximately 5 times as many subjects had polysomnographic evidence 
of at least mild OSA (Young 1993). These figures are confirmed in other studies of 
predominantly Caucasian populations (Stradling 1991, Bearpark 1995, Bixler 2001) 
with prevalence figures varying slightly depending on the definition of OSA used 
and the method of diagnosis. Studies of Asian and Indian populations suggest similar 
prevalence rates (Sutherland 2012). However, there is some evidence to suggest that 
African-Americans are at greater risk of developing OSA (Ruiter 2010). Other racial 
or ethnic differences have been reported but these may relate to greater levels of 
obesity or differing craniofacial morphology seen in those populations (Villaneuva 
2005). 
Recent reviews of accumulating epidemiological evidence suggest that the 
prevalence of OSA and OSAHS are increasing (Garvey 2015, Franklin 2015) and 
given the known association between OSA and obesity (Young 2005), this has been 
12 
linked to increasing levels of obesity in the population. Indeed a recent re-analysis of 
the original Wisconsin Sleep Cohort adjusting for current levels of obesity estimated 
that 34% of males and 17.4 % of females would have an AHI >5 and that 14% of 
males and 5% of females would have an AHI of >5 and evidence of EDS (Peppard 
2013). 
Given the known prevalence it is clear that much of the OSA within the population 
remains undiagnosed. 
 
1.7.2 Risk factors for developing obstructive sleep apnoea (OSA) 
The biggest risk factors for OSA are obesity, male sex and ageing.  More than 40% 
of patients with OSA are obese (Young 2005) and obesity is thought to contribute to 
disease pathophysiology in a number of ways as described above. Additionally, 
obesity is independently associated with EDS (Bixler 2005, Slater 2013) and thus 
may make daytime symptoms associated with OSA appear worse. The BMI is not 
the most sensitive measure of risk in patients with OSA: neck circumference (Davies 
1992) and measures of central obesity may correlate better with disease severity 
(Vgontzas 2000). Epidemiological studies show males are 2-3 times more likely to 
develop OSA than females (Punjabi 2008). This is likely to be due to a number of 
anatomical factors, including their predisposition to develop central (rather than 
peripheral) obesity (Lemieux 1993). Differences exist in upper airway structure and 
function between the sexes with the male upper airway larger, but more prone to 
collapse (Martin 1997, Mohsenin 2003). In females, the menopause is a risk factor 
for OSA, which may be attenuated by hormone replacement therapy (Bixler 2001), 
suggesting a hormonal aetiology for gender differences. Post-menopausal women 
however are still less likely to develop OSA than men. Even taking into account the 
difference in prevalence between the sexes, female patients are under-represented in 
sleep clinics and hence in studies. The reasons for this are unclear but it may reflect 
an increase in disease severity amongst males (O'Connor 2000). There is some 
evidence to suggest that females are less likely to report ‘classical’ symptoms of 
OSA than men and may be more likely to report other symptoms, such as fatigue or 
difficulty initiating sleep (Jordan 2003). This may contribute to a lower index of 
suspicion amongst patients and physicians. 
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The prevalence of OSA increases with age up to an age of between 55 and 65 years, 
after which it seems to plateau (Bixler 1998, Young 2002b). The increase is likely to 
be multifactorial and weight gain may be a significant factor. However, a number of 
studies suggest that in the older population, the reasons for developing OSA may be 
different to that seen in the (more commonly described) middle aged population 
(Edwards 2014). Physiological and anatomical changes predisposing the upper 
airway to collapse appear to increase with age (Malhotra 2006, Eikermann 2007, 
Martin 1997). The number of spontaneous arousals from sleep has also been shown 
to increase with age (Redline 2004), suggesting that the arousal threshold becomes 
lower with age, although this has not been a universal finding (Edwards 2010). 
Additionally, OSA may present differently in the elderly, with nocturia, falls and 
cognitive impairment seen more frequently than in the middle aged population 
(Launois 2007). These factors, along with the observation that OSA may have less 
effect on mortality in the elderly population (Lavie 2005) have led to speculation as 
to whether OSA in the elderly represents a separate entity (Launois 2007). 
As discussed above, craniofacial abnormalities are a risk factor for OSA including 
congenital syndromes such as Down’s syndrome and Pierre Robin syndrome among 
others (Kent 2010). Aside from these well characterised genetic syndromes there is 
evidence of a genetic basis for OSA from family and twin studies (Riha 2009). In 
addition, known risk factors for OSA such as obesity and craniofacial abnormalities 
may be heritable. It has been estimated that up to 40% of the variance in AHI is 
attributable to familial factors (Redline 2000). Given the complex pathophysiology 
of OSA, it is likely to be a polygenic condition interacting with environmental 
factors, particularly obesity. The lack of a single OSA phenotype makes 
identification of genetic influences more complex with interest so far focusing on 
genes involved in obesity, craniofacial morphology, ventilatory control and sleep 
regulation. Acquired conditions such as hypothyroidism and acromegaly increase the 
risk of developing OSA, as can pregnancy. Sedative drugs and alcohol can 
exacerbate OSA which may in part be due to relaxation of the upper airway dilator 
muscles. Cigarette smoking has also been associated with OSA (Wetter 1994), 
although the exact nature of the relationship remains unclear. 
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1.8 Clinical presentation of obstructive sleep apnoea (OSA) 
Patients with OSA may present with nocturnal symptoms (usually reported by a bed 
partner), daytime symptoms (secondary to sleep disturbance) or both. Nocturnal 
symptoms include snoring, frequent awakenings, choking sensations resulting in 
awakening from sleep, apnoeas and enuresis. Most patients with OSA snore, but 
absence of snoring does not exclude a diagnosis. Patients may also report a dry 
mouth or headache in the morning and often awaken feeling unrefreshed. Daytime 
symptoms include excessive daytime sleepiness (EDS), fatigue, poor concentration, 
low mood and cognitive impairment. These symptoms can impact on patients’ 
quality of life and on their ability to drive or work safely. Subjective scales can be 
used in order to try and determine the presence of EDS, the best-known and used of 
which is the Epworth Sleepiness Score (ESS) (see Appendix 1) (Johns 1991). 
Patients grade the likelihood of falling asleep in a variety of situations from ‘would 
never doze’ to 3, ‘high chance of dozing’. A score of ≥11 out of a maximum of 24 is 
deemed to represent EDS, although this is not specific to OSA. The ESS has the 
advantage of being cheap and easy to administer and has been shown to reliably 
differentiate between normal and abnormal levels of sleepiness (Johns 1991, Johns 
1992), and improves following successful treatment (McDaid 2009). However it 
does not correlate with disease severity, as measured during overnight sleep 
monitoring; neither does it closely correlate with more objective measures of 
sleepiness such as the modified sleep latency test (MSLT) or maintenance of 
wakefulness test (MWT) (Benbadis 1999, Johns 2000). For a variety of reasons, 
patients may under- or overestimate their symptoms and so a partner’s perspective is 
useful and may correlate slightly better with objective measures of sleepiness 
(Kingshott 1995). The onset of OSA is usually insidious, occurring over years and so 
a high index of suspicion is required, particularly in patients presenting with vague 
symptoms of fatigue or mood disturbance. A detailed sleep history should always be 
obtained in these cases. Clinical examination in patients with OSA is often normal; 
however there are some salient features to be noted. A significant proportion of 
patients are obese and a BMI should be recorded: however, neck circumference and 
waist to hip ratio are probably more useful measurements in this condition than BMI 
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alone (Davies 1992, Vgontzas 2000). Patients should be examined to exclude 
obvious craniofacial abnormalities and their oral cavities inspected.  
Given the association of OSA with cardiovascular disease (McNicholas 2007) and 
hypertension in particular (Stradling 2001), a blood pressure should also be recorded. 
 
1.9 Diagnosis of obstructive sleep apnoea (OSA) 
A diagnosis of OSA is made based on the history and objective overnight monitoring 
of sleep to determine if there is any evidence of sleep disordered breathing. To fulfil 
the definition of OSHAS, patients additionally need to have symptoms of EDS and 
this can be determined using the Epworth Sleepiness Score (see section 1.8 above).  
Sleep can be monitored in a number of ways. The current ‘gold standard’ is 
considered to be overnight polysomnography (PSG) which provides the most 
comprehensive assessment of a nights’ sleep. A PSG requires an in-patient stay and 
involves the recording of numerous sleep and respiratory variables. These routinely 
include electroencephalography (EEG), electro-oculography (EOG), 
electromyography (EMG), oxygen saturations, nasal airflow, snoring, thoraco-
abdominal movement, and body position. The various sleep stages are scored (see 
section 1.4 for details) enabling the total sleep time to be determined. As described 
above in section 1.3, respiratory events during sleep, namely the number of apnoeas 
and hypopnoeas per hour can then be determined and expressed as the 
apnoea/hypopnoea index (AHI). A less labour intensive option is a limited sleep 
study (or polygraphy) which involves the monitoring of respiratory variables but 
without EEG monitoring. After appropriate instruction, patients can apply the 
equipment themselves at home, avoiding a hospital admission and the associated 
costs. A recent systematic review suggested that while the AHI determined at PSG 
and limited study were not directly comparable, limited studies were an acceptable 
means of diagnosing obstructive apnoea in patients with a high pre-test probability of 
the disease under the supervision of an appropriately qualified service (Fleetham 
2011). Limited studies are felt to be less useful in those with other co-morbidities 
(Fleetham 2011, Collop 2007) and the lack of sleep staging information means that 
arousals cannot be scored and hence some hypopnoeas may be missed giving an 
underestimate of disease severity. In addition, the rate of data loss with limited 
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studies ranges from 3 to 18% (Flemons 2003), which if the facilities are available, 
require repeat investigation, usually with a full PSG. Single channel oximetry is used 
as a screening tool in some centres, but it is generally felt to be insufficient as the 
sole means of investigating OSA, missing approximately one third of cases in one 
series (Douglas 1992). 
 
1.10 Consequences of obstructive sleep apnoea (OSA) 
The ‘immediate’ consequences of OSA include excessive daytime sleepiness, 
cognitive impairment, subsequent impairment of quality of life and increased risk of 
road traffic (and probably) workplace accidents (George 2004, Ulfberg 2000, 
Lindberg 2001). Importantly, OSA is also associated with a significant increase in 
morbidity and mortality largely due to cardiovascular disease (McNicholas 2007) 
and as the main subject of this thesis, will be discussed in depth in the following 
chapter. 
 
1.10.1 Excessive daytime sleepiness (EDS) 
The presence of excessive daytime sleepiness (EDS) along with evidence of OSA is 
the hallmark of the obstructive sleep apnoea/ hypopnoea syndrome (OSAHS). EDS 
affects quality of life and is a significant risk factor for road traffic accidents (see 
section 1.9.3 below). The often insidious nature of OSA means that patients may not 
appreciate how abnormally sleep they are, with this only becoming apparent 
retrospectively following commencement of treatment (Engleman 1997). CPAP 
therapy improves EDS in patients with OSA, with the greatest effect seen in patients 
with more severe disease (McDaid 2009). 
 
1.10.2 Cognitive impairment 
OSA has been associated with cognitive impairment across a broad range of 
functions including attention, learning and executive function which is most 
significant in those with moderate or severe disease (Beebe 2003, Engleman 2004, 
Lal 2012). Proposed mechanisms for cognitive impairment include the impact of 
EDS, sleep fragmentation itself and intermittent hypoxia (Bucks 2013). 
Improvements in cognitive function have been shown with CPAP treatment, but this 
17 
is not a universal finding (Kielb 2012) and certainly is not as impressive as the 
improvements in EDS seen with CPAP. 
 
1.10.3 Road traffic accidents   
Patients with OSAHS are 2-4 times more likely to be involved in a road traffic 
accident (George 2004), with just over a third of patients in one study retrospectively 
admitting to driving impairment due to sleepiness prior to commencing therapy 
(Engleman 1997). Current UK Driver and Vehicle Licensing Agency (DVLA) 
guidelines require patients with OSAHS to report their condition and mandate that 
driving must cease until satisfactory control of symptoms is achieved; regulations are 
stricter for those holding a group 2 licence (DVLA 2013). The relationship between 
disease severity, as measured by the AHI, and the risk of accident is not clear 
(Turkington 2001), although this is not too surprising given the often multifactorial 
nature of road traffic accidents. Equally unclear is the relationship between reported 
sleepiness and driving risk, as for a variety of reasons, not least concerns regarding 
the potential loss of their driving licence, patients may under-report their symptoms 
(Engleman 1997). Worryingly, commercial drivers appear to be at even greater risk 
of developing OSA (Tregear 2009). 
 
1.10.4 Quality of life 
OSA is associated with significant impairment of health-related quality of life across 
a number of domains and not simply related to EDS or cardiovascular complications 
(Jenkinson 1997, Lacasse 2002). The degree of impairment does not appear to 
correlate with disease severity as determined objectively using the AHI (Flemons 
2002). An OSA-specific questionnaire, the Calgary Sleep Apnea Quality of Life 
Index (SAQLI) has been validated for measuring changes in quality of life with 
treatment (Flemons 1998). Early studies using general (rather than disease-specific) 
measures of quality of life suggested that improvements were seen with CPAP 
treatment (Engleman 1999, Jenkinson 1999), however this was not confirmed in a 
more recent meta-analysis (Jing 2008) and further studies using disease-specific 
measures of quality of life are required. 
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1.11 Treatment of obstructive sleep apnoea (OSA) 
The ‘gold standard’ treatment for OSA is continuous positive airway pressure 
(CPAP) therapy. It is not however a cure and only alleviates symptoms if satisfactory 
compliance is achieved. In milder disease, oral devices may play a role and are often 
better tolerated. Given the association with obesity, lifestyle modification resulting in 
weight reduction would seem an obvious treatment for OSA and is widely 
recommended by physicians and in guidelines. Over the years numerous surgical 
procedures for the upper airway have been proposed. However the role of these 
operations is usually limited to situations where there is a clearly defined anatomical 
abnormality that can be ameliorated, such as tonsillar hypertrophy. At present there 
is no role for drug treatment in OSA. 
 
1.11.1 Continuous Positive Airway Pressure (CPAP) Therapy 
Continuous positive airway pressure (CPAP) therapy was first described as a 
treatment for OSA over 30 years ago (Sullivan 1981) and remains standard therapy 
(SIGN 2003, NICE 2008). Positive pressure is delivered to the airway via a tight 
fitting nasal or oro-nasal mask, creating a pneumatic splint, holding open the upper 
airway and preventing both sleep fragmentation and oxygen desaturation. The mask 
is connected, via tubing, to a flow generator. To determine pressure requirements, a 
titration study (either performed manually with PSG monitoring or using an 
intelligent auto-setting CPAP device) is usually performed, with the aim of reducing 
the AHI to below 5. Numerous CPAP devices are available commercially and can 
either deliver a fixed pressure of air, or may be auto-titrating; meaning the device 
continually adjusts the pressure delivered during the night to keep the airway open.  
CPAP is an effective treatment for EDS, particularly in those with moderate to 
severe disease (McDaid 2009), and may improve quality of life and cognitive 
function. Observational studies showa reduction in road traffic accident risk in 
CPAP-treated patients (Tregear 2010). CPAP use is associated with a reduction in 
the cardiovascular morbidity and mortality associated with OSA (Marin 2005) and 
numerous studies have shown that CPAP is effective in reducing blood pressure in 
patients with OSA (Bazzano 2007). The effects of CPAP on the cardiovascular 
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system constitute one of the main themes of this thesis and this is discussed in detail 
in the following chapter. 
CPAP therapy is not without side-effects and due to the tight-fitting nature of the 
mask, the positive pressure of air blowing through it and the noise associated with 
this, it may not be tolerated by patients (or their bed partners). The side effects 
include local skin irritation from the mask, conjunctivitis due to air leak and nasal 
congestion or dryness. CPAP is not a ‘cure’ for OSA and is only effective in 
reducing symptoms if it is worn regularly at night.  Side effects, along with the 
intrusiveness and inconvenience of wearing the device on a nightly basis mean, that 
despite the proven efficacy of CPAP, there are significant issues with compliance. 
Early studies suggested that CPAP was rejected initially or within the first week of 
treatment by between 5 and 50% of patients with another significant proportion 
discontinuing CPAP in the subsequent three years (Engleman 2003). Amongst those 
who continue to use CPAP, it is not entirely clear what constitutes adequate use and 
this is variably defined in studies. The use of CPAP for four hours per night on 70% 
of nights is often quoted as being adequate (Sawyer 2011). A significant proportion 
of subjects in research studies are non-compliant using this standard (Weaver 2008) 
and ‘real-life’ compliance is likely to be even lower.  
 
1.11.2 Oral appliances 
Numerous oral appliances (also known as mandibular repositioning splints or 
mandibular advancement devices) are available (both custom made and 
commercially) and are worn at night, with the aim of advancing the mandible and 
thus increasing the size of the upper airway. Oral appliances have been the subject of 
fewer randomised controlled trials than CPAP, but there is evidence to support their 
use in the treatment of OSA at the milder end of the spectrum, with improvements 
seen in AHI and EDS (Mehta 2001, Gotsopoulos 2002, Barnes 2004), although these 
have generally been shown to be inferior to the improvements seen with CPAP 
(Barnes 2004, Lim 2009). In the recently published and largest randomised 
controlled trial to date, both CPAP and oral appliance led to significant 
improvements in the AHI (although the reduction with CPAP was greater) and ESS. 
Both treatments led to similar improvements in disease-specific quality of life and 
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driving simulator performance (Phillips 2013a). Oral appliances may also be 
effective in lowering blood pressure in patients with OSA, although most of the 
evidence is not from randomised controlled trials (Iftikhar 2013). 
Despite their poorer efficacy, oral appliances are often more acceptable to patients 
than CPAP (Hoffstein 2007, Phillips 2013a), particularly in those with milder disease 
(Barnes 2004). Oral appliances are not without side effects, which can include a dry 
mouth, excessive salivation, local irritation and pain, and in the longer term can 
cause changes to the bone structure of the lower face and bite (Clark 2000, Roberston 
2001). National guidelines (SIGN 2003, Kushida 2006) recommend the use of oral 
appliances in those with mild disease or in those whom CPAP cannot be tolerated. 
 
1.11.3 Lifestyle modification 
Given the clear association with obesity it would seem logical that weight reduction 
would be important in the management of OSA. More than 10 years ago, Peppard et 
al showed that in the general population a weight gain of 10% was associated with a 
32% increase in the AHI, with a 26% reduction in AHI following a weight loss of 
10% (Peppard 2000a). Intensive lifestyle counselling and a weight reduction 
programme has been shown to reduce the AHI to below 5 in around two-thirds of 
overweight patients with mild OSA (Tuomilehto 2009) and a very low calorie diet 
regime significantly reduced the AHI in obese patients with moderate to severe OSA, 
with the effects persisting at one year (Johansson 2009). Tuomilehto et al went on to 
show that if successful weight loss was maintained, then disease progression over 5 
yr follow up was also reduced (Tuomilehto 2014). A recent meta-analysis identified 
12 randomised controlled studies of the effect of weight loss, exercise, or other 
lifestyle modification upon sleep apnoea severity and concluded that intensive 
lifestyle interventions that included caloric restriction +/- exercise regimes were 
effective at reducing indices of OSA severity (Thomasouli 2013). A subsequent 
meta-analysis reports similar findings, but noted that despite improvements in indices 
of OSA severity only a minority of patients were effectively ‘cured’ of OSA 
(Mitchell 2014). The effectiveness of weight loss for OSA is an area of increasing 
interest with a recent RCT showing greater improvements in CRP, insulin resistance 
and serum triglyceride levels in patients with OSA randomised to weight loss alone 
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when compared to CPAP therapy. Similar reductions in blood pressure were seen in 
both the weight loss and CPAP groups (Chirinos 2014). Further research is needed to 
determine the effectiveness of weight loss strategies in the longer term. Current 
Scottish Intercollegiate Guidelines Network (SIGN) guidelines recommend advising 
overweight patients to lose weight, but in recognition of the fact that this is rarely 
achieved, warn that this should not delay the institution of proven therapies such as 
CPAP (SIGN 2003). More recently however it has also been suggested that there is a 
bi-directional relationship between obesity and OSA, with OSA perhaps perpetuating 
the overweight state (Ong 2013). Advice is usually also given to patients to improve 




The first surgical treatment for OSA was tracheostomy which, while effective 
(Guilleminault 1981), is invasive and carries significant side effects and is now only 
recommended in severe cases where all other treatments have failed (SIGN 2003). 
Subsequently, numerous upper airway procedures have been used to treat OSA, 
including uvulopalatopharyngoplasty (UPPP), laser-assisted uvulopalatoplasty, 
maxillo-mandibular osteotomy and palatal implants. There is a lack of randomised 
controlled trial evidence regarding the efficacy of surgery in adults (Caples 2010). As 
such surgery is not recommended (SIGN 2003) and may actually make future 
treatment with CPAP more difficult. The exceptions to this are cases in which there 
are obstructing lesions affecting the upper airway, including adenotonsillectomy in 
children. Evidence from non-randomised controlled studies suggests that 
adenotonsillectomy is effective in the treatment of paediatric OSA (Redline 2011). 
More recently the results of a multicentre randomised controlled trial comparing 
early adenotonsillectomy with watchful waiting in paediatric patients with OSA have 
been published (Marcus 2013). No differences were noted in the primary outcome 
measures of attention or executive function as measured by the Developmental 
Neuropsychological Assessment. However in children undergoing 
adenotonsillectomy, greater improvements were seen in the secondary outcomes of 
polysomnographic findings, symptoms, quality of life and behaviour at 7 months. 
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Bariatric surgery for the control of morbid obesity may be effective in reducing the 
AHI (Greenberg 2009), but a recent study showed that although it resulted in a 
greater weight loss than calorie restriction and exercise, the effect upon the AHI was 
not statistically greater (Dixon 2012). 
 
1.11.5 Drug treatment 
Given the challenges of the above treatments, pharmacotherapy would be an 
appealing option and numerous drugs have been investigated including respiratory 
stimulants, promoters of upper airway dilatation and REM sleep suppressants (Lin 
2012). Despite this, drug therapy currently plays no significant role in the treatment 
of OSA.  An exception to this may be the treatment of an underlying condition such 
as hypothyroidism, although there is no good evidence that this is an effective 
treatment for OSA. Adjunctive therapies such as the use of intra-nasal steroids in 
concomitant rhinitis may be useful (Kiely 2004), and stimulants such as modafinil 
have been shown to reduce sleepiness that persists despite CPAP use (Pack 2001, 
Black 2005). The latter is not a universal finding and may actually reduce CPAP 
compliance (Kingshott 2001, Lin 2012). Due to concerns regarding side effects and 
potential illicit use, modafinil is no longer licensed for the treatment of residual 
sleepiness in OSA in Scotland (SMC 2010). 
Given the often multifactorial aetiology of OSA, it seems unlikely that a single drug 
treatment would be effective for in all cases. More work is clearly required in this 
area, not least in determining the phenotypes that may benefit from specific 
treatments. 
 
1.12 Concluding remarks 
OSA is a common and underdiagnosed condition that carries with it a significant 
symptom burden, and when it is associated with EDS it is termed OSAHS .The 
aetiology of OSA is often multifactorial, but obesity is an important risk factor. 
CPAP therapy is an effective treatment for obstructive events and EDS, however 
despite its efficacy, it is not always tolerated by patients. Over the last three decades 
it has become increasingly clear that untreated OSA is associated with increased 
cardiovascular morbidity and mortality and the evidence for this, along with the 
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potential pathophysiological mechanisms linking OSA and CVD, will be discussed 




Chapter 2: Obstructive sleep apnoea and cardiovascular disease 
 
2.1 Introduction  
Cardiovascular disease (CVD) is common, as is OSA, and the two conditions share a 
number of risk factors including increasing age, male gender and obesity (Kiely 
2000, Leung 2001). Untreated moderate to severe OSA is associated with greater 
cardiovascular morbidity and mortality (Marin 2005). OSA is an independent risk 
factor for hypertension and has been associated with most other types of CVD 
(Stradling 2001, McNicholas 2007, Parati 2013). Numerous mechanisms for the 
development of CVD in OSA have been proposed, namely intermittent hypoxia (IH), 
repetitive arousals/sleep fragmentation and intra-thoracic pressure swings 
(McNicholas 2007). These variously lead to activation of the sympathetic nervous 
system, systematic inflammation and oxidative stress; the common end point of 
which may be increased arterial stiffness and endothelial dysfunction. CPAP therapy 
may reduce CVD risk (Marti 2002, Marin 2005) and has been shown to reduce blood 
pressure in patients with OSA (Bazzano 2007). Prior to starting this study, evidence 
from small studies suggested that CPAP therapy could reduce arterial stiffness 
(Kitihara 2006) and improve endothelial function (Ip 2004). In this chapter, the 
available evidence for the association between OSA and CVD prior to the start of 
this study in 2007 will be discussed, along with the potential pathophysiological 
mechanisms behind such an association. More recent work will be discussed along 
with the findings of this study in Chapter 7. 
 
2.2 Cardiovascular disease (CVD) 
CVD is the leading cause of death globally (WHO 2002) and encompasses a broad 
spectrum of diseases affecting the cardiovascular system including, but not 
exclusively, hypertension, ischaemic heart disease (IHD), cerebrovascular disease 
and congestive cardiac failure. Hypertension is a risk factor for other CVDs, 
particularly IHD and cerebrovascular disease (Kannel 2000). CVD has traditionally 
been viewed as a disease of the developed world, however the incidence is also 
increasing in the developing world where it has been linked to increasing 
urbanisation, dietary changes and increases in smoking rates, obesity and diabetes 
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(Celermajer 2012). Most CVD is the result of vascular dysfunction due to 
hypertension or atheromatous disease and numerous risk factors have been identified. 
Common risk factors for CVD include obesity, lack of physical activity, smoking 
alcohol use, hypertension, hypercholesterolaemia and type II diabetes mellitus. In the 
UK, mortality from CVD has fallen in recent years, but despite public health 
campaigns aimed at lifestyle modification and advances in the treatment of CVD,  
the disease burden remains high (Department of Health 2013). In view of this, there 
has been much interest in the identification of preclinical CVD and the prediction of 
which patients are at risk of developing clinically overt CVD so that therapeutic 
intervention can be offered earlier.  Along with interest in circulating biomarkers 
(van Holten 2013), arterial stiffness and endothelial function (see sections 2.3 and 2.4 
below) have been established as measures of vascular ‘health’. Evidence of increased 
arterial stiffness and endothelial dysfunction may be seen in the absence of overt 
CVD or hypertension (Celermajer 1992, Reddy 1994, Laurent 2006, Lane 2006), but 
both have been associated with subsequent CVD and indeed a poorer prognosis from 
pre-existing CVD (Laurent 2006, Perticone 2001, Yeboah 2007). 
 
2.3 Arterial stiffness  
Arterial stiffness, essentially a measure of vascular ageing, refers to a reduction in 
the normal expansion and contraction of arteries in response to changes in pressure 
and can be measured non-invasively in a number of ways at a variety of sites along 
the vascular tree. A consequence of increased arterial stiffness is increased 
propagation velocity of blood flow through the arterial tree. Arterial stiffness has 
been shown to be an independent predictor of CVD in both the general population 
and in high risk groups (Laurent 2006). 
The structure and function of arteries changes along the arterial tree. Elastic fibres 
predominate within the thoracic aorta providing a cushioning function (Safar 2003). 
There has been much interest in measurement of arterial stiffness in this region as 
this is the arterial segment that the left ventricle ‘sees’, with greater stiffness here 
leading to increased cardiac afterload and impaired coronary blood flow (Weber 
2004).  Stiffness in the thoracic aorta is primarily determined by the relative 
contributions of the major scaffolding proteins within the extra-cellular matrix 
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(ECM), namely collagen and elastin (Laurent 2006, Safar 2003). Collagen and 
elastin are subject to a constant process of production and degradation, which in 
normality retains the status quo. Any process leading to elastin damage or an 
increase in the relative collagen content leads to increased arterial stiffness (Alvolio 
1998, Zieman 2005). Factors known to increase relative collagen content within the 
vascular ECM include; ageing (London 2004, Sawabe 2010), systemic inflammation 
and increased pressure within the vessel lumen (i.e. systemic hypertension) (Zieman 
2005, Tomiyama 2010). Arterial calcification, such as that seen with ageing 
(Dunmore-Buyze 2002) and renal disease (Guerin 2000), is probably also important 
in promoting stiffening (McEniery 2009, Cecelja 2012). Arterial stiffening can also 
occur in conjunction with the intimal lipid and inflammatory cell deposition seen in 
atherosclerosis. However, it is unclear if atherosclerosis alone is sufficient to cause 
arterial stiffening (Zieman 2005, Quinn 2012).  Histological examination of intima 
from stiffened vessels confirms increased collagen content, degraded elastin fibres, 
abnormal endothelial cells, inflammatory cell infiltrate and increased vascular 
smooth muscle cells (Zieman 2005). 
Collagen and smooth muscle fibres predominating within the arterial wall of 
peripheral arteries and stiffness here is primarily modulated by vasomotor tone as 
influenced by endothelial function (See section 2.4 below), the sympathetic nervous 
system, the renin aldosterone system and vessel wall hypertrophy. In health, arterial 
stiffness increases along the arterial tree, although in later life or in CVD disease, the 
central vessels may become stiffer than those more peripherally (Safar 2003). 
Prior to commencing this study there was emerging evidence that OSA was 
associated with increased arterial stiffness and this is discussed in section 2.11 
below. 
 
2.4 Endothelial dysfunction  
The endothelium is a single layer of cells lining the vascular intima throughout the 
entire vascular tree and forms the interface between circulating blood and the vessel 
wall. In health the endothelium has a number of important roles including; the 
regulation of vascular tone, haemostasis, cellular adhesion, vascular inflammation 
and smooth muscle cell proliferation (Deanfield 2007). In response to a variety of 
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physical and chemical signals, the endothelium can produce a wide range of 
vasoactive factors, of which the most studied is probably nitric oxide (NO), the main 
mediator of vascular function (Hayward 2002, Tomiyama 2009, Marti 2012). NO is 
produced by endothelial NO synthetase (eNOS) in response to endogenous signalling 
molecules such as acetylcholine and bradykinin, drugs such as beta-2 agonists 
(Hayward 2002, Wilkinson 2001), ischaemia, temperature change and mechanical 
factors including shear stress (Marti 2012). On release, NO acts upon vascular 
smooth muscle cells, activating guanylate cyclase and leading to cyclic guanosine 
monophosphate (GMP)-mediated vasodilatation (Marti 2012).  Under normal 
conditions, shear stress is primarily responsible for NO release, enabling tissue 
perfusion to adapt to changes in cardiac output (Deanfield 2007). Along with 
vasodilation, NO also acts to prevent atheroma formation (Wilkinson 2002) by 
inhibiting vascular smooth muscle proliferation, platelet aggregation, leucocyte 
adhesion to endothelial cells and nuclear transcription of cell adhesion molecules 
(Tomiyama 2009). Integral to this inhibition is the s-nitrosylation of cysteine 
residues within a wide variety of key regulator proteins including the transcription 
factor NFκB (Deanfield 2007). 
Prostacyclin released by the endothelium also vasodilates. The endothelium can also 
effect vasoconstriction through the release of prostanoids and endothelin, along with 
the conversion of angiotensin I to angiotensin II on the endothelial surface 
(Deanfield 2007). The obligatory role of the endothelium in vasodilatation provides a 
means of quantifying endothelial function, with impaired vasodilatation following 
the application of an appropriate stimulus (Anderson 1999, Wilkinson 2002) and is 
termed endothelium-dependent vasodilation. 
Endothelial dysfunction (usually regarded as impaired endothelium-dependent 
vasodilation) represents a preclinical vascular abnormality which occurs prior to 
atheroma formation (Celermajer 1992, Reddy 1994) and reflects an activation of the 
vascular endothelium that can be induced by a variety of stimuli (Deanfield 2007). 
Pathological stimulation of the endothelium leads to a switch to redox signalling and 
mitochondrial release of ROS which react with cysteine groups in the same key 
regulator proteins leading to increased transcription and protein activation. Under 
normal conditions NO is produced by eNOS, however following endothelial 
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activation eNOS can also generate ROS, thus setting up a vicious cycle (Deanfield 
2007, Feng 2012). Numerous risk factors for CVD, including age (Taddei 1995), 
hypertension (Perticone 2001), diabetes (Clarkson 1996), smoking (Celermajer 
1993), hypercholesterolaemia (Creager 1990, Chowienczyk 1992) and obesity 
(Arcaro 1999, Suh 2005) are associated with endothelial dysfunction. Interventions 
aimed at reducing these risk factors, such as the use of antihypertensives, smoking 
cessation, lipid lowering drugs and physical exercise have been shown to improve 
endothelial function, suggesting endothelial dysfunction plays an important 
pathophysiological role in the development of CVD (Vita 2002). Indeed, studies 
have shown endothelial dysfunction to be an independent predictor of cardiovascular 
morbidity and mortality (Perticone 2001, Heitzer 2001, Heitzer 2005, Yeboah 2007). 
Prior to commencing this study, evidence of a link between OSA and endothelial 
dysfunction was beginning to emerge and this is discussed in section 2.12 below. 
Endothelium-independent vasodilation refers to the vasodilatatory response to 
exogenous NO (such as GTN, used in this study). This is a vascular smooth muscle 
response and in the presence of exogenous NO, is not dependent on NO release from 
an intact endothelium. GTN is converted to NO within the smooth muscle cell, 
activating guanylate cyclase and leading to cyclic guanosine monophosphate (GMP) 
accumulation, effecting vasodilation (Adams 1998). Whilst many studies have 
demonstrated impaired endothelium-dependent vasodilation in CVD and in subjects 
with cardiovascular risk factors (see above), fewer studies have reported a 
statistically significant impairment in endothelium-independent vasodilation in 
similar patients (Schachinger 1995, Adams 1998). In a large study of adults without 
overt CVD or hypertension, endothelium-independent vasodilation was significantly 
correlated with endothelium dependent vasodilation (r=0.41; p<0.001) (Adams 1995) 
and in another study was shown in coronary vessels to be predictive of 
cardiovascular events (Schachinger 2000). Potential mechanisms for impaired 
endothelium-independent vasodilation are smooth muscle cell dysfunction, including 
altered responsiveness to any of the stimulators of guanylate cyclase within the cell 
and mechanical factors preventing vessel wall dilatation, such as vessel wall fibrosis 
(Adams 1998, Schachinger 1995). More recently, it has been speculated that damage 
to vascular smooth muscle requires a longer exposure to a given risk factor than is 
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required for damage to the endothelium, which theoretically may explain why 
impairment of endothelium-dependent vasodilation is more commonly seen (Hoyos 
2015). 
Endothelial function can be considered in both the microvasculature and 
microvasculature, although a distinction between the two is often not made in the 
literature. Both have been shown to correlate with coronary artery endothelial 
function (Anderson 1995, Bonetti 2004) but macrovascular and microvascular 
endothelial function are only weakly correlated with each other (Hamburg 2011) and 
this may reflect their different physiological roles of conduit and resistance arteries 
(Flammer 2012). It has been suggested that macrovascular endothelial impairment 
may be more important in patients with pre-existing CVD whereas microvascular 
endothelial dyfunction may be important in detecting pre-clinical CVD (Flammer 
2012, Yannoutsos 2014). 
 
2.5 Evidence for a link between OSA and cardiovascular disease 
Evidence of an association between OSA and cardiovascular disease (CVD) began to 
emerge in the 1980s. Early studies reported associations between snoring, 
cardiovascular risk factors (Jennum 1993a, Jennum 1993b) and a variety of CVDs 
(Parish 1990). With a high incidence of undiagnosed OSA found amongst snorers 
(Block 1987) however, and work suggesting that snoring alone (in the absence of 
OSA) was not associated with an increased risk of hypertension (Hoffstein 1988), 
snoring was deemed likely to be a confounder (Waller 1989). The focus switched to 
examining the relationship between OSA and CVD.  A later longitudinal study with 
follow up over ten years did not show simple snorers to be at increased 
cardiovascular risk when compared to healthy non-snorers (Marin 2005). 
Initial observational studies reported that patients with OSA who were not treated 
with either tracheostomy or CPAP therapy had mortality rates of between 11 and 
13% at five years, largely due to vascular disease (Parish 1990). Subsequently the 
population based Sleep Heart Health Study, reported the (self-reported) prevalence of 
CVD to be 1.42 times greater in those with an AHI in the upper quartile of the study, 
as compared to those in the lower quartile. This, despite the fact that the median AHI 
in the upper quartile was only 19 (Shahar 2001). In a study of patients referred to a 
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sleep laboratory, free from known CVD at baseline, subjects found to have OSA had 
a five-fold increase in the incidence of CVD after seven years of follow up when 
compared to those without OSA, independently of age, BMI, blood pressure or 
smoking status. This figure rose to 11-fold in subjects who were deemed to be 
incompletely treated (Peker 2002). The association between OSA and CVD is further 
evidenced by studies showing that patients with untreated OSA are at greater risk of 
death due to CVD than those receiving effective treatment (Marti 2002, Marin 2005, 
Doherty 2005, Martinez-Garcia 2012a). In the largest prospective observational 
study to date, patients with severe untreated OSA had an approximately three-fold 
increase in both fatal and non-fatal cardiovascular events after ten years, after 
adjustment for potential confounders (Marin 2005). A significant source of bias in 
this study was the possibility that patients who declined CPAP treatment differed 
from those who accepted treatment in other unmeasurable ways, i.e. compliance with 
other treatments and risk taking behaviour. 
Marti et al compared the mortality in patients with severe OSAHS who were 
considered to be treated following weight loss, surgery or CPAP therapy with 
untreated patients from the same centre. To reduce bias, patients who declined 
treatment with CPAP after it became available at the study centre in 1988 were 
excluded. Overall mortality was significantly higher in the untreated group than in 
those treated, particularly in patients under 50 years of age. In treated patients, 
mortality was not significantly different than in the general population (Marti 2002). 
Doherty et al followed 168 patients with OSAHS who had been commenced on 
CPAP therapy at least five years previously. Approximately one third of the original 
cohort were intolerant of CPAP at the time of follow-up and outcomes in this group 
were compared to the group still using CPAP therapy.  Although there was no 
difference in the development of CVD morbidity between the two groups, death due 
to CVD was significantly higher in the CPAP intolerant group (14.8% vs. 1.9%; 
p=0.009) (Doherty 2005). More recently, in a large prospective observational study, 
Martinez-Garcia et al showed that in subjects over 65 years of age, moderate to 
severe OSA was associated with increased cardiovascular mortality (hazard ratio of 
2.25). Cardiovascular mortality was significantly lower (hazard ratio 0.93) in those 
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receiving effective CPAP therapy (defined as CPAP use ≥4 hours per night) 
(Martinez-Garcia 2012a). 
CVD is a broad term, encompassing a number of diseases including, but not 
exclusively, hypertension, IHD, cerebrovascular disease and congestive cardiac 
failure and is also closely linked with the metabolic syndrome. OSA is established as 
an independent risk factor for hypertension (Stradling 2001) and this is discussed in 
section 2.6 below.  Evidence for individual associations between OSA and IHD, 
cerebrovascular disease and congestive cardiac failure are examined separately 
below (See sections 2.7, 2.8 and 2.9 below).  There is a significant amount of 
evidence that OSA is associated with CVD, but with the exception of hypertension, it 
has not been possible to conclusively demonstrate that OSA is an independent risk 
factor for CVD. This lack of evidence has led in the past to concern that the adverse 
cardiovascular effects of OSA have been overemphasised (Wright 1997). However, 
more recent evidence particularly with respect to hypertension would contradict this 
view. 
 
2.6 OSA and hypertension    
Hypertension is a major, but potentially modifiable, risk factor for CVD and OSA 
and hypertension commonly co-exist. Indeed it has been estimated that 40% of 
patients with OSA have hypertension and a similar percentage of patients with 
hypertension have OSA (Phillips B 2005, Parati 2013). However, as for CVD in 
general, OSA and diurnal hypertension have a number of shared risk factors, most 
notably obesity, increasing age and gender, which in the past have confounded the 
issue of OSA as an independent risk factor for hypertension (Stradling 2001). Several 
large scale epidemiological studies have sought to control for known confounders 
(Grote 1999, Lavie 2000, Nieto 2000, Peppard 2000) and studies have subsequently 
shown CPAP therapy to reduce blood pressure in patients with OSA (Bazzano 2007). 
In light of these studies and prior to the commencement of our study, OSA had been 
established as an independent risk factor for hypertension (Stradling 2001, Buyse 
2007, McNicholas 2007) and had been recognised in European (Mancia 2007) and 
American (Chobanian 2003) guidelines as a cause of secondary hypertension. Given 
the prevalence of OSA in patients with hypertension, it is likely that OSA is 
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responsible for a proportion of what was previously deemed essential hypertension. 
OSA is particularly recognised as a cause of treatment-resistant hypertension (Grote 
2000, Logan 2001). 
  
2.6.1 Hypertension – an overview  
At the time of starting this study, hypertension was defined by the then current 
National Institute for Health and Care Excellence (NICE) guidelines as a clinic blood 
pressure of greater than 140/90 mmHg on at least two separate measurements (NICE 
2006).  However, the first sign of hypertension may be the loss of the normal 
nocturnal dip (approximately 20 mmHg) in blood pressure (Phillips B 2005). 
Hypertension is usually asymptomatic but is estimated to be responsible for 4.5 % of 
worldwide disease burden (Whitworth 2003) and has a prevalence of over 30% in the 
adult population in Scotland (Scarborough 2010). Following many epidemiological 
studies, including notably a wealth of information gained from studying over 5000 
inhabitants of Framingham, Massachussets since 1948, hypertension is a well- 
established risk factor for IHD, cerebrovascular disease, cardiac failure and 
peripheral arterial disease (Kannel 2000), accounting for around a third of all 
atherosclerotic events (Kannel 1996). Between the ages of 40 and 69 years, every 
sustained 20 mmHg increase in systolic blood pressure (or 10 mmHg increase in 
diastolic blood pressure) leads to a two-fold increase in cardiovascular mortality 
down to a blood pressure as low as 115/75 mmHg (Lewington 2002).  A full 
discussion of the treatment of hypertension is outwith the scope of this thesis. 
However, in general terms, unless an underlying cause is identified, initial treatment 
involves lifestyle modification including weight loss, increased exercise and a 
reduction in salt and alcohol intake. Pharmacotherapy is the next step and numerous 
classes of drugs are available and are often used in combination.  Following the 
recognition of OSA as a cause of hypertension there have been numerous studies 
examining the effect of CPAP therapy upon blood pressure (Bazzano 2007) and 





2.6.2 Blood pressure and sleep   
Blood pressure is normally lower during sleep in both the normotensive and 
hypertensive populations (Bristow 1969, Millar-Craig 1978, Pickering 1982), so 
called ‘dipping’, with a gradual fall in blood pressure from the onset of sleep with a 
prompt rise on wakening (Bristow 1969). The exception to this is during REM sleep, 
which is accompanied by increased sympathetic activity and fluctuations in blood 
pressure (Phillips B 2005). It has long been established that OSA causes a rise in 
mean nocturnal blood pressure (Davies 1993a, Leung 2001) due to the recurrent 
acute elevations in blood pressure associated with each obstructive event.  This has 
been demonstrated in response to intermittent hypoxia (Leuenberger 1995) and 
transient arousals from sleep (Davies 1993b), such as that seen in OSA.  
A significant proportion of patients with OSA do not experience a nocturnal drop in 
blood pressure (so called ‘non-dippers’) and in other populations, this lack of a 
nocturnal drop in blood pressure, has been shown to be associated with increased 
cardiovascular risk and a poorer prognosis (Parati 2006).  
   
2.6.3 OSA – an independent risk factor for hypertension 
There has long been an appreciation of an association between OSA and 
hypertension. Early case series reported an increased frequency of hypertension in 
patients with OSA (Guilleminault 1976, Stradling 2001), followed by reports of a 
high prevalence of OSA among patients attending hypertension clinics compared to 
non-hypertensive controls ( Lavie 1984b, Kales 1984). Although subsequent studies 
seemed to support a causative role for OSA in hypertension, they were largely 
subject to the same criticisms, namely that they failed to account for the fact that 
OSA and hypertension share a number of important risk factors including, most 
notably, obesity (and particularly upper body obesity that may not be well accounted 
for by measuring BMI alone), age and alcohol intake (Stradling 2001). These risk 
factors are difficult to disentangle or indeed account for, in study design. For 
example, patients with OSA and excessive daytime sleepiness are likely to lead a 
more sedentary lifestyle than subjects without OSA, this is in itself a risk factor for 
hypertension (before even considering the effect of a sedentary lifestyle on obesity) 
and could certainly confound any study of the relationship between the two 
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conditions. These factors, along with other confounders such as the way in which 
blood pressure was measured and indeed in the way that OSA was diagnosed, along 
with the inclusion of patients taking antihypertensive therapy led to varying opinions 
as to the relationship between OSA and hypertension (Wright 1997).  
Evidence for a causal relationship between OSA and hypertension was derived from 
animal studies as early as 1992, with a rise in diurnal blood pressure seen in rats 
exposed to periods of intermittent hypoxia (Fletcher 1992). Brooks et al were able to 
simulate OSA in tracheostomised dogs by intermittently occluding the tracheostomy 
tube during sleep over several months (Brooks 1997). This led to a rise in diurnal 
blood pressure which subsequently resolved after the removal of the simulated OSA. 
Following the publication of four large well-conducted studies (Grote 1999, Lavie 
2000, Nieto 2000, Peppard 2000) between 1999 and 2000, there has been a general 
acceptance of OSA as an independent risk factor for hypertension (Stradling 2001, 
McNicholas 2007). The cross-sectional community based Sleep Heart Health study 
(Nieto 2000) examined blood pressure and sleep disordered breathing in 6132 middle 
aged and older subjects. Blood pressure and the prevalence of hypertension increased 
significantly with increased AHI. Subjects with an AHI of ≥30 had an odds ratio of 
1.37 for hypertension compared to those with an AHI of <1.5 after adjusting for 
confounders including BMI, neck circumference, waist-to-hip ratio, alcohol use and 
smoking. Again, after adjustment for confounders, subjects who spent ≥12% of sleep 
time with oxygen saturations of less than 90% had an odds ratio of 1.45 for 
hypertension when compared to subjects who spent <0.05% of sleep time with 
oxygen saturations of less than 90%, after adjusting for the same confounders. In the 
prospective, population based Wisconsin Sleep Cohort, a dose response relationship 
between the severity of OSA and presence of hypertension (defined as a blood 
pressure of ≥140/90 mmHg or the use of anti-hypertensive medication) four years 
later was demonstrated (n=709).  After adjusting for BMI, neck and waist 
circumference, age, sex, alcohol use and smoking, the odds ratio for hypertension 
was 2.89 for subjects with an AHI >15. Interestingly, the odds ratio for hypertension 
was raised at 1.42 in those with an AHI generally considered to be within the normal 
range (AHI 0.1-4.9) (Peppard 2000). Similarly, in two studies of patients referred to 
a sleep clinic (Grote 1999, Lavie 2000), the severity of OSA (as measured by the 
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RDI and AHI respectively) was independently and linearly associated with blood 
pressure, despite adjustment for confounders. When hypertension was defined as 
≥160/95 mmHg, rather than ≥140/90 mmHg, the odds ratio was higher still for each 
category of OSA severity (Grote 1999). Additionally the relationship between OSA 
and hypertension was found to be greater in those aged ≤50 years (Grote 1999).  
Several studies have reported that the association between OSA and hypertension is 
greater in younger patients (Bixler 2000, Grote 2000) and indeed in the Sleep Heart 
Health Study, the association between the AHI and blood pressure was lost when 
patients aged ≥65 years were examined separately. An association did however 
remain between blood pressure and the percentage of sleep time with oxygen 
saturations below 90% (Nieto 2000). 
 
2.6.4 The effect of CPAP therapy on blood pressure in OSA 
Good evidence, from randomised controlled trials that regular CPAP use reduces 
blood pressure in OSA followed the initial observational studies on OSA and 
hypertension. Over ten years ago, Faccenda et al showed a small reduction in 24-
hour diastolic blood pressure with CPAP compared to a tablet placebo. A greater 
reduction, along with a reduction in 24-hour systolic blood pressure was seen in 
those with the most severe disease (Faccenda 2001). A subsequent study confirmed 
this finding, with a small reduction in mean 24-hour blood pressure (2.5mmHg 
reduction) seen with CPAP compared to sham CPAP (Pepperell 2002). Numerous 
studies followed and subsequent meta-analyses reported significant, albeit small 
(around 2-3mmHg) reductions in blood pressure with CPAP therapy (Bazzano 2007, 
Haentjens 2007, Schein 2014) with the greatest reductions in those with more severe 
OSA, higher BMI and higher baseline blood pressures (Bazzano 2007). In more 
recent meta-analyses of the effect of CPAP on blood pressure in patients with OSA 
and resistant hypertension a greater reduction in blood pressure was seen (Iftikhar 
2014, Liu 2015), suggesting that it is this group of patients who have the most to gain 
from CPAP in terms of blood pressure reduction. A reduction in blood pressure with 
CPAP therapy has not however been a universal finding, with studies in patients with 
mild OSA (Barnes 2002), patients with OSA in the absence of EDS (Barbe 2001, 
Robinson 2006) and a study of patients with OSA and treated hypertension (Campos-
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Rodriguez 2006) finding no change in blood pressure following CPAP therapy. This 
remains an area of interest as it may provide further insights into the pathophysiology 
of the association between OSA and hypertension.  
 
2.7 OSA and Ischaemic heart disease (IHD) 
More than 20 years ago Hung et al reported an increased prevalence of OSA in 
patients following an acute myocardial infarction compared to an age-matched 
control group, which persisted after adjustment for other cardiovascular risk factors 
(Hung 1990). Subsequent epidemiological studies confirmed that OSA was over-
represented in patient populations with IHD (Mooe 1996a, Mooe 1996b, Peker 
1999). In the population based, Sleep Heart Health Study there was a modest 
increase in self-reported coronary heart disease in the upper quartile of AHI 
compared to the lower quartile (1.27 (95 % CI 0.99–1.62) (Shahar 2001). Patients 
with OSA were found to be at high risk of future coronary heart disease, using 
Framingham-derived risk prediction methods (Kiely 2000) and after 7 years of 
follow-up, patients with OSA, free from CVD at baseline, were significantly more 
likely to develop coronary artery disease than snorers without OSA (16.2% vs. 5.4%; 
p=0.003) (Peker 2006). 
In patients with known coronary artery disease, the presence of co-existing OSA 
indicated a poor prognosis with a relative risk of 1.62 (1.09- 2.41: p=0.017) of the 
composite end point (death, cerebrovascular event or myocardial infarction) in 
subjects with an AHI ≥10 (Mooe 2001). Increased cardiovascular mortality at five 
years was also reported by Peker et al in a relatively small group of patients 
hospitalized with CVD who had an RDI of  ≥10. They also found the respiratory 
disturbance index (RDI) to be an independent predictor of cardiovascular mortality 
(Peker 2000). In relatively small numbers of patients, effective CPAP therapy has 
been shown to attenuate this increased risk of coronary artery disease (Peker 2006). 
Additionally, in a prospective non-randomised study, patients with OSA and 
coronary artery disease who received effective CPAP therapy experienced a hazard 
ratio of 0.24 (95% CI 0.09-0.62; p<0.01) for a composite cardiovascular end-point 
including cardiovascular death, acute coronary syndrome, hospitalisation for heart 
failure, or need for coronary revascularisation (Milleron 2004).  
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2.8 OSA and cerebrovascular disease 
OSA is common in patients following a cerebrovascular accident (CVA) and indeed 
is much commoner than central sleep apnoea (CSA) (Good 1996, Kaneko 2003). 
Several studies have shown a similar prevalence of OSA in patients following a 
transient ischaemic attack (TIA) (Bassetti 1999, Parra 2000) suggesting that OSA 
predates, rather than is a consequence of, the CVA (Leung 2001, Hamilton 2004). 
This has not been a universal finding however, with McArdle et al finding OSA to be 
no more common in patients with TIA than in matched controls (McArdle 2003). No 
clear pattern of CVA, in terms of location or severity has been associated with OSA. 
This, along with the finding that although there may be a reduction in central apnoeic 
events, the severity of OSA remained constant three months after a CVA, further 
suggests that OSA is a risk factor for cerebrovascular disease (Parra 2000).  
In a large population-based study, the odds ratio for CVA were raised in the highest 
AHI quartile compared to the lowest quartile (1.58 [95% CI 1.02-2.46]) (Shahar 
2001). Subsequently Yaggi et al showed that, after adjustment for known 
confounders (including hypertension), the presence of OSA was associated with a 
hazard ratio of 1.97 for the composite end point of CVA or all-cause mortality. They 
also demonstrated a dose-response effect, with those with the most severe OSA being 
at greatest risk (Yaggi 2005). This finding was made, despite the fact that a 
significant number of patients were receiving treatment for OSA. A greater than two-
fold increased stroke risk has been shown in elderly subjects with an AHI ≥30 after 
adjustment for known confounders (Munoz 2006). In the population based 
Wisconsin Sleep Cohort, an AHI ≥20 was associated with a four-fold risk of 
prevalent CVA, independently of confounders. In the prospective arm of the study, 
the odds ratio of having a first CVA during the four year follow- up was similarly 
high. However this finding failed to remain statistically significant after adjustment 
for age, sex and BMI (Arzt 2005). 
The concomitant presence of OSA and CVA leads to a poorer prognosis, both in 
terms of mortality (Parra 2004) and functional recovery (Good 1996, Kaneko 2003a). 
There is evidence from non-randomised studies to suggest that commencing CPAP 
treatment in patients with OSA following a CVA reduces subsequent CVA risk 
(Martinez-Garcia 2005, Martinez- Garcia 2012b) and in moderate to severe OSA, 
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may reduce all-cause mortality (Martinez-Garcia 2009). CPAP therapy may improve 
wellbeing (Wessendorf 2001) and in one randomised study reduced depressive 
symptoms (Sandberg 2001), but had no effect in another study (Hsu 2006). In a 
randomised study, subjects found to have OSA (AHI ≥20) after a first ischaemic 
stroke who received CPAP therapy, were more likely to have had a neurological 
improvement at one month. They also had a longer time interval before the incidence 
of subsequent cardiovascular events, but after 18 months follow-up there was no 
difference in cardiovascular mortality in those randomised to receive CPAP therapy 
(Parra 2011). Further follow-up of these patients at five years however, did show a 
reduction in cardiovascular mortality in those treated with CPAP (Parra 2014). 
It is unclear whether CPAP therapy in OSA is beneficial in terms of primary 
prevention of cerebrovascular disease due to the lack of prospective, randomised 
studies (See section 2.10 below). 
 
2.9 OSA and congestive cardiac failure (CCF) 
OSA is variably reported to be present in between 11 and 53% of patients with 
congestive cardiac failure (CCF) (McNicholas 2007), a higher proportion than the 2-
4% prevalence (Young 1993) in the general population. CSA is commoner still 
(Javaheri 1998), but further discussion of this is beyond the scope of this thesis. 
In the Sleep Heart Health Study, the odds ratio for self-reported heart failure between 
those in the highest and lowest AHI quartiles was 2.38 (95% CI 1.22-4.62) 
independently of other known risk factors (Shahar 2001). As above, OSA is an 
independent risk factor for hypertension (Stradling 2001), itself a risk factor for CCF. 
It has also been postulated that the negative intra-thoracic pressure seen during 
obstructive events may, along with the acute haemodynamic impact of such events, 
exert direct deleterious effects on the left ventricle (Hamilton 2004). CCF itself may 
predispose to the development of OSA, with the periodic breathing commonly seen 
in CCF making the pharyngeal wall more vulnerable to collapse with the subsequent 
development of obstructive apnoea (Shamsuzzaman 2003). Additionally fluid 
redistribution at night from dependant regions such as the lower limbs to the upper 
body and neck may predispose to airway collapse (Chiu 2006, Shiota 2007). 
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Animal studies show that dogs exposed to intermittent nocturnal apnoeas over 
several months had a decrease in left ventricular ejection fraction (LVEF) (Parker 
1999). Following myocardial infarction and subsequent percutaneous coronary 
intervention PCI, the presence of OSA inhibits left ventricular systolic recovery 
(Nakashima 2006). There is little evidence regarding the impact of OSA on mortality 
in CCF patients. In a study of patients with severe CCF, referred to a specialist 
centre, the presence of concomitant OSA did not increase mortality after a median of 
52 months follow-up (Roebuck 2004). However, some of the patients with OSA did 
receive CPAP therapy during the follow-up period. 
Two randomised studies have shown CPAP to improve LVEF after one and three 
months of CPAP therapy respectively, in patients with CCF and concomitant OSA 
(Kaneko 2003b, Mansfield 2004). The study by Kaneko was small, with only 12 
patients randomised to receive CPAP therapy, but also demonstrated an improvement 
in blood pressure (Kaneko 2003). However more recently Smith et al, using a 
placebo controlled cross over study design, did not show any improvement in LVEF 
after six weeks of CPAP therapy (Smith 2007). Therefore, whilst CPAP therapy may 
improve symptoms of OSA in patients with CCF, it is not clear whether it is 
beneficial in terms of measures of left ventricular function or mortality. A 
confounding issue relates to the observation that patients with OSA and CCF are 
much less likely to report EDS than patients with OSA alone (Kaneko 2003, Arzt 
2006). The reasons for this are unclear, but it is interesting to note that for any given 
AHI, patients with OSA and CCF are likely to have a lower BMI than patients with 
OSA alone (Arzt 2006). The consequence of patients being less sleepy prior to 
commencing CPAP therapy is that they may well be less compliant with CPAP 
therapy due to a lack of a perceived benefit. The absence of EDS may also mean they 
are less likely to be investigated for possible OSA in the first instance. Additionally, 
CPAP therapy has previously been shown to be ineffective in reducing blood 
pressure in OSA patients without EDS (Barbe 2001, Robinson 2006). The 




2.10 Difficulties in establishing OSA as in independent risk factor for 
CVD  
Significant difficulties exist in trying to determine whether OSA is an independent 
risk factor for CVD. OSA and CVD share numerous risk factors, the most important 
of which are likely to be increasing age, male gender and obesity (Kiely 2000, Leung 
2001, McNicholas 2007), particularly upper body obesity (Davies 1990, Ben–Noun 
2003). The number of potential shared risk factors makes accounting for these in 
study design, and hence demonstrating OSA as an independent risk factor, very 
difficult. Equally, OSA is now known to be an independent risk factor for 
hypertension (Stradling 2001), which is itself a major risk factor for most other CVD 
(Kannel 2000). Therefore, teasing out any extra risk from OSA alone is likely to be 
difficult and would require, among other things, very careful blood pressure 
matching of subjects. 
A further significant issue is the clear association between OSA and the metabolic 
syndrome. The metabolic syndrome is essentially a clustering of cardiovascular risk 
factors and in 2001 the diagnosis was defined as comprising three of the following: 
increased waist circumference, high blood pressure, increased fasting glucose, 
increased triglycerides and decreased high density lipoprotein (HDL) cholesterol 
(Cleeman 2001). Obesity (Young 1993, Young 2005), hypertension (Stradling 2001), 
insulin resistance (Ip 2002, Punjabi 2002) and dyslipidaemia (Ip 2000, Kiely 2000) 
have all individually been reported in association with OSA, leading to the 
suggestion from some that OSA could be considered a component of the metabolic 
syndrome rather than a separate disease entity (Vgontzas 2005). Coughlin et al were 
the first to examine the prevalence of all the component parts of the metabolic 
syndrome in patients with OSA (Coughlin 2004). The prevalence of the metabolic 
syndrome in patients with OSA was 87%. After adjustment for known confounders 
including BMI, patients with OSA were nine times more likely to fulfil the diagnosis 
of the metabolic syndrome than subjects without OSA. The exact mechanism behind 
this association is unclear, but hormonal control of sleep and metabolism are linked 
(McNicholas 2007) and in healthy subjects, acute hypoxia induces glucose 
intolerance (Oltmanns 2004). Further evidence of an association comes from studies 
showing that CPAP therapy is effective at improving individual components of the 
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syndrome, namely blood pressure (Stradling 2001) and HDL cholesterol (Borgel 
2006). The effect of CPAP therapy on insulin sensitivity is not clear, with some 
studies showing an improvement whilst other report no change (Punjabi 2005). This 
association between OSA and metabolic syndrome makes teasing out the relative 
contribution of OSA to CVD risk extremely difficult.  
CVD typically develops over many years and as such, long term follow up studies 
are required. Much of the evidence for an association between OSA and CVD comes 
from studies showing that patients treated with CPAP therapy suffer less CVD 
morbidity and mortality (Marti 2002, Marin 2005, Doherty 2005). Ideally, these 
would be randomised controlled studies; however given the already proven benefits 
of CPAP therapy in terms of OSA symptom control (Engleman 1999, McDaid 2009), 
it would be unethical to withhold CPAP therapy for prolonged periods of time. 
 
2.11 OSA and arterial stiffness 
Prior to starting this study, evidence was beginning to emerge that OSA was 
associated with increased arterial stiffness. Arterial stiffness, as measured by the 
augmentation index (AIx), is transiently increased during obstructive events in 
patients with OSA, in the absence of changes in non-invasively measured blood 
pressure (Jelic 2002). Philips et al subsequently showed in 57 otherwise healthy 
patients referred with suspected OSA that the AIx correlated with OSA severity 
(Phillips C 2005). Arterial stiffness, as measured by brachial-ankle pulse wave 
velocity, was shown to be higher in patients with OSA (some of whom also had 
CVD) (Nagahama 2004, Shiina 2006) and aortic distensibility was shown to be lower 
in a small group of patients with OSA (free from CVD) (Kasikcioglu 2005), as 
compared to control groups. Furthermore, in a case-control study of 30 subjects with 
OSA in the absence of CVD, Drager et al showed that aortic pulse wave velocity 
(PWV) was elevated even in patients with mild to moderate disease. They also found 
PWV to correlate significantly with OSA severity (Drager 2005). A subsequent small 
(n=17) non-randomised study of the effect of CPAP on arterial stiffness showed 
reductions in brachial-ankle pulse wave velocity after two months of treatment, 
raising the possibility that arterial stiffness may be reversed, or at least attenuated by 
CPAP (Kitihara 2006). Since starting this study, there has been an explosion of work 
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in this area, and this will be discussed along with the findings of this study in Chapter 
7. 
 
2.12 OSA and endothelial dysfunction 
Almost 20 years ago, Carlson et al reported impaired endothelial function (both 
endothelium-dependent and -independent vasodilatation) in subjects with OSA 
compared to control subjects (Carlson 1996). Endothelium–dependent vasodilatation 
was subsequently shown to be impaired in OSA in a number of studies (Kato 2000, 
Duchna 2000, Imadojemu 2002, Ip 2004, Oflaz 2006), even in those with only mild 
OSA (Duchna 2006). These studies were all small (number of patients with OSA 
ranging from 8 to 30) and reported a number of different measures of endothelium-
dependent vasodilatation including flow-mediated dilatation (Kato 2000, Ip 2004, 
Olfaz 2006, El Solh 2007), hand vein compliance (Duchna 2000,Duchna 2006) and 
venous occlusion plethysmography (Carlson 1996, Imadojemu 2002). None of these 
subsequent studies confirmed the impairment of endothelium-independent 
vasodilatation reported by Carlson et al (Carlson 1996). In a small study of male 
patients with OSA, without known CVD, endothelium-dependent vasodilatation was 
negatively correlated with the degree of nocturnal hypoxaemia (Kraiczi 2001). A 
subsequent larger study reported flow mediated-dilatation to be negatively correlated 
with the AHI, but on sub-group analysis by sex, this only remained true in females, 
with no correlation in the male population (Faulx 2004). A large population based 
study appeared to confirm these findings, with endothelial dysfunction correlating 
with measures of OSA severity including the AHI and the percentage of sleep time 
with oxygen saturations below 90% (Nieto 2004). BMI was, however, a significant 
confounder in this study and on multiple regression analysis the association 
weakened, with only the hypoxaemia index remaining significant (p=0.041). 
Proposed circulating markers of endothelial dysfunction were shown to be altered in 
patients with OSA, including soluble adhesion molecules (Ohga 1999), nitric oxide 
(Lavie 2003) and vascular endothelial growth factor (Lavie 2002) with higher 
numbers of circulating apoptotic endothelial cells noted in patients with OSA (El 
Solh 2007). 
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On the basis of these studies, and prior to commencing this study, several small 
studies had shown an improvement in endothelial function after a period of CPAP 
treatment (Duchna 2000, Imadojemu 2002,Ip 2004, Duchna 2005, Duchna 2006, 
Lattimore 2006, El Sohl 2007) ranging from two weeks (Imadojemu 2002) to six 
months (Duchna 2005) and in one case in patients with mild OSA (AHI 6.7 +/-3.8) 
(Duchna 2006). Only one of these was a randomised controlled trial and this 
additionally showed that in a subset of patients in whom CPAP therapy was then 
withdrawn for a week, endothelial function returned to baseline levels (Ip 2004).  
As with arterial stiffness, interest in the association between OSA and endothelial 
dysfunction has grown considerably since starting the study and this will be 
discussed, along with the findings of this study in Chapter 7. 
 
2.13 Mechanisms of cardiovascular damage in OSA 
 
2.13.1 Introduction 
The immediate physiological effects of OSA have been well documented for some 
time and include intermittent hypoxia, repeated arousals/sleep fragmentation and 
intra-thoracic pressure swings leading to activation of the sympathetic nervous 
system. Any causal link between OSA and CVD is likely to be multifactorial 
(McNicholas 2007), but prior to starting this study, it was felt that intermittent 
hypoxia might play the most important role (Lavie 2003, Foster 2007). The precise 
mechanisms underlying the association between OSA and CVD were (and indeed 
remain) incompletely understood, but the important biological consequences of the 
abnormal physiology seen in OSA are likely to include activation of the sympathetic 
nervous system, systemic inflammation and oxidative stress along with the metabolic 
dysregulation commonly seen in OSA.  Increased arterial stiffness and endothelial 
dysfunction are known to be precursors of overt CVD (Celermajer 1992, Reddy 
1994, Laurent 2006, Lane 2006) and as such may represent the final common 
pathway for damage to the cardiovascular system from OSA. This is represented 




Figure 2.1 Mechanisms of cardiovascular damage in OSA 
 
 
Figure 2.1 Diagram of the pathophysiological mechanisms linking OSA and cardiovascular 
disease. The broken line represents a possible link between intra-thoracic pressure changes 
and activation of the sympathetic nervous system.  
 
In the sections below, the available evidence for the potential pathophysiological 
mechanisms linking OSA and CVD at the time of starting this study will be laid out, 
with more recent studies discussed along with the findings of this study in Chapter 7. 
 
2.13.2 Intermittent hypoxia (IH) 
Unique to OSA, intermittent hypoxia (IH) refers to the repetitive episodes of 
desaturation and subsequent rapidly occurring re-oxygenation which often follow 
obstructive events. These episodes have been likened to ischaemia-reperfusion 
injuries (Ryan 2005) and unlike the well described adaptive changes associated with 
sustained hypoxia; the molecular response to IH is incompletely understood.  A 
number of deleterious consequences have been described, including activation of the 
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sympathetic nervous system, systemic inflammation and oxidative stress, and in 
animal models, exposure to chronic IH leads to sustained arterial hypertension 
(Fletcher 1992, Greenberg 1999). 
 
2.13.2.1 Intermittent hypoxia (IH) and sympathetic nervous system 
activity 
It is well recognised that the recurrent apnoeas associated with OSA lead to an acute 
increase in blood pressure that is preceded by increased sympathetic nerve activity 
(SNA) (Hedner 1988, Katraggada 1997). However, patients with OSA also have 
evidence of persistently elevated SNA as evidenced by increased urinary 
catecholamines (Fletcher 1987, Dimsdale 1995) and by directly measured muscle 
SNA (Carlson 1993, Somers 1995, Narkiewicz 1998a). Evidence for the association 
between intermittent hypoxia (IH), increased SNA and hypertension initially came 
from animal studies (Prabhakar 2005). Rats exposed to 30 days of IH, achieved by 
intermittently altering the fraction of inspired oxygen, developed significant dose-
dependent increases in arterial blood pressure compared to those kept at normoxia. 
The rise in blood pressure however, was not apparent in rats exposed to IH in whom 
the sympathetic nervous system had been inhibited, suggesting a crucial role for 
SNA in the development of hypertension (Lesske 1997, Bao 1997). Similarly, in 
dogs with a tracheostomy inserted to enable intermittent nocturnal airway 
obstruction, an elevation in day time blood pressure was seen. In the same dogs, 
subsequently subjected to sleep fragmentation under a separate protocol, but without 
airway obstruction, no increase in daytime blood pressure was seen (Brooks 1997), 
again suggesting an important role for IH. Furthermore, animals exposed to chronic 
IH show an increased sympathetic response to subsequent hypoxia (Greenberg 
1999). Healthy humans exposed to sustained or intermittent hypoxia over a 20 
minute period show evidence of increased muscle SNA, which persists for at least 20 
minutes (Morgan 1995, Xie 2000) and maybe beyond three hours (Cutler2004) after 
the cessation of hypoxia.  During voluntary breath holds and the Mueller manoeuvres 
in healthy humans, arterial blood pressure and SNA increase (Morgan 1993, 
Katragadda 1997). This increase can be abolished by ganglionic blockade of the 
autonomic nervous system with trimethaphan, again suggesting that an intact 
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sympathetic nervous system is required (Katragadda 1997). CPAP therapy has been 
shown to reduce urinary catecholamines (Hedner 1995), plasma noradrenaline 
(Heitmann 2004) and directly measured SNA (Narkiewicz 1999). CPAP however 
attenuates all of the immediate physiological effects of OSA and so this does not 
itself directly implicate IH. Further evidence for IH as an important cause of 
increased SNA comes from studies in patients with OSA in whom the increase in 
SNA was attenuated by the provision of 100% oxygen (Leuenberger 1995, 
Narkiewicz 1998b). 
 
2.13.2.2 Intermittent hypoxia (IH) and systemic inflammation 
Systemic inflammation is now recognised as playing a central role in the initiation 
and progression of atherosclerosis (Faxon 2004). C-reactive protein (CRP) is a well-
recognised marker of systemic inflammation and predicts cardiovascular risk in 
healthy subjects (Ridker 2001) and along with tumour necrosis factor α (TNFα), 
predicts future cardiovascular events in patients with underlying CVD (Lindahl 2000, 
Ridker 2000). Chronic hypoxia is associated with an elevated CRP (Hartmann 2000) 
and initial studies in patients with OSA, both with (Yokoe 2003), and without 
(Shamsuzzaman 2002) CVD, showed the CRP to be elevated and related to the 
severity of OSA, independently of the BMI (Shamsuzzaman 2002, Yokoe 2003). 
Interleukin (IL)-6, a pro-inflammatory cytokine involved in the synthesis of acute 
phase proteins including CRP, has also been shown to be elevated in OSA (Yokoe 
2003, Ciftci 2004) and both CRP and Il-6 fell with CPAP therapy (Yokoe 2003). 
This finding has not however been replicated in more recent studies. In a large study, 
Guiileminault et al did not find the CRP to be elevated in patients with OSA 
(Guilleminault 2004). Philips et al showed no change in CRP after withdrawal of 
CPAP therapy, despite confirmation of OSA recurrence and evidence of increased 
sympathetic activity (Phillips 2007).  
Further evidence for the role of IH in systemic inflammation comes from a cell 
culture model of IH. The molecular effects of chronic hypoxia are well defined and 
via the transcription factor hypoxia-inducible factor -1 (HIF-1), mediate an adaptive 
response directed at increasing oxygen delivery to the tissues (Semenza 2004). HeLa 
cells exposed to IH however appear to preferentially up-regulate pro-inflammatory 
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pathways via nuclear factor-κB (NFκB) (Ryan 2005). Furthermore, Ryan et al 
showed that TNFα (part of the NFκB -mediated inflammatory cascade) was 
increased in patients with OSA as compared to control subjects and decreased 
following 6-weeks of CPAP therapy (Ryan 2005). Other studies have reported 
similar findings (Minoguchi 2004, Ryan 2006), along with increased levels of other 
NFκB-mediated inflammatory markers such as Il-6 (Yokoe 2003, Minoguchi 2005), 
Il-8 (Dyugovskaya 2003, Ryan 2006) and intercellular adhesion molecule (ICAM)-1 
(Ohga 1999). There is evidence from human studies suggesting that the increases in a 
number of the above markers of inflammation are dose-dependent (Shamsuzzaman 
2002, Yokoe 2003, Minoguchi 2005), often using the AHI as a measure of severity. 
This however, does not necessarily imply that hypoxia is the main, or only driver of 
inflammation, as intra-thoracic pressure changes and arousals also increase with the 
AHI. In an animal model, where IH can be simulated by altering the fraction of 
inspired oxygen without inducing airway obstruction or arousal, NFκB activation has 
also been reported (Greenberg 2006) lending further weight to the theory that IH 
causes systemic inflammation. Whilst NFκB seems to be preferentially activated in 
IH, there is evidence to suggest that, as with chronic hypoxia, there is activation of 
HIF-1 pathways in patients with severe OSA-related hypoxaemia (Schulz 2002, 
Winnicki 2004). This is largely an adaptive pathway (Semenza 2004), however HIF-
1 may also have an inflammatory function (Cramer 2003).  
NFκB also mediates the expression of both tissue factor and Factor VIII, important 
components in the extrinsic and intrinsic coagulation cascades, respectively 
(Greenberg 2006). There is evidence that patients with OSA have increased blood 
viscosity, fibrinogen and platelet activation (McNicholas 2007). This, along with 
numerous studies pointing to hypercoagulability as a risk factor for CVD in the 
general population (von Känel 2003) has led to speculation that this may be a factor 







2.13.2.3 Intermittent hypoxia (IH) and oxidative stress 
Oxidative stress refers to an imbalance between the production of reactive oxygen 
species (ROS) and the antioxidant capabilities of a biological system. Under normal 
conditions, ROS have an essential signalling role. However, due to their reactive 
nature, when present in excess, ROS can directly interact with cellular components, 
leading to cellular dysfunction (Dröge 2002). Additionally, superoxide -a common 
ROS- reacts with nitric oxide (NO), diminishing the availability of NO to the 
endothelium (Beckman 1996), which may contribute to endothelial dysfunction 
(Lavie 2003). Cell culture work suggests that IH leads to increased ROS production 
(Peng 2003) and animal models of IH have demonstrated an increase in ROS and 
oxidation products (Xu 2004, Chen 2005). Markers of oxidative stress have been 
shown to be increased in patients with OSA (Schulz 2000, Dyugovskaya 2002). This 
has not however been a universal finding (Svatikova 2005, Suzuki 2006), with 
further work required to elucidate the importance of oxidative stress in the 
mechanism of cardiovascular damage in OSA. 
 
2.13.3 Sleep fragmentation/arousals 
Not all obstructive events are associated with significant oxygen desaturation, 
particularly in young, otherwise healthy patients, in whom arousals may be more 
important from a pathophysiological point of view. Obstructive events are commonly 
associated with a degree of arousal from sleep, which serves to activate the upper 
airway dilator muscle, permitting resumption of unobstructed breathing 
(Shamsuzzaman 2003). Repeated arousals lead to sleep fragmentation, sleep 
deprivation and excessive daytime sleepiness, the latter being the hallmark of 
OSAHS. During non-REM sleep, in healthy human subjects, arousal stimuli (such as 
a loud noise) are accompanied by bursts of SNA (Somers 1993a). In snorers, with 
polysomnographic evidence of frequent arousals but not OSA, hypertension was 
much commoner than in snorers with less frequent arousals (Lofaso 1996). In dogs, 
spontaneous arousals led to an increase in heart rate that could be significantly 
attenuated by sympathetic blockade, suggesting a role for arousals in SNA (Horner 
1995). This is however somewhat at odds with subsequent work in dogs exposed to 
sleep fragmentation, where no increase in blood pressure was seen (Brooks 1997) 
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and further studies are required in this area. Significantly fragmented sleep can lead 
to sleep deprivation and experimental sleep deprivation is known to affect glucose 
metabolism (Knutson 2007). Short sleep duration has been linked to obesity (Chaput 
2007, Taheri 2004) and experimental sleep restriction has been shown to be 
associated with raised inflammatory markers (Vgontzas 2004, Irwin 2006). Irwin et 
al found evidence of raised SNA, as measured by increased plasma catecholamines, 
in sleep deprivation (Irwin 1999). These studies reflect sleep deprivation rather than 
sleep fragmentation per se and the role of arousal in CVD remains unclear. 
 
2.13.4 Intra-thoracic pressure changes  
OSA leads to repetitive forced inspiration against an obstructed (or partially 
obstructed) airway, generating significant intra-thoracic pressure swings, with 
negative pressures as low as -80mmHg reported (Shiomi 1991). Negative intra-
thoracic pressure results acutely in increased left ventricular transmural pressure, 
which in turn leads to increased afterload (Buda 1979, Virolainen 1995) and 
increased myocardial oxygen demand (Bradley 2001), culminating in decreased 
stroke volume (Stoohs 1992). It remains unclear whether these acute physiological 
changes result in ventricular hypertrophy and cardiac remodelling over time. 
Intra-thoracic pressure swings also increase the pressure gradient across the aortic 
wall (Magder 1983) and this may exert shear stress upon the aortic walls. In animal 
studies, aortic diameter was acutely increased during episodes of negative intra-
thoracic pressure (Peters 1988 a and b).This along with the observation, albeit in a 
small study, that OSA is common in patients with Marfan’s syndrome (Cistulli 1993) 
and in patients presenting with dissection of the thoracic aorta (Sampol 2003) has led 
to the suggestion that negative intra-thoracic pressure may contribute to aortic 
dilatation and dissection (Cistulli 1997, Sampol 2003). More recently there has been 
increased interest in this area and this will be discussed in Chapter 7. 
It has also been postulated that intra-thoracic pressure swings may contribute to the 
increased sympathetic activity seen in OSA (Somers 1993b, McNicholas 2007). The 
autonomic response to the Mueller manoeuvre is complex, with sympathetic activity 
initially falling and subsequently increasing to more than twice the baseline levels. A 
similar magnitude of increase in sympathetic activity was seen in voluntary apnoea 
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however, albeit without the initial drop in sympathetic activity (Somers 1993b). 
Similar studies have shown an increase in sympathetic activity in both the Mueller 
manoeuvre and voluntary apnoea (Morgan 1993, Katragadda 1997). In one (Morgan 
1993), this was significantly attenuated by the application of supplemental oxygen, 
perhaps suggesting that intra-thoracic pressure change alone may not be a significant 
factor in the pathophysiology of increased sympathetic activity although further work 
is required. 
 
2.14 Impact of the acute pathophysiological consequences of OSA on 
vascular function 
In health, the vascular endothelium is primarily responsible for the regulation of 
vascular tone and haemostasis and has a number of roles in preventing vascular 
stiffening and atherosclerosis (see Sections 2.3 and 2.4). Endothelial dysfunction is 
widely recognised as a precursor to overt CVD (Celermajer 1992, Reddy 1994) and 
most CVD risk factors are known to adversely affect endothelial function (Deanfield 
2007). Accumulating evidence suggests that impairment of endothelial function and 
a reduced capability for repair are important mechanisms linking OSA and CVD 
(Kohler 2010). 
Endothelial dysfunction actually reflects an activation of the vascular endothelium 
that can be induced by a variety of stimuli. This activation is mediated by a change in 
intracellular signalling mechanisms and forms part of the acute physiological 
response to infection, but is considered abnormal if induced by pathological stimuli 
such as those encountered in OSA (Deanfield 2007). Under normal circumstances, 
the endothelium remains quiescent due to the inhibitory effects of nitric oxide (NO) 
upon inflammation, cellular proliferation and thrombosis. Integral to this inhibition is 
the s-nitrosylation of cysteine residues within a wide variety of key regulator proteins 
including the transcription factor NFκB. Pathological stimulation of the endothelium 
leads to a switch to redox signalling and mitochondrial release of ROS which react 
with cysteine groups in the same key regulator proteins leading to increased 
transcription and protein activation. Under normal conditions NO is produced by 
endothelial NO synthetase (eNOS), however following endothelial activation eNOS 
can also generate ROS, thus setting up a vicious cycle (Deanfield 2007, Feng 2010). 
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The acute pathophysiological consequences of OSA, namely intermittent hypoxia 
(IH), sleep fragmentation/arousals and intra-thoracic pressure changes, have all been 
proposed as causes of endothelial dysfunction, although the mechanisms are not fully 
elucidated (Kohler 2010, Feng 2012, Hoyos 2015). Of these, intermittent hypoxia 
(IH) has been the most studied (Feng 2012) and has been linked to endothelial 
dysfunction through oxidative stress, systemic inflammation and increased 
sympathetic nervous system activity (SNA). 
Oxidative stress secondary to IH increases the production of reactive oxygen species 
(ROS) (Peng 2003, Xu 2004, Chen 2005) which have been implicated in endothelial 
dysfunction in a number of ways. Oxidative stress acts to inhibit the phosphorylation 
of eNOS (Tanaka 2005) and may also promote the breakdown of NO (Deanfield 
2005) leading to a reduction in NO bioavailability. Additionally the oxidation of a 
crucial eNOS co-factor (tetrahydrobiopterin) leads eNOS to preferentially produce 
ROS, rather than NO (Deanfield 2007, Feng 2010). This further compounds the 
reduction in NO bioavailability and resultant endothelial dysfunction and drives 
increased oxidative stress. It is also suggested that ROS may upregulate the 
endothelial production of adhesion molecules which may then promote the migration 
of circulating leukocytes into the subendothelial space (Deanfield 2007) leading to 
structural changes within the endothelium. 
IH is associated with systemic inflammation with preferential activation of NFκB 
pathways (Ryan 2005). Evidence for inflammation of the vascular endothelium 
comes from the upregulation of COX-2 and inducible nitric oxide synthetase (iNOS) 
in endothelial cells harvested from patients with OSA compared to control subjects 
(Jelic 2008). NFκB stimulates production of circulating adhesion molecules (Kohler 
2010), which as described above can lead to structural changes within the 
endothelium.  
As described in section 2.13.2.1, IH leads to increased sympathetic nervous system 
activation (SNA) which leads to acute increases in blood pressure and sustained 
arterial hypertension, both of which have been linked to arterial stiffness and 
endothelial dysfunction (Kohler 2010).  
Other proposed mechanisms linking IH with endothelial dysfunction include the 
promotion of endothelial cell apoptosis (Feng 2012) and the release of vasoactive 
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substances such as endothelin-1 and angiotensin II, leading to vasoconstriction 
(Kohler 2010). 
Similar to IH, arousals are associated with increased SNA (Somers 1993a) and acute 
increases in blood pressure which may exert shear stress upon the vasculature 
causing endothelial damage. OSA generates significant intra-thoracic pressure 
swings (Shiomi 1991) and there is evidence from animal (Peters1988 a and b) and 
human (Stöwhas 2011) studies to suggest that the resulting shear stress has a direct 
damaging effect on vasculature.  
Repeated exposure to endothelial damage (such as that seen in OSA) can overwhelm 
the endogenous protective mechanisms within endothelial cells leading to endothelial 
dysfunction and endothelial cells damage (Deanfield 2007). Markers of such damage 
include the presence of circulating endothelial microparticles (EMPs) released from 
activated or apoptotic endothelial cells which can themselves have a direct effect 
upon endothelial function (Ayers 2013). Some studies have shown circulating EMPs 
to be increased in OSA (Ayers 2013, Trzepizur 2014), but this has not been a 
universal finding (Feng 2012). When injected into mice, EMPs from patients with 
OSA have however been shown to impair endothelial function (Priou 2010). 
Following endothelial damage, repair can occur by replication of local mature 
endothelial cells, however in the presence of on-going risk factors this is unlikely to 
be sufficient to maintain endothelial integrity. Circulating endothelial progenitor 
cells (EPCs) provide an alternative repair mechanism and can be mobilised from the 
bone marrow via a process that is in part NO-dependent (Deanfield 2007). Several 
studies have shown EPCs to be reduced in OSA, but again this has not been a 
universal finding (Feng 2012). 
As described above the known pathophysiological effects of OSA may directly 
impair endothelial function thorough a variety of mechanisms, some of which may 







2.15 Overview of Chapter 2  
The discussion above demonstrates that there is a strong association between OSA 
and CVD, but with the exception of hypertension, there is insufficient evidence to 
conclusively state that OSA is an independent risk factor for CVD. OSA appears 
to be associated with increased arterial stiffness and impaired endothelial function, 
although the evidence for this was limited prior to starting this study. The potential 
pathophysiological mechanisms of any association are likely to be complex and 
remain incompletely understood, particularly in subjects without evidence of CVD at 
the time of OSA diagnosis. CPAP therapy has been shown to lower blood pressure 
and may attenuate cardiovascular risk, but it is not clear which groups of patients are 
most likely to benefit from this.  
 
2.16 Aims of study  
Many of the studies discussed above included patients with concomitant 
cardiovascular disease and/or hypertension. Additionally, with respect to the effect of 
CPAP on arterial stiffness and endothelial function there was a paucity of placebo-
controlled randomised trial data prior to commencing this study. 
With this in mind, the main aims of this study were: 
 
1. To determine whether CPAP therapy has an effect upon measures of arterial 
stiffness and endothelial function in patients with OSA, in the absence of 
known cardiovascular disease or hypertension. 
2. To compare arterial stiffness and endothelial function in a subset of 20 
patients with OSAHS (defined as OSA plus EDS) and a group of well-









Chapter 3: Methods 
 
3.1 Introduction 
As discussed in the previous chapter, the aim of this study was to determine whether 
CPAP had any effect upon measures of arterial stiffness and endothelial function in 
patients with OSA, in the absence of known cardiovascular disease (CVD). This was 
undertaken within the context of a double-blind randomised placebo-controlled 
crossover trial. Additionally, arterial stiffness and endothelial function in a subset of 
20 patients with OSAHS (defined as OSA plus EDS) were compared with a group of 
well-matched control subjects.  
Subjects were recruited for the study between March 2007 and February 2009. The 
study was approved by the Lothian Local Research Ethics Committee and written 
informed consent was obtained from all subjects. The study is registered with the 
International Standard Randomized Controlled Trial Number Register 
(ISRCTN48783995).  
 
3.2 Study design 
 
3.2.1 The randomised placebo-controlled trial 
Eligible subjects (see Table 3.1 below for inclusion and exclusion criteria) underwent 
vascular assessments at baseline and were then randomised to receive either CPAP 
(S8 Autoset TM, ResMed, Abingdon, UK) or sham CPAP for 12 weeks before 
crossing into the second arm of the study for a further 12 weeks. Vascular 
assessments comprising measurements of arterial stiffness, endothelial function 
along with blood pressure were repeated after each arm of the study (see Figure 3.1 
below). The primary end point of the study was aortic distensibility with secondary 
endpoints of pulse wave velocity, augmentation index and endothelial function (as 
measured by the effects of salbutamol and GTN on the augmentation index). 









Figure 3.1 Flowchart of the study design. Anthropometric data, blood pressure 
measurements and ESS were also recorded at each of the three vascular assessments. 
 
Randomisation was performed by a single researcher (MV) who was not involved in 
the measurement of vascular outcomes, by means of a computer generated balanced 
block. Both the subjects and the researchers undertaking the vascular assessments 
(AJ and MC) were blinded to treatment allocation.  Unblinding occurred after all of 
the patients had completed the study and all trial data had been entered into a 




3.2.2 The case-control study 
Twenty of the patients recruited to the randomised controlled trial were matched with 
20 healthy controls (see section 3.4 below for inclusion and exclusion criteria). On 
the grounds that patients who report EDS are usually deemed to have more severe 
disease, it was decided a priori to match only patients who fulfilled the criteria for 
OSAHS (i.e. AHI  ≥15 and ESS  ≥11). On initial screening of control subjects their 
height and weight was ascertained to ensure that, assuming they remained eligible 
after polysomnography, they would be a suitable match for a subject with OSAHS. 
Controls were matched on a one-to one basis for sex, age (+/- 5 years) and BMI (+/-
10%). This was done individually for each control subject by examining their sex, 
age and BMI details against the baseline demographics of patients with OSAHS. 
Given the prevalence of undiagnosed OSA in the general population, it was 
anticipated that recruitment of matched (particularly BMI-matched) controls without 
polysomnographic evidence of OSA may be challenging. On this basis a pragmatic 
decision to match 20 subjects one-to-one with control subjects was made and this 
was not based upon a formal power calculation. 
Control subjects underwent vascular assessments (along with ESS and 
anthropometric measurements) on one occasion and this was compared to baseline 
measurements for the matched patients. Subjects and controls were matched on a 
one-to-one basis for age (+/-5 years), sex and BMI (+/-10%). 
 
3.3 Recruitment of subjects with obstructive sleep apnoea 
Consecutive subjects aged 18 years or over attending the Department of Sleep 
Medicine at the Royal Infirmary of Edinburgh were approached if they met the 








Table 3.1 Inclusion and exclusion criteria for subjects with OSA 















Potentially eligible subjects were given or posted a patient information sheet and a 
reply slip to denote interest. For patients indicating interest in participating, a 
detailed past medical history (including a smoking history) was taken, medical 
records examined and a fasting venous glucose sample was taken to ensure the 
inclusion/exclusion criteria were met. Of the 1698 patients commenced on CPAP 
during the study period, 166 were considered eligible to participate (prior to 
commencing CPAP). Of the 166 patients, 75 declined to participate or did not reply, 
with a further 38 subsequently found to be ineligible. In total, 53 patients entered the 
study (see Figure 4.1 for CONSORT diagram).  
Patients entering the study provided written consent, and a copy of this, along with a 
patient information sheet was sent to their general practitioner. Subjects and controls 






Obstructive sleep apnoea diagnosed as an AHI ≥15 on overnight polysomnography 
Exclusion criteria 
History of cardiovascular disease (including hypertension)  
History of cerebrovascular disease 
History of diabetes mellitus (type I or type II) 
History of respiratory failure 
Use of anti-hypertensive medications 
Previous CPAP use 
History of sleepiness when driving 
Professional drivers 
Contra-indications to MRI scanning (e.g. implanted metal) 
Inter-current illness 
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3.4 Recruitment of healthy controls 
In order to recruit 20 healthy controls, advertisements were placed around the 
hospital and on the hospital and university intranet requesting volunteers for the 
study. The advert did not refer to obstructive sleep apnoea.  As a result of this 73 
responses were received, of whom 12 were eligible and could be matched to patients 
with obstructive sleep apnoea/hypopnoea syndrome (OSAHS).  
Following further ethics committee approval, and with the assistance of Dr Kelly 
McGorm at the Scottish Primary Care Research Network (SPCRN), several local GP 
practices were approached to help with control recruitment. One GP practice, 
Inchpark Surgery in Edinburgh, agreed to assist and a practice database search was 
carried out for men aged between 30 and 55 who had no history of cardiovascular 
disease (including hypertension), cerebrovascular disease, diabetes mellitus or OSA. 
Information sheets and reply slips were posted out to all of the potentially eligible 
subjects. Two hundred and fifty-six letters were mailed out inviting recipients to 
consider volunteering as control subjects. We received 25 positive responses, 
following which a detailed medical history (including a smoking history) was taken 
and a fasting venous glucose sample was taken to exclude diabetes mellitus. Of the 
25, eight were eligible and could be matched to patients with OSAHS.  
Controls were subject to the same exclusion criteria as patients with obstructive sleep 
apnoea (see above). To determine eligibility, an ESS was completed (Appendix I) 
and all subjects underwent overnight polysomnography within the Department of 
Sleep Medicine. In order to participate further, controls were required to have an ESS 
of ≤10 and an AHI of <10. The decision to use this AHI cut off was a pragmatic a 
priori decision based upon the confirmed asymptomatic nature of the control 
subjects. 
 
3.5 Polysomnography (PSG) 
All patients and controls underwent attended 16-channel in-patient overnight 
polysomnography (PSG) (Compumedics Ltd., Abbotsford, Australia) performed in 
single rooms within the Department of Sleep Medicine. In patients recruited to the 
randomised control study the median time between PSG and the first vascular 
assessment was 53 days (31-185). This was principally due to delays in the reporting 
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of routine PSGs within the department of Sleep Medicine at the time this study was 
conducted. It was ascertained that all subjects remained symptomatic on the day of 
the initial vascular assessment. 
Polysomnography at this centre consists of continuously recorded 
electroencephalography (EEG), electrooculography (EOG), electromyography 
(EMG) of submentalis and tibialis muscles, oronasal flow, oxygen saturations, 
respiratory effort (thoracic and abdominal), snoring and body position. Information 
was recorded and stored using a computerised system (Compumedics Ltd) and later 
scored manually by trained sleep physiologists working within the department. Sleep 
was categorised by stage (stage I, II, III, IV, REM sleep or awake) in 30 second 
epochs using the then standard Rechtschaffen and Kales criteria (Rechtschaffen 
1968) enabling a calculation of total sleep time.  
Respiratory events were scored manually and categorised as apnoeas or hypopnoeas. 
An apnoea was defined as a reduction in airflow of ≥90% from baseline for at least 
10 seconds and a hypopnoeas as a reduction in airflow of ≥30% for at least 10 
seconds with an oxygen desaturation of ≥4% from baseline or a ≥50% reduction in 
airflow for at least 10 seconds with a ≥3% oxygen desaturation or associated arousal 
(Iber 2007). The apnoea/hypopnoea index (AHI) was then calculated as number of 
events per hour of sleep.  
 
3.6 Epworth Sleepiness Score (ESS) 
Excessive daytime sleepiness (EDS) was defined as a score of ≥11 on the Epworth 
Sleepiness Score (ESS) (Johns 1991). A copy of the ESS is found in Appendix 1. 
Subjects with OSA completed an ESS at baseline and at the end of each limb, with 
controls completing an ESS at baseline only as they were assessed only once. 
 
3.7 Anthropometric data  
Anthropometric measurements were made in all participants at baseline and after 
each limb of the study to ensure there had been no significant change in weight. 
Weight was measured using electronic scales (Seca 704, SECA, Birmingham, UK) 
and height was measured with a stadiometer (Bodycare, Warwickshire, UK) enabling 
calculation of the BMI (kg/m2). Using a cloth tape measure, neck circumference was 
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measured at the level of the crico-thyroid membrane, with waist and hip 
measurements made at the level of the umbilicus and iliac crests respectively.  
 
3.8 Serum glucose and cholesterol 
Fasting glucose and cholesterol measurements were taken in the morning and 
processed by the clinical biochemistry laboratory at the Royal Infirmary of 
Edinburgh. Serum glucose (mmol/L) was determined using a commercial kit 
(Olympus Life Science Research Europa GmbH, Munich, Germany) on an Olympus 
AU460 analyser (Olympus Analyzers, Center Valley, PA, USA). Glucose is oxidised 
by glucose oxidase into gluconic acid and hydrogen peroxide which, in the presence 
of peroxidase, reacts with 4-aminoantipyrine and hydroxybenzoic acid, forming a red 
compound. Colour intensity monitored at 500nm is proportional to the concentration 
of glucose in the sample. 
Serum cholesterol (mmol/L) was measured using a commercial kit (Alpha 
laboratories Ltd., Eastleigh, UK) adapted for use on a Cobas Fara centrifugal 
analyser (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Cholesterol is 
hydrolysed into free cholesterol and fatty acids by cholesterol esterase. Free 
cholesterol is oxidized into H2O2 and cholestene-3-one in the reaction catalysed by 
cholesterol oxidase.  Peroxidase catalyses the reaction between H2O2, 4-
aminoantipyrine and hydroxybenzoate to produce a red colour which is monitored at 
505 nm. 
 
3.9 Continuous Positive Airway Pressure (CPAP) Therapy  
 
3.9.1 Pressure titration and treatment 
Optimum CPAP pressures were determined during an overnight study using an 
automated CPAP titration device (SpiritTM, ResMEd, Abingdon, UK) within the 
Department of Sleep Medicine. During titration the pressure required to abolish 
apnoeas and hypopnoeas is recorded. The CPAP unit is usually then set at the 
pressure that which has been shown to abolish 95% of respiratory events. Mask 
fitting was undertaken by MV or specialist nurses within the department. Following 
randomisation, CPAP units (S8 AutosetTM, ResMed, Abingdon, UK) were set up 
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either at the prescribed pressure or as sham units (see section 3.9.3 below) by MV to 
maintain blinding of the chief investigator (AJ). Contact telephone numbers were 
provided to patients with details of whom to contact should they experience any 
problems. 
 
3.9.2 Choice of placebo 
There has been much debate over the years regarding the ideal placebo for trials 
involving CPAP (Karlawish 2001, Brown 2011). The Declaration of Helsinki 
permits the use of a placebo ‘Where for compelling and scientifically sound 
methodological reasons the use of placebo is necessary to determine the efficacy or 
safety of an intervention and the patients who receive placebo or no treatment will 
not be subject to any risk of serious or irreversible harm’ (WMA 2008). Evidence to 
date shows that patients with OSAHS are at increased risk of cardiovascular disease. 
Although CPAP is clearly effective in improving sleep quality and reducing daytime 
symptoms (McDaid 2009), its effect on cardiovascular disease is not yet proven 
beyond doubt. Thus, within the confines of a randomised controlled study, the use of 
a placebo is considered to be justified (Brown 2011).  
Randomising patients to receive no treatment is clearly an option, but this prevents 
the blinding of patients and researchers and may conceal a placebo-effect due to 
therapeutic CPAP. Both sham (or sub-therapeutic) CPAP (Smith 2007, Cross 2008) 
and oral placebos (Faccenda 2001, McArdle 2001) have been used successfully in 
the past in studies at this centre. Oral placebos were initially favoured in part due to 
(subsequently unfounded) concerns regarding the safety of sham CPAP (Douglas 
2002), but this requires patients to believe in the possibility of an effective drug 
treatment for OSA. Also an oral placebo does not replicate any of the potential 
mystique associated with the provision of a CPAP machine and the experience of 
wearing a mask. Sham CPAP has been shown to have a placebo-effect upon the ESS 
(Jenkinson 1999) but little (Rodway 2010) or no (Jenkinson 1999, Farre 1999) effect 
on respiratory events during sleep. For these reasons, sham CPAP is currently the 




3.9.3 Sham CPAP 
Sham CPAP was delivered using the same machine, circuit and mask as therapeutic 
CPAP (S8 AutosetTM, ResMed, Abingdon, UK) and appeared almost identical. Sub-
therapeutic pressure was achieved by setting the delivered airway pressure to a 
minimum and adding a flow-restricting connector to the machine outlet along with 
the addition of extra holes to the mask allowing air to escape and to prevent re-
breathing. This delivers a CPAP pressure at the mask of around 1cm H2O and has 
been used successfully in two previous placebo-controlled studies at this centre 
(Smith 2007, Cross 2008), a landmark study examining the effect of CPAP upon 
blood pressure (Pepperell 2002) and in the recent study of the effect of CPAP 
withdrawal (Kohler 2011). This method was chosen as pressures around 1cm H20 
have previously been shown to be ineffective in treating OSA (Jenkinson 1999). 
 
3.9.4 Compliance Monitoring 
Studies show that patients significantly over-report CPAP compliance, as do CPAP 
machines that simply record the amount of time for which the machine has been 
switched on (Sawyer 2011). In this study, compliance (with both CPAP and sham) 
was recorded by the CPAP machine as the time spent at pressure (i.e. the time spent 
actually wearing the mask) every night during the study. After each limb, this 
information was downloaded giving a very accurate measure of average nightly 
usage over each 12 week period. 
 
3.10 Assessment of vascular function 
 
3.10.1 Introduction 
In this study we non-invasively examined a number of measures of arterial stiffness 
along with endothelial function. The three measures of arterial stiffness employed 
were aortic distensibility, measured directly during cardiac magnetic resonance 
imaging (MRI), along with aortic pulse wave velocity (sometimes referred to as 
carotid-femoral pulse wave velocity and hereafter referred to as PWV in this thesis) 
and augmentation index (AIx) measured by applanation tonometry. These are 
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measures of local aortic stiffness, regional stiffness and wave reflection respectively, 
giving a comprehensive assessment of arterial stiffness throughout the arterial tree. 
All vascular studies were conducted at the same time of day (early morning) 
beginning with the cardiovascular MRI. In line with the Expert Consensus Document 
on Arterial Stiffness (Laurent 2006), subjects were asked to fast overnight prior to 
attending and to abstain from smoking, alcohol and caffeine for at least 10 hours.  
The analysis of the MRI images was performed throughout by MC (Department of 
Medical Physics, Royal Infirmary of Edinburgh) and the remainder of the vascular 
assessments were undertaken by AJ. Both AJ and MC were blind to patient treatment 
arm throughout. 
 
3.10.2 Arterial pressure waveforms and pulse wave analysis (PWA) 
The arterial pressure waveform is generated by contraction of the left ventricle and 
changes as it travels along the arterial tree (see Figure 3.2 below). In keeping with 
the propagative model of the arterial tree, the waveform is a composite of the 
forward pressure wave and the reflected wave from the periphery arising from sites 
















Figure 3.2 Schematic diagrams of the radial and corresponding aortic 
pressure waveforms 
 
  Radial waveform                                    Aortic waveform 
 
Figure 3.2 Waveform obtained at the radial pulse and the corresponding aortic waveform 
 
In young healthy subjects the reflected wave returns during diastole aiding coronary 
perfusion. As arteries stiffen, the reflected wave returns earlier in the cardiac cycle 
increasing central pressure and cardiac afterload (Weber 2004, Laurent 2006). This is 













Figure 3.3 Schematic diagrams of aortic pressure waveforms from 
‘normal’ and stiffened aortas 
 
A) ‘Normal’ aorta                                 B) Stiffened aorta 
 
Figure 3.3 Schematic diagrams of waveforms from ‘normal’ (A) and stiffened (B) aortas. In 
(A) the reflected wave returns in diastole. In (B) the reflected wave arrives earlier in the 
cardiac cycle. 
 
Whilst there has long been interest in the arterial pressure waveform, it is only since 
the development of highly sensitive micromanometer-tipped probes that accurate 
non-invasive recordings of the waveform have been possible using a technique called 
applanation tonometry. By using a micromanometer-tipped probe to flatten but not 
occlude a peripheral pulse, the circumferential pressures are equalised permitting a 
recording of the waveform similar to that obtained invasively (O’Rourke 2001).  
Once recorded, a generalised transfer function can be applied to the peripheral 
waveform giving the corresponding central waveform. The generalised transfer 
function corrects for pressure wave amplification in the upper limb and has been 
validated in a number of patient populations and haemodynamic states (Karamanoglu 
1993, Chen 1997, Pauca 2001, Sharman 2006, Payne 2010). The derived central 
waveform can then be analysed, known as pulse wave analysis (PWA), allowing the 
calculation of a number of central parameters including the augmentation index 
(AIx) which was measured in this study (see Figure 3.4 below). 
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Figure 3.4 Annotated aortic pressure waveform 
 
 
Figure 3.4 Aortic pressure waveform annotated with the components required to calculate 
the augmentation index (AIx). The augmentation pressure (AP) is the contribution that the 
reflected wave makes to systolic pressure.  The AIx is calculated as (AP/PP) x 100 and is 
expressed as a percentage 
 
3.11 Measurement of arterial stiffness 
 
3.11.1 Aortic distensibility  
Aortic distensibility was measured using cardiovascular MRI with all studies 
performed on the same 1.5 Tesla MRI (Philips Medical Systems, Best, Netherlands) 
within the Department of Radiology at the Royal Infirmary of Edinburgh. Studies 
were conducted in the supine position with images acquired during a breath-hold. 
Sagittal oblique images of the aorta were used to define planes perpendicular to the 
aortic axis for ECG-gated steady state free precession imaging with full R-R 
coverage in the ascending and descending aorta at the level of the right pulmonary 
artery and at the level of the diaphragm. 
MRI parameters were repetition time (TR) 3.2 ms, echo time (TE) 1.6 ms, in-plane 
resolution 1.5mm, slice thickness 8mm and temporal resolution 22 ms. 
Non-invasive blood pressure measurements (S/5TM monitor, Datex-Ohmeda, 
Helsinki, Finland) were taken immediately before and after the acquisition of each 
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image with the mean of the two readings used to calculate the pulse pressure. The 
minimum and maximum aortic cross-sectional areas during the cardiac cycle were 
subsequently identified by MC for all subjects using an automated edge-finding 
algorithm (EasyVision, Philips Medical Systems) and used to determine 
distensibility at each of the sites according to the formula below (Resnick 1997): 
Aortic distensibility =  (Amax-Amin)/(Amin x Pulse pressure) where Amax and Amin are 
the maximum and minimum aortic areas during the cardiac cycle. 
 
3.11.1.1 Reproducibility of aortic distensibility measurements 
Repeated aortic distensibility measurements were undertaken at each of the three 
levels in five patients during the study. These measurements were obtained under the 
same conditions and during the same MRI session as the initial measurements by 
MC. The intraclass correlation coefficient (ICC) across all three sites (15 repeat 
measurements in total) was 0.85 (95% CI 0.60-0.95); p<0.001. The number of repeat 
measurements that could be performed was limited by the availability of the MRI 
scanner. 
 
3.11.2 Aortic pulse wave velocity (PWV) 
Aortic pulse wave velocity (PWV) records the speed at which the systolic pressure 
wave reaches the peripheries. PWV is a measure of regional aortic stiffness along the 
aortic and aorto-iliac pathways, (Laurent 2006) with PWV increasing with arterial 
stiffness. PWV is reproducible (Wilkinson 1998) and considered to be the ‘gold 
standard’ measurement of arterial stiffness (Laurent 2006). PWV is an independent 
predictor of cardiovascular outcome in both high risk groups (Blacher 1999a, 
Blacher 1999b) and the general population (Willum-Hansen 2006). 
All studies were carried out in a temperature-controlled room after at least 30 
minutes rest and in accordance with the Expert Consensus Document on Arterial 
Stiffness (Laurent 2006) by a single operator (AJ). PWV was measured with the 
subject in the supine position by the sequential acquisition of carotid and femoral 
pressure waveforms  obtained during applanation tonometry at the respective pulses 
using a hand-held micromanometer (Millar Instruments, Houston Tx) connected to 
the SphygmoCor® system (version7, AtCor Medical, Sydney, Australia). 
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Waveforms were gated to the R-wave of a simultaneously recorded 
electrocardiogram and collected directly onto a laptop computer. Straight line 
distances between the sternal notch and each of the measurement sites (carotid and 
femoral) were determined using a tape measure and the path length was calculated as 
the difference between the two distances. 
After approximately 10 waveforms had been acquired at each peripheral site, the 
SphygmoCor® software identified the foot of each pulse waveform by means of the 
intersecting tangent algorithm (Chiu 1991). The mean time from the peak of the QRS 
complex of each ECG waveform and the onset of the corresponding waveform at the 
pulse site was then determined giving a mean time difference for both the carotid and 
femoral pulse sites. The mean difference in time between the two peripheral sites 
(Δt) was then used to calculate PWV as shown in the equation below. 
 
PWV =   distance travelled    m/s 
  Δt 
 
Real-time quality control information is provided by the SphygmoCor® software and 
readings were only accepted for analysis if they met the suggested quality control 
standards (AtCor). Results with a standard deviation of 15% or greater were 
excluded as were those with a standard deviation of 10-15% if the onset of the 
waveform was not clearly identified (McAllister 2007). Where possible, three 
technically acceptable PWV readings were taken at each visit and the mean used for 
analysis. An example of a PWV report generated by the SphygmoCor® software is 
included in Appendix 1. 
 
3.11.2.1 Reproducibility of PWV measurements 
In order to assess the reproducibility of PWV measurements in this study, the first 
two consecutive PWV readings taken at the baseline visits of all subjects and 
controls were examined. As will be reported later, it was not possible to obtain any 
PWV readings in four participants, and of the 69 remaining participants, 66 had at 
least two measurements of PWV taken at baseline. Therefore the ICC calculation is 
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based upon 66 pairs of measurements. The ICC was 0.95 (95% CI 0.92-0.97); 
p<0.001. 
 
3.11.3 Augmentation index (AIx) 
The augmentation index (AIx) is the difference between the first and second systolic 
peaks of the central waveform expressed as a percentage of the pulse pressure (see 
Figure 3.4 above).  The first systolic peak represents left ventricular ejection whilst 
the second is due to wave reflection from the periphery. 
AIx is a reproducible measurement (Wilkinson 1998) of wave reflection and 
indirectly of stiffness throughout the entire arterial tree. Immediately after PWV 
measurements were taken, with the patient still in the supine position, applanation 
tonometry was performed by a single operator (AJ) at the radial artery using an 
automated tonometer (CBM 7000, Colin Corp., Komaki City, Japan) connected to 
the SphygmoCor® system. In order to obtain steady waveforms, a splint was first 
applied to the subject’s wrist keeping it in a supine, extended position throughout. 
The tonometer was then attached to the wrist allowing continual radial waveform 
acquisition for determination of the AIx and subsequently for assessment of 
endothelial function (see section 3.12 below). Radial waveforms were calibrated to 
non-invasively obtained oscillometric brachial blood pressure measurements (CBM 
7000, Colin Corp., Komaki City, Japan).  
For each measurement of AIx, approximately ten sequential radial waveforms were 
averaged and a generalised transfer function (Chen 1997) was applied by the 
SphygmoCor® software giving a ‘mean’ central waveform. 
 
From this, the AIx was determined as follows:  
 
Augmentation Index (AIx) = (AP/PP) x100  and is expressed as a percentage. 
 
Heart rate has been shown to influence AIx (Wilkinson 2002a) and so all values were 
corrected by the integral software to a heart rate of 75 beats per minute. Real-time 
quality control information is provided by the SphygmoCor® software and readings 
with greater than 10% variability in pulse height or in the diastolic portion of the 
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compiled radial waveforms were excluded. Where possible, five technically 
acceptable measurements of AIx were taken approximately three minutes apart at 
each visit and the mean used for analysis. An example of a PWA report generated by 
the SphygmoCor® software is included in Appendix 1. 
 
3.11.3.1 Reproducibility of augmentation index (AIx) measurements 
To assess the reproducibility of AIx measurements in this study, baseline measures 
of AIx taken for subjects and controls were examined. 100% of participants had at 
least two baseline AIx results and therefore an ICC calculation for 73 pairs of AIx 
readings was 0.96 (95%CI 0.94-0.98); p<0.001. Fifty of the participants had five 
baseline AIx measurements and an ICC based upon this data was 0.96 (95% CI 0.95-
0.98); p<0.001. 
 
3.12 Assessment of endothelial function 
Vasomotor endothelial function was assessed non-invasively by measuring the 
endothelium-dependent effect of salbutamol (a β2-agonist) and endothelium-
independent effect of glyceryl trinitrate (GTN) on the AIx (Wilkinson 2002b, 
Hayward 2002). Endothelium-dependent vasomotion is the most widely used clinical 
end-point in the assessment of endothelial function (Deanfield 2007) and relies on 
the release of nitric oxide (NO) from an intact endothelium given the appropriate 
physiological or pharmacological stimuli. NO acts as a vasodilator for vascular 
smooth muscle and is synthesised from L-arginine by endothelial nitric oxide 
synthetase (eNOS) (Förstermann 2006). β2 agonists, such as salbutamol, are known 
to exert an endothelium-dependent effect upon the vasculature with substantial 
inhibition of β2 agonist-mediated vasodilatation in the presence of NG-monomethyl-
L-arginine, a substrate analogue inhibitor of NO synthetase (Dawes 1997, Wilkinson 
2002b). The endothelium-dependent response is often compared to the response to 
direct stimulators of vascular smooth muscle GTN, known as the endothelium-
independent response.  
Endothelium-dependent changes in AIx measured using this non-invasive technique 
are reproducible, give an assessment of global endothelial function (Wilkinson 
2002b, Hayward 2002) and correlate with invasively measured changes in forearm 
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blood flow in response to acetylcholine during venous occlusive plethysmography 
(Wilkinson 2002b). Using this technique, reductions in endothelium-dependent 
vasodilatation have been described in patients with coronary artery disease (Hayward 
2002), hypercholesterolaemia (Wilkinson 2002b) and in a group of patients (many of 
whom also had underlying cardiovascular disease) with minimally symptomatic OSA 
(Kohler 2008). 
Throughout this assessment, the calculation of AIx (corrected to a heart rate of 75 
bpm) and the technical acceptability of the measurements remained the same as 
described above (see section 3.11.3). Immediately after baseline recordings of AIx 
were obtained as detailed in section 3.11.3 above, and under the same conditions, a 
500µg tablet of GTN was given sub-lingually for three minutes and then removed. 
Based on previous research experience at this centre, the AIx was then recorded 
every minute for 10 minutes and then every 5 minutes for a further 15 minutes. The 
haemodynamic effects of GTN have previously been shown to persist for 25 minutes 
(Greig 2005) and therefore, 30 minutes after the administration of GTN, 400µg of 
inhaled salbutamol was given as two puffs (i.e. 2x200µg) via a spacer device. The 
AIx was subsequently recorded every minute for 10 minutes and then every 5 
minutes for a further 10 minutes. The response to each of the drugs was defined a 
priori as the maximum change in AIx after drug administration (Wilkinson 2002b, 
McEniery 2006). 
 
3.13 Measurement of blood pressure 
Office blood pressure and 24-hour ambulatory blood pressure were measured at 
baseline and at the end of each limb of the study (see Figure 3.1 above).  
 
3.13.1 Office blood pressure 
Office blood pressure was measured using the validated Omron 705IT (HEM 759-E) 
oscillometric device (Omron, Milton Keynes, UK) (Coleman 2006). Two 
measurements were taken after at least 30 minutes’ rest in the supine position on 
each occasion with the mean being used for analysis. Mean arterial pressure (MAP) 
was calculated in mmHg using the formula below: 
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MAP (mmHg) = 1/3 x (systolic BP-diastolic BP) + diastolic BP. 
 
3.13.2 Ambulatory blood pressure measurement (ABPM) 
Ambulatory blood pressure was measured over a 24-hour period using a SpaceLabs 
90207 (Spacelabs Medical Ltd, Hertford, UK), a validated (O’Brien 2001) 
lightweight battery powered device. The device consists of a microprocessor 
weighing 347g connected by tubing to a cuff wrapped around the upper arm. The 
monitor utilises the oscillometric method of blood pressure determination and bleeds 
pressure in discrete (approximately 4 mmHg) steps. 
On each occasion, prior to fitting, the device was initialised, enabling calibration of 
the ‘real-time’ clock and the assignment of a study number to the data collection. 
Four different cuff sizes are available for adults and the appropriate size was 
determined by first measuring the circumference of the upper limb. The cuff was 
applied to the non-dominant arm with the centre of the inflatable bladder directly 
over the brachial artery. The microprocessor was carried in a pouch attached to a belt 
around the waist. After fitting, the accuracy of the device was checked by performing 
a measurement during which the cuff was connected, via a T-tube splitter to both the 
device and a mercury sphygmomanometer, whilst auscultating the pulse at the 
brachial artery.  
The device was programmed to take a blood pressure measurement every 30 min 
during the daytime (0700 - 2159), heralded by a beep. On hearing the beep, 
participants were urged, if safe to do so, to relax their arm at their side whilst the 
measurement was taken. During the night (2200 - 0659), in order to minimise the 
effect upon sleep, readings were taken every hour and were not accompanied by a 
beep. The cuff initially inflated to 170mmHg and subsequently to 30mmHg above 
the previous reading. If a reading was unsuccessful for any reason, the device was 
programmed to attempt one further measurement approximately one minute later. If 
both readings were unsuccessful no further attempts were made until the next 
scheduled measurement. Participants were asked to continue their normal daily 
activities whilst wearing the device and to only to remove the device for the purposes 
of bathing. Instructions on how to reposition the device after bathing were provided. 
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Once returned, raw data and summary statistics were downloaded from the device 
via a PC interface. Mean ABPM was deemed suitable for further analysis if it was 
based upon at least 12 daytime and 6 nocturnal measurements. The devices were 
serviced regularly throughout the study by the Department of Medical Physics. 
  
3.14 Data analysis  
All data were entered into a database and locked before unblinding of treatment order 
occurred. Data were subsequently transferred to SPSS version 19 (IBM) for 
statistical analysis. Depending upon the distribution of the data, differences between 
treatment arms were analysed using paired t-tests or Wilcoxon signed rank tests. 
Breslow and Day emphasised the importance of using matched analyses when 
examining matched data in their text on the analysis of case-control studies (Breslow 
1980). This approach has subsequently been reinforced (Swinscow 1997, Niven 
2012), with recommendations to use the statistical tests outlined above. Repeated 
measures analysis of variance (ANOVA) was used to look for evidence of an order 
effect. Differences between patients with OSAHS and control subjects were analysed 
using paired t-tests or Wilcoxon signed rank tests depending on the distribution of 
the data, with differences in categorical data assessed using McNemar’s test.  
The unpaired t-test, Mann Whitney U test and chi-squared test were used to analyse 
baseline differences between; 1) the subset of patients with OSAHS who were 
matched in the case-control study and the 43 patients who completed the randomised 
controlled trial, 2) those who completed the randomised controlled trial and those 
who dropped out and 3) patients with and without EDS. In the case-control study, 
one way ANOVA was used to look for differences in AIx and changes in AIx after 
salbutamol according to smoking history. 
Depending on the distribution of the data, either Spearman’s rank correlation 
coefficient or Pearson correlation coefficient were used to examine the relationships 
between measures of vascular function and OSA severity. A stepwise linear 
regression analysis was performed with variables entered into the model if the initial 
significance of their correlation with the dependent variable was ≤0.05. 
Reproducibility of vascular measurements was assessed by determining the intra-
class correlation coefficient (ICC). In all analyses a p value of <0.05 was considered 
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statistically significant. Data are reported as mean (standard deviation) or median 
(interquartile range) depending on the distribution of the data. Unless stated 
otherwise, results are expressed as mean (standard deviation) throughout. 
The primary analysis of the randomised controlled trial was a modified intention-to-
treat analysis. An a priori decision was made not to impute missing data, however 
results for all subjects who attended for all three vascular assessments were analysed, 
irrespective of their compliance with CPAP (or sham CPAP) therapy. A sensitivity 
analysis of this approach in which baseline values were carried forward in patients 
who dropped out of the study was subsequently performed and is reported in Section 
4.7 
A sample size of 40 patients was determined on the basis of pilot data, to provide a 
90% chance of detecting a 10% difference in mean aortic distensibility (the primary 
endpoint of this study at a significance level of 5%. The aim had therefore been to 
recruit 60 patients into the randomised control trial to allow for dropouts. The pilot 
data was the result of a study that compared MRI-determined aortic distensibility in 














Chapter 4: Results of the Randomised Controlled Trial 
 
4.1 Recruitment and Demographics 
Of 1698 patients commenced on CPAP in the Department of Sleep Medicine during 
the study period (2007-2009), 166 were considered to be potentially eligible to 
participate. Seventy-five of these patients either did not respond to the invitation or 
declined to participate and a further 38 were subsequently found to be ineligible on 
the basis of the inclusion and exclusion criteria of the trial. In total, 53 patients 
entered the study, ten of whom subsequently dropped out, leaving 43 patients 
completing both limbs of the study and attending all three vascular assessments (see 
Figure 4.1). Of these 43, 24 had EDS and 19 did not. The mean age of patients 
completing the study was 46 (9) years and 65% of the participants were male. 
Baseline characteristics for those completing the study are shown below in Table 4.1 
below. The median AHI was 31 (IQR 20-41), indicative of moderate to severe 
disease severity. However, the 4% desaturation rate was relatively low at 9.3 (12.3) 
per hour, the mean minimum oxygen saturations were relatively high at 86.1% (5.1) 
and the mean percentage of sleep time spent with oxygen saturations below 90% was 
low at 4.4% (13.2). These patients did not experience significant nocturnal 
intermittent hypoxia. 
There were no changes in smoking status during the duration of the study. A small 
but statistically significant increase in BMI was noted in the six months between the 













Figure 4.1 Study Flowchart 
 
Figure 4.1 CONSORT diagram for the randomised controlled trial 
*Number of patients diagnosed with OSA and commenced on CPAP therapy within the 










Table 4.1 Baseline characteristics of subjects completing the study 
(n=43) 
 
Age (years) 46 (9) 
Sex 28 male 
BMI (kg/m2)* 29.9 (27.3-31.6) 
Neck circumference (cm)* 40 (37-41.5) 
Waist to hip ratio 0.95 (0.07) 
Systolic blood pressure (mmHg) 128 (13) 
Diastolic blood pressure (mmHg) 76 (9) 
MAP (mmHg) 93 (10) 
Fasting glucose (mmol/L) 4.9 (0.4) 
Total cholesterol (mmol/L) 5.3 (1.0) 
Current smokers 
Ex-smokers 
Cigarette pack year history  




On no regular medication 56 % 
Antidepressant medication 16 % 
Inhaled asthma medication 14 % 
Proton pump inhibitor medication 12 % 
Thyroxine medication 7 % 
Orlistat medication 2 % 
Non-steroidal anti inflammatory medication 2 % 
Apnoea/hypopnoea index (AHI)* 31 (20-41) 
     4% O2 desaturation rate/hour 9.3 (12.3) 
     Minimum O2 saturation (%) 86.1 (5.1) 
     TST90 (%) 4.4 (13.2) 
Epworth sleepiness score (ESS)* 13 (6-15) 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range)  
Abbreviations: body mass index (BMI); mean arterial blood pressure (MAP), percentage of 
sleep time spent with oxygen saturations of less than 90% (TST90) 
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Although it was not a formal exclusion criteria, none of the patients recruited to the 
study were receiving statin therapy.  
The ten subjects who did not complete the study were not significantly different from 
those who did (n=43) in terms of demographic data or baseline vascular function (see 
Table 4.2 below). Of those who dropped out, two received CPAP in the first limb 
and were unable to tolerate it, three were unable to tolerate sham CPAP (two of 
whom had already received therapeutic CPAP in the first limb) and a further five 

























Table 4.2 Demographic and baseline vascular function in subjects 
completing the study and those who dropped out  
 Subjects who 
dropped out of 






Age (years) 46 (9) 46 (9) 1.0 
Sex 70% male 65 % male 0.54 
BMI (kg/m2)* 30.6 (28.4-34.0) 29.9 (27.3-31.6) 0.54 
Neck circumference (cm)* 41.5 (36.8-45.1) 40 (37.0-41.5) 0.16 
Waist to hip ratio 0.97 (0.05) 0.95 (0.07) 0.34 
Systolic blood pressure (mmHg) 131 (14) 128 (13) 0.51 
Diastolic blood pressure (mmHg) 77 (7) 76 (9) 0.55 
MAP (mmHg) 95 (9) 93 (10) 0.51 
Fasting glucose (mmol/L) 4.7 (0.4) 4.9 (0.4) 0.07 
Total cholesterol (mmol/L) 5.3 (0.8) 5.3 (1.0) 0.92 
Current smokers 40 % 23 % 0.43 
Ex-smokers 40 % 23 % 0.43 
Apnoea/hypopnoea index (AHI)* 30 (24-37) 31 (20-41) 0.53 
Epworth sleepiness score (ESS) * 12 (9.5-16.5) 13 (6-15) 0.34 
AoD Ascending aorta  
(mmHg-1 x10-3) 
5.2 (2.3) 5.0 (1.9) 0.89 
AoD Descending aorta  
(mmHg-1 x10-3) 
4.4 (3.3-6.7) 4.8 (3.3-5.4) 0.53 
AoD at level of diaphragm  
(mmHg-1 x10-3) 
7.5 (3.1) 6·5 (1·9) 0.38 
PWV (m/s)   7.8 (1.7) 7.6 (1.5) 0.75 
AIx (%) 18.3 (8.2) 17.1 (11.6) 0.73 
Change in AIx (%) following 
salbutamol   
-3.0 (-8- -1.5) -4.5 (-6 - -3) 0.50 
Change in AIx (%) following GTN   -13.9 (3.6) -14.0 (4.6) 0.94 
Results presented as mean (standard deviation) unless otherwise stated. *Median 
(Interquartile range). Abbreviations: aortic distensibility (AoD); body mass index (BMI); 
mean arterial blood pressure (MAP). 
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4.2 Baseline blood pressure measurements  
Baseline office blood pressure measurements are reported above (Table 4.1). Of the 
43 patients completing the study, 38 had technically adequate 24 hour ambulatory 
blood pressure measurements (ABPM) at baseline, giving a median 24 hour systolic 
BP of 116 (113-124) mmHg, mean diastolic BP of 73 (8) mmHg and a median MAP 
of 87 (83-94 mmHg).  
Office blood pressure measurements were available for all subjects who entered the 
study at baseline and at each subsequent visit whereas the dataset of ABPM readings 
is incomplete. At baseline the reasons for missing ABPM data were as follows; 
equipment failure in one subject, three subjects removing the ABPM machine 
overnight due to concerns regarding sleep disruption and one subject who declined 
an ABPM monitor at the time it was being applied. The ability to repeat inadequate 
ABPM recordings was limited due to the availability of ABPM devices and patients’ 
other commitments.  In view of the above, office blood pressure measurements are 
presented first throughout this chapter with ABPM results shown subsequently. 
Office and ambulatory blood pressure measurements were significantly correlated for 
systolic (r=0.59; p<0.001), diastolic (r=0.60; p<0.001) and MAP readings (r=0.59; 
p<0.001) at baseline. 
 
4.3 Baseline vascular function  
Baseline measurements of arterial stiffness and endothelial function are given in 
Table 4.3 below. The images obtained during MRI scanning were of insufficient 
quality to determine aortic distensibility in the ascending and descending aorta in 
eight subjects and at the level of the diaphragm in one subject at baseline. For 









Table 4.3 Baseline vascular function in subjects completing the study 
(n=43) 
 
AoD Ascending aorta (mmHg-1 x10-3) (n=35) 5.0 (1.9) 
AoD Descending aorta (mmHg-1 x10-3) 
(n=35)* 
4.8 (3.3-5.4) 
AoD at level of diaphragm (mmHg-1 x10-3) 
(n=42) 
6.5 (1.9) 
PWV (m/s)  (n=40) 7.6 (1.5) 
AIx (%) ( n= 43) 17.1 (11.6) 
Change in AIx (%) following Salbutamol   
(endothelium-dependent) (n=43)* 
-4.5 (-6 - -3) 
Change in AIx (%) following GTN  (n=43) 
(endothelium-independent) (n=43) 
-14.0 (4.6) 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); augmentation 
index (AIx); glyceryl trinitrate (GTN) 
 
4.4 Baseline measurements in sub-groups with and without excessive 
daytime sleepiness (EDS) 
EDS (defined as an ESS ≥11) was not a requirement for recruitment to the study. Of 
the 43 subjects who completed the study, 24 had EDS and 19 did not. Those without 
EDS were older [50 (9) vs. 43 (7) years; p=0.005], but otherwise they were similar in 










Table 4.4 Baseline characteristics of subjects with and without EDS 
(defined as ESS ≥11) 
 







Age (years) 43 (7) 50 (9) 0.005 
Sex 58% male 74% male 0.29 
BMI (kg/m2)* 30.7 (27.4-35.6) 29.5 (27.1-30.4) 0.08 
Neck circumference (cm)* 40.3 (36.3-41.5) 39.5 (38.0-41.0) 0.81 
Waist to hip ratio 0.94 (0.07) 0.96 (0.07) 0.37 
Systolic blood pressure (mmHg) 127 (14) 129 (12) 0.62 
Diastolic blood pressure 
(mmHg) 
76 (10) 75 (9) 0.73 
MAP (mmHg) 93 (11) 93 (10) 0.99 
ABPM systolic blood pressure 
(mmHg) 
116 (114-124) 116 (111-124) 0.70 
ABPM diastolic blood pressure 
(mmHg) 
73 (8) 72 (8) 0.84 
ABPM MAP (mmHg) 87 (83-94) 87 (83-93) 0.87 
Fasting glucose (mmol/L) 4.9 (0.5) 4.9 (0.3) 0.73 
Total cholesterol (mmol/L) 5.3 (1.0) 5.3 (1.0) 0.81 
Current smokers 33% 11% 0.15 
Apnoea/hypopnoea index* 32 (19-41) 31 (20-49) 0.83   
     4% O2 desaturation rate/hour 7.6 (11.0) 11.3 (13.8) 0.33 
     Minimum O2 saturation (%) 86.4 (6.5) 85.8 (2.6) 0.71 
     TST90 2.7 (5.0) 6.2 (19.0) 0.39 
Epworth sleepiness score * 15 (14-18) 6 (4-8)         <0.001 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range)  
Abbreviations: ambulatory blood pressure measurement (ABPM); body mass index (BMI); 
mean arterial blood pressure (MAP); percentage of sleep time spent with oxygen saturations 
of less than 90% (TST90). 
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Sub-group analysis showed subjects with EDS to have increased distensibility in the 
ascending aorta [5.8 (1.9) vs. 4.3 (1.6); p=0.02] with a non-significant trend towards 
increased distensibility at the level of the diaphragm [7.0 (1.9) vs. 5.8 (1.9); p=0.06] 
than those without EDS (see Table 4.5). As noted above in Table 4.4, subjects 
without EDS were significantly older and as shown below (Section 4.19), 
distensibility in the ascending aorta correlated well with age in the study group 
overall, which may explain this finding. There were no other differences in arterial 
stiffness or endothelial function between the two groups at baseline (see Table 4.5). 
 
Table 4.5 Baseline vascular function in subjects with and without EDS 
(defined as ESS ≥11) 
 
 Subjects 







AoD Ascending aorta (mmHg-1 x10-3) 5.8 (1.9) 4.3 (1.6) 0.019 
AoD Descending aorta (mmHg-1 x10-3)* 4.6 (3.3-5.9) 4.8 (3.2-5.3) 0.63 
AoD at level of diaphragm (mmHg-1 x10-3) 7.0 (1.9) 5.8 (1.9) 0.06 
PWV (m/s)   7.5 (1.2) 7.9 (1.8) 0.45 
AIx (%) 18.8 (11.2) 15.1 (12.1) 0.31 
Change in AIx (%) following salbutamol * -4 (-6- -2) -5.5 (-6- -4) 0.21 
Change in AIx (%) following GTN   -14 7 (4.8) -13.0 (4.1) 0.24 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); augmentation 
index (AIx); excessive daytime somnolence (EDS); glyceryl trinitrate (GTN) 
 
4.5 Compliance with continuous positive airway pressure (CPAP) 
therapy 
There was a difference in CPAP usage between the two limbs of the study with 
subjects using CPAP for an average of 3.0 hrs per night (range 0-8.1hrs) and sham 
CPAP for an average of 2.0 hrs per night (range 0-5.8hrs); p=0.001. Compliance was 
very accurately measured as time at pressure throughout the entire study period (see 
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section 3.9.4). As discussed in Chapter 1, there is no clear cut definition of adequate 
compliance but four hours per night on 70% of nights is often quoted as being 
sufficient (Sawyer 2011). In this group, 17 patients (40%) used CPAP for four hours 
or more on average every night throughout the 12 week period. CPAP usage in this 
sub-group was 5.9 hrs per night (range 4-8.1hrs).  
CPAP usage amongst those who entered the CPAP limb first did not differ 
significantly from those who entered the sham limb first (p=0.09). Somewhat 
surprisingly, sham CPAP usage was also unaffected by the order in which the 
patients received CPAP and sham CPAP (p=0.83). Compliance with CPAP 
correlated well with compliance with sham CPAP during the study, r=0.62; p<0.001. 
There was no correlation between CPAP compliance and severity of OSA as 
measured by the AHI(r= 0.23; p=0.134). CPAP compliance in this study was 
negatively correlated with EDS as measured by the ESS (r= -0.39; p=0.009), 
suggesting that those patients who were subjectively sleepier had poorer CPAP 
compliance. CPAP compliance in subjects with an ESS ≥11 appeared lower than in 
those without EDS (ESS <11), but this was not statistically significant (p=0.06).  
 
4.6 Results of the Randomised Controlled Trial 
Across the group as a whole (n=43), the ESS fell more on CPAP than on sham CPAP 
[7 (4-11) vs. 10 (5-13); p<0·001]. In those with EDS at baseline, the ESS was 10 (7-
13) on CPAP compared to 13 (11-15) on sham CPAP (p=0.002). Those without EDS 
at baseline also had a lower ESS on CPAP than on sham CPAP [4 (2-6) vs. 5 (2-8); 
p=0.04]. Using repeated measures ANOVA, no significant treatment order effects 
were seen for any of the measured vascular variables detailed below.  
 
4.6.1 Arterial Stiffness 
The images obtained during MRI scanning were of insufficient quality to make 
comparisons of aortic distensibility in the ascending aorta in five subjects, the 
descending aorta in four subjects and at the level of the diaphragm in three subjects. 
Additionally one patient who underwent MRI scanning at baseline subsequently 
reported claustrophobia and did not undergo MRI scanning at the second and third 
vascular assessments. For reasons of body habitus it was not possible to obtain PWV 
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measurements in three subjects at the second and third vascular assessment (the same 
three subjects in whom baseline PWV measurements were not possible). In one 
subject it was not possible to obtain a radial pulse waveform of sufficient quality 
(See Chapter 3, section 3.11.3) to measure the AIx at the second vascular assessment.  
Twelve weeks of CPAP therapy did not alter aortic distensibility or PWV. There was 
a non-significant trend towards a lower AIx on CPAP than on sham CPAP (see Table 
4.6). 
 
Table 4.6 Arterial stiffness following CPAP and sham CPAP treatment 
periods 
 
 CPAP  Sham CPAP  p value 
AoD Ascending aorta  
(mmHg-1 x10-3) (n=37) 
4.9 (1.7) 5.1 (1.9) 0.44 
AoD Descending aorta  
(mmHg-1 x10-3) (n=38)* 
4.6 (3.9-5.7) 4.5 (3.7-5.1) 0.22 
AoD at level of diaphragm  
(mmHg-1 x10-3) (n=39) 
6.8 (1.9) 6.9 (2.3) 0.80 
PWV (m/s) (n=40) 7.5 (1.2) 7.6 (1.4) 0.29 
AIx (%) (n=42) 15.5 (11.9) 16.6 (11.7) 0.08 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); augmentation 
index (AIx); continuous positive airway pressure (CPAP) 
 
4.6.2 Endothelial Function  
As reported above (Section 4.6.1), it was not possible to obtain a radial pulse 
waveform of sufficient quality to measure the AIx, and hence the effect of 
salbutamol or GTN on the AIx at the second vascular assessment in one subject. 
Twelve weeks of CPAP therapy did not affect endothelial function, with no 
difference in endothelium-dependent on endothelium-independent change in AIx 
seen (see Table 4.7 below). 
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Table 4.7 Endothelial function following CPAP and sham CPAP 
treatment periods 
 
 CPAP  Sham CPAP  p value 
Change in AIx (%) following salbutamol 
(n=42)* (endothelium-dependent) 
 
-5 (-8 - -3) -4 (-6.8 - -2.5) 0·50 
Change in AIx (%) following GTN  
(n=42) (endothelium-independent) 
 
-14.1 (5.1) -15.3 (4.6) 0·13 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: augmentation index (AIx); continuous positive airway pressure (CPAP); 
glyceryl trinitrate (GTN) 
 
4.6.3 Sub-group analysis of patients using CPAP for ≥4 hours per night. 
Seventeen patients had a CPAP compliance of  ≥4 hours per night and vascular 
function results were analysed separately for these patients. Twelve weeks of CPAP 
therapy did not lead to any change in arterial stiffness or endothelial function in these 













Table 4.8 Vascular function following CPAP and sham CPAP treatment 
periods in patients using CPAP for ≥4 hours per night. 
 
 CPAP Sham CPAP p 
value 
AoD Ascending aorta  
(mmHg-1 x10-3) (n=15) 
4.9 (1.5) 5.1 (1.9) 0.59 
AoD Descending aorta  
(mmHg-1 x10-3) (n=15)* 
4.2 (3.3-4.9) 4.3 (3.4-5.1) 0.63 
AoD at level of diaphragm  
(mmHg-1 x10-3) (n=15) 
6.5 (2.0) 6.7 (2.4) 0.75 
PWV (m/s) (n=16) 7.9 (1.6) 8.1 (1.7) 0.12 
AIx (%) ( n= 17) 12.5 (12.5) 13.6 (11.1) 0.28 
Change in AIx (%) following salbutamol 
(endothelium-dependent) (n=17)* 
-5.5 (-7- -3) 3.5 (-5.5- -2.5) 0.37 
Change in AIx (%) following GTN  
(endothelium-independent) (n=17) 
-12.5 (4.37) -14.9 (4.6) 0.08 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); augmentation 
index (AIx); continuous positive airway pressure (CPAP); glyceryl trinitrate (GTN) 
 
4.6.4 Sub-group analysis of patients with and without excessive 
daytime sleepiness (EDS) 
As in the group overall, in patients with EDS there was a non-significant trend 
towards a lower AIx on CPAP than on sham [16.5 (11.4)% vs. 18.2 (11.2)%; 
p=0.058]. Aside from this there were no differences in arterial stiffness between the 






Table 4.9 Vascular function following CPAP and sham CPAP treatment 
periods in patients with EDS (n=24) 
 
 CPAP Sham CPAP p 
value 
AoD Ascending aorta (mmHg-1 x10-3) 
(n=20) 
5.5 (1.7) 6.0 (1.9) 0.12 
AoD Descending aorta (mmHg-1 x10-3) 
(n=21)* 
4.7 (3.9-6.3) 4.7 (3.8-5.5) 0.69 
AoD at level of diaphragm  
(mmHg-1 x10-3) (n=22) 
7.3 (1.9) 7.2 (2.3) 0.89 
PWV (m/s) (n=22) 7.4 (1.1) 7.5 (1.3) 0.31 
AIx (%) ( n=23) 16.5 (11.4) 18.2 (11.2) 0.058 
Change in AIx (%) following salbutamol 
(n=23)* (endothelium-dependent) 
-4.8 (-7.6- -3) -4.3 (-7- -3.4) 0.59 
Change in AIx (%) following GTN 
(n=23) (endothelium-independent) 
-14 6 (5.1) -16.2 (3.8) 0.14 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); augmentation 













Table 4.10 Vascular function following CPAP and sham CPAP treatment 
periods in patients without EDS (n=19) 
 
 CPAP Sham CPAP p value 
AoD Ascending aorta  
(mmHg-1 x10-3) (n=17) 
4.2 (1.4) 4.0 (1.1) 0.38 
AoD Descending aorta  
(mmHg-1 x10-3) (n=17)* 
4.3 (3.8-5.5) 4.3 (3.5-4.7) 0.12 
AoD at level of diaphragm  
(mmHg-1 x10-3) (n=17) 
6.2 (1.7) 6.5 (2.3) 0.54 
PWV (m/s) (n=18) 7.6 (1.4) 7.8 (1.5) 0.32 
AIx (%) ( n=19) 14.3 (12.7) 14.7 (12.3) 0.68 
Change in AIx (%) following 
salbutamol (endothelium-dependent) 
(n=19)* 
-5.5 (-8- -1.5) -4 (-6.5- -2) 0.72 
Change in AIx (%) following GTN  
(endothelium-independent) (n=19) 
-13.4 (5.2) -14.1 (5.4) 0.56 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); augmentation 
index (AIx); continuous positive airway pressure (CPAP); glyceryl trinitrate (GTN) 
 
4.6.5 Blood pressure (office and ABPM) 
Office systolic blood pressure was slightly lower on CPAP than on sham CPAP as 









Table 4.11 Office blood pressure measurements following CPAP and 
sham CPAP treatment periods (n=43) 
 
 CPAP  Sham CPAP  p value 
Systolic blood pressure (mmHg) 126 (12) 129 (14) 0·03 
Diastolic blood pressure (mmHg) 77 (8) 77 (8) 0·90 
MAP (mmHg) 94 (8) 94 (9) 0·29 
Results presented as mean (standard deviation)  
Abbreviations: continuous positive airway pressure (CPAP); mean arterial blood pressure 
(MAP) 
 
Thirty-three of the 43 patients completing the study had adequate ABPM readings in 
both the CPAP and sham CPAP limbs. Missing data was due in two cases to patients 
refusing the ABPM monitor, in six cases patients removed the cuff for significant 
periods of time resulting in insufficient data for analysis and in two cases was due to 
equipment failure. No differences in systolic, diastolic or mean arterial pressures 
were seen (Table 4.12).  
 
Table 4.12 ABPM blood pressure measurements following CPAP and 
sham CPAP treatment periods (n=33) 
 
 CPAP  Sham CPAP  p value 
ABPM systolic blood pressure 
(mmHg)* 
119 (113-127) 117 (111-127) 0.32 
ABPM diastolic blood pressure 
(mmHg) 
73 (8) 72 (8) 0.54 
ABPM MAP (mmHg)* 88 (85-95) 88 (83-96) 0.28 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: ambulatory blood pressure measurement (ABPM); continuous positive 
airway pressure (CPAP); mean arterial blood pressure (MAP) 
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When daytime (0700 – 2159) and night time (2200 – 0659) ABPM readings were 
analysed separately, no differences in systolic, diastolic or mean arterial pressures 
(MAP) between the CPAP and sham CPAP limbs were seen (see Table 4.13 below). 
 
Table 4.13 Daytime and night time ABPM results following CPAP and 
sham CPAP treatment periods 
 
 CPAP  Sham CPAP  p value 
DAYTIME (0700-2159)    
ABPM systolic blood pressure 
(mmHg)* 
124 (116-132) 123 (115-128) 0.10 
ABPM diastolic blood pressure 
(mmHg) 
78 (9) 77 (9) 0.23 
ABPM MAP (mmHg)* 94 (88-101) 94 (87-98) 0.11 
NIGHT TIME (2200-0659)    
ABPM systolic blood pressure 
(mmHg)* 
106 (103-117) 106 (102-117) 0.79 
ABPM diastolic blood pressure 
(mmHg) 
64 (8) 65 (8) 0.58 
ABPM MAP (mmHg)* 78 (74-85) 78 (74-83) 0.39 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: ambulatory blood pressure measurement (ABPM); continuous positive 
airway pressure (CPAP); mean arterial blood pressure (MAP) 
 
4.6.5.1 Sub-group analyses 
 
4.6.5.1.1 Subjects with and without EDS 
When sub-groups with and without EDS were examined separately there was no 
significant difference between office blood pressures in the CPAP and sham CPAP 
treatment periods (Tables 4.14 and 4.15). A non-significant trend towards a lower 
systolic blood pressure was noted in the group without EDS. 
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Table 4.14 Office blood pressure measurements following CPAP and 







Systolic blood pressure (mmHg) 125 (12) 128 (13) 0.16 
Diastolic blood pressure (mmHg) 78 (8) 77 (8) 0.39 
MAP (mmHg) 94 (8) 94 (9) 0.82 
Results presented as mean (standard deviation)  
Abbreviations: continuous positive airway pressure (CPAP); excessive daytime somnolence 
(EDS); mean arterial blood pressure (MAP) 
 
Table 4.15 Office blood pressure measurements following CPAP and 







Systolic blood pressure (mmHg) 127 (12) 130 (14) 0.09 
Diastolic blood pressure (mmHg) 77 (9) 77 (9) 0.56 
MAP (mmHg) 93 (9) 95 (10) 0.21 
Results presented as mean (standard deviation)  
Abbreviations: ambulatory blood pressure measurement (ABPM); continuous positive 
airway pressure (CPAP); excessive daytime somnolence (EDS); mean arterial blood pressure 
(MAP) 
 
Complete ABPM data was available for 18 patients with EDS and 15 patients 
without EDS. There were no significant differences in ABPM readings between the 
CPAP and sham CPAP treatment periods in either of these groups as shown in 





Table 4.16 ABPM measurements following CPAP and sham CPAP 




Sham CPAP p value 
ABPM systolic blood pressure 
(mmHg)* 
118 (113-128) 118 (112-127) 0.53 
ABPM diastolic blood 
pressure (mmHg) 
73 (9) 73 (8) 0.50 
ABPM MAP (mmHg)* 
 
88 (84-96) 88 (83-96) 0.46 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: ambulatory blood pressure measurement (ABPM); continuous positive 
airway pressure (CPAP); excessive daytime somnolence (EDS); mean arterial blood pressure 
(MAP) 
 
Table 4.17 ABPM measurements following CPAP and sham CPAP 




Sham CPAP p value 
ABPM systolic blood pressure 
(mmHg)* 
119 (113-125) 116 (107-127) 0.41 
ABPM diastolic blood 
pressure (mmHg) 
73 (8) 72 (8) 0.84 
ABPM MAP (mmHg)* 
 
88 (86-92) 88 (81-93) 0.42 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: ambulatory blood pressure measurement (ABPM); continuous positive 
airway pressure (CPAP); excessive daytime somnolence (EDS); mean arterial blood pressure 
(MAP) 
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4.6.5.1.2 Subjects using CPAP for ≥4 hours per night 
In those patients using CPAP for ≥4 hours per night there was no difference in office 
blood pressure (n=17) or ABPM readings (n=14) between the CPAP and sham CPAP 
treatment periods (see Table 4.18). 
 
Table 4.18 Office blood pressure and ABPM measurements following 
CPAP and sham CPAP treatment periods in patients using CPAP ≥4 




Sham CPAP p value 
Systolic blood pressure  
(mmHg) 
126 (10) 129 (11) 0.11 
Diastolic blood pressure  
(mmHg) 
77 (8) 78 (8) 0.49 
MAP (mmHg) 93 (8) 95 (9) 0.24 
ABPM systolic blood pressure 
(mmHg)* 
122 (114-128) 124 (107-129) 0.48 
ABPM diastolic blood pressure 
(mmHg)  
76 (10) 75 (9) 0.29 
ABPM MAP (mmHg)* 90 (85-97) 90 (81-98) 0.34 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: ambulatory blood pressure measurement (ABPM); continuous positive 
airway pressure (CPAP); mean arterial blood pressure (MAP) 
 
4.6.6 Association between OSA severity and vascular function 
Amongst the 53 patients with OSA who entered the randomised controlled trial there 
was no significant correlation found between any of the measures of arterial stiffness 
or endothelial function and the AHI. All measures of arterial stiffness correlated with 




Table 4.19 Association between arterial stiffness, office blood pressure 
and age amongst patients entering the study (n=53) 
 




















































Table 4.19 Values represent correlation coefficients (r). 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); augmentation 
index (AIx); blood pressure (BP); mean arterial pressure (MAP) 
 
Aortic distensibility in the ascending aorta was negatively correlated with systolic 
ABPM (r = -0.36; p=0.026) and at the level of the diaphragm with systolic ABPM   
(r = -0.48; p=0.001), diastolic ABPM (r = -0.31; p=0.043) and MAP ABPM  
(r = -0.36; p=0.016). PWV was correlated with systolic ABPM (r = 0.46; p=0.002), 
diastolic ABPM (r = 0.31; p= 0.045) and MAP ABPM (r = 0.42; p=0.016) 
There was no significant correlation between any measures of arterial stiffness and 
BMI. A weak trend was noted between PWV and fasting glucose (r = 0.26; p=0.08) 
and fasting cholesterol (r = 0.27; p=0.06) along with a weak trend between aortic 
distensibility at the level of the diaphragm and fasting glucose ( r = -0.25; p=0.08). 
Endothelial function did not correlate with age, blood pressure (office or ABPM), 




4.7 Sensitivity analyses 
Sensitivity analyses were performed for the main outcome measures of the study in 
which baseline values were carried forward in patients who dropped out of the study. 
These results of these analyses (see Table 4.20 below) were very similar to those in 
the primary analyses (see Table 4.6, 4.7 and 4.14). 
 
Table 4.20 Sensitivity analysis. Measured vascular parameters following 
CPAP and sham CPAP treatment periods using baseline values carried 
forward for subjects who did not attend for all three vascular 
assessments. 
 CPAP  Sham CPAP  p value 
AoD Ascending aorta  
(mmHg-1 x10-3)  
4.9 (1.8) 5.1 (1.9) 0.39 
AoD Descending aorta  
(mmHg-1 x10-3)* 
4.5 (3.8-6.1) 4.4 (3.5-5.3) 0.23 
AoD at level of diaphragm  
(mmHg-1 x10-3)  
7.1 (2.1) 6.9 (2.3) 0.55 
PWV (m/s)  7.6 (1.3) 7.7 (1.4) 0.15 
AIx (%)  16.1 (11.2) 17.0 (11) 0.08 
Change in AIx (%) following 
salbutamol*  
-4.5 (-8 - -2.6) -4 (-6.5 - -2.5) 0.60 
Change in AIx (%) following GTN  -14.1 (4.9) 15.1 (4.5) 0.12 
Systolic blood pressure (mmHg) 127 (12) 129 (13) 0.03 
Diastolic blood pressure (mmHg) 77 (8) 77 (8) 0.90 
MAP (mmHg) 94 (9) 95 (9) 0.29 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); augmentation 
index (AIx); continuous positive airway pressure (CPAP); glyceryl trinitrate (GTN); mean 
arterial pressure (MAP) 
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4.8 Summary of results presented in Chapter 4 
In this double-blind randomised placebo-controlled crossover trial of patients with 
OSA but without overt CVD, 12 weeks of CPAP had no significant effect upon any 
measure of arterial stiffness or endothelial function. A trend towards a lower AIx was 
seen with CPAP; however this was not statistically significant. In keeping with 
previous findings (Bazzano 2007), office systolic blood pressure was lower on CPAP 
than on sham CPAP. CPAP compliance was sub-optimal; however sub-group 
analysis of those with CPAP usage of ≥4 hours per night also showed CPAP to have 
no significant effect upon arterial stiffness or endothelial function. Sub-group 
analysis of patients with EDS showed a non-significant trend towards a lower AIx on 
CPAP, but no other improvements in arterial stiffness or endothelial function were 
seen with CPAP in this group. In the group of patients with OSA, no correlation was 
noted between arterial stiffness or endothelial function and the AHI. 
These results and those reported in Chapter 5 will be discussed in detail along with 













Chapter 5: Results of the Case–Control Study 
 
5.1 Recruitment and Demographics 
Ninety-eight positive responses were received from potential control subjects 
following the advertisements and the mail-out from the GP surgery (see Figure 5.1). 
Of these, 20 eligible control subjects were matched for age, sex and BMI on a one-
to-one basis, with a subset of 20 patients with OSAHS (defined as OSA plus EDS) 
recruited to the randomised controlled study (RCT).  
The 20 patients that we were able to match with control subjects did not differ in 
terms of demographic information from the 43 patients who completed the RCT, 
other than having a higher Epworth Sleepiness Score (ESS) (Table 5.1). Excessive 
daytime sleepiness (EDS), defined as an ESS ≥11, was a requirement for patients 
recruited to the case-control study (see Section 3.2.2), but not the RCT.  
There was no difference in measured vascular parameters at baseline between the 20 




Figure 5.1 Flowchart detailing recruitment of control subjects to the 
























19 declined to participate 
after further consideration 
25 subjects could not be 
matched to OSAHS subjects 
on 1:1 basis (matched for age, 
sex and BMI) 





Invite letters sent from GP 
practice (256 letters) 
25 positive responses 
1 subject uncontactable 
24 subjects underwent 
further screening 
15 subjects could not be 
matched to OSAHS subjects 
on 1:1 basis (matched for 
age, sex and BMI) 
 
1 subject ineligible due to: 
-PMH 
8 control subjects 
recruited 
12 control subjects 
recruited 
20 control subjects recruited 
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Table 5.1 Baseline demographics for the 20 patients with OSAHS 
matched to control subjects in the case-control study and the 43 
patients completing the randomised controlled trial (RCT) 
 








Age (years) 44 (7) 46 (9) 0.57 
Sex 65% male 65% male 0.99 
BMI (kg/m2)* 29.7 (27.4-32.7) 29.9 (27.3-31.6) 0.84 
Neck circumference (cm)* 40.5 (38.1-41.9) 40.0 (37.0-41.5) 0.39 
Waist to hip ratio 0.94 (0.07) 0.95 (0.07) 0.48 
Systolic blood pressure (mmHg) 127 (14) 128 (13) 0.87 
Diastolic blood pressure (mmHg) 76 (10) 76 (9) 0.99 
Mean Arterial Pressure (mmHg) 93 (11) 93 (10) 0.95 
Fasting glucose (mmol/L) 4.9 (0.5) 4.9 (0.4) 0.67 
Total cholesterol (mmol/L) 5.5 (1.0) 5.3 (1.0) 0.58 
Current  smokers  30% 23% 0.38 
Ex-smokers 35% 23% 0.38 
Apnoea/hypopnoea index (AHI)* 32 (22-41) 31 (20-41) 0.69 
     4% O2 desaturation rate/hour 8.1 (11.7) 9.3 (12.3) 0.73 
     Minimum O2 saturation (%) 87.4 (4.3) 86.1 (5.1) 0.33 
     TST90 (%) 1.2 (3.3) 4.4 (13.2) 0.32 
Epworth sleepiness score (ESS)* 16 (14-18) 13 (6-15) 0.002 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) 
Abbreviations: body mass index (BMI); obstructive sleep apnoea/hypopnoea syndrome 
(OSAHS); randomised controlled trial (RCT), percentage of sleep time spent with oxygen 






Table 5.2 Vascular measurements for the 20 patients with OSAHS 
matched to control subjects in the case-control study and the 43 












AoD Ascending aorta (mmHg-1 x10-3) 5.5 (1.6) 5.0 (1.9) 0.43 
AoD Descending aorta (mmHg-1 x10-3) 4.9 (1.4) 4.8 (3.3-5.4)* 0.68 
AoD at level of diaphragm (mmHg-1 x10-3) 6.9 (2.1) 6.5 (1.9) 0.40 
PWV (m/s) 6.8 (2.6) 7.6 (1.5) 0.11 
AIx (%) 19.3 (10.9) 17.1 (11.6) 0.50 
Change in AIx (%) following salbutamol -4.3 (3.2) -4.5 (-6- -3)* 0.58 
Change in AIx (%) following GTN -15.1 (5.5) -14.0 (4.6) 0.38 
Results presented as mean (standard deviation) unless otherwise stated 
*Median (Interquartile range) Abbreviations: aortic distensibility (AoD); aortic pulse wave 
velocity (PWV); augmentation index (AIx);  glyceryl trinitrate (GTN); obstructive sleep 
apnoea/hypopnoea syndrome (OSAHS); randomised controlled trial (RCT) 
 
The demographics of the subjects with OSAHS and controls subjects are shown 
below in Table 5.3. Baseline characteristics for the subjects with OSAHS and 
matched controls were similar with the exception of neck circumference. Given the 
association between neck circumference and OSA, this is unsurprising (Davies 1990, 
Davies 1992). However, BMI and waist-to-hip ratio were not statistically different 
between the groups. Blood pressure results given in Table 5.3 below reflect office 
blood pressure measurements. Ambulatory blood pressure measurements (ABPM) 
were similar in subjects with OSAHS and control subjects [systolic pressure 117 (8) 
vs. 119 (7) mmHg; p=0.54, diastolic pressure 72 (6) vs. 73 (6) mmHg; p=0.77, mean 
arterial pressure 88 (6) vs. 87 (10) mmHg; p=0.71] but complete data was only 
available for 14 of the 20 pairs. 
There were more current smokers in the OSAHS group, but this was not statistically 
significant. The number of ex-smokers was similar in each group. Cigarette pack 
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year history (amongst current and ex-smokers) was similar in subjects with OSAHS 
and control subjects [14.6 (14.5) vs. 11.4 (4.71) years; p=0.47].  
The 20 patients with OSAHS had a median AHI of 32 (IQR 22-41) which suggests at 
least moderate disease severity. The 4 % desaturation rate was however relatively 
low at 8.1 (11.7) per hour with a mean minimum oxygen saturation of 87.4 (4.3)%. 
The mean percentage of total sleep time with oxygen saturations below 90% was also 



























Table 5.3 Baseline characteristics of patients with OSAHS and controls 






Age (years) 44 (7) 44 (7) 0.94 
Sex 65% male 65% male 1.0 
BMI (kg/m2)* 29.7 (27.4-32.7) 29.4 (27.4-33.5) 0.20 
Neck circumference (cm)* 40.5 (38.1-41.9) 39.0 (36.6-41.5) 0.02 
Waist to hip ratio 0.94 (0.07) 0.93 (0.08) 0.54 
Systolic blood pressure (mmHg) 127 (14) 124 (11) 0.33 
Diastolic blood pressure (mmHg) 76 (10) 75 (9) 0.75 
Mean Arterial Pressure (mmHg) 93 (11) 91 (9) 0.42 
Fasting glucose (mmol/L) 4.9 (0.5) 4.9 (0.3) 0.68 
Total cholesterol (mmol/L) 5.5 (1.0) 5.6 (0.9) 0.79 
Current  smokers  30% 5% 0.13 
Ex-smokers 35% 40% 1.00 
On no regular medication 60% 80% 0.22 
Inhaled asthma medication 20% 5% 0.38 
Antidepressant medication 10% 5% 1.00 
Thyroxine medication 10% 5% 1.00 
Proton pump inhibitor medication 0% 5% 1.00 
Apnoea/hypopnoea index (AHI)* 32 (22-41) 4 (3-6) Part of 
selection 
criteria 
     4% O2 desaturation rate/hour 8.1 (11.7) 0.7 (0.9) 0.01 
     Minimum O2 saturation (%) 87.4 (4.3) 89.3 (2.3) 0.05 
     TST90 (%) 1.2 (3.3) 0.6 (1.5) 0.44 
Epworth sleepiness score (ESS)* 16 (14-18) 4 (2-8) Part of 
selection 
criteria 
Results presented as mean (standard deviation) unless otherwise stated. *Median 
(Interquartile range). Abbreviations: body mass index (BMI); obstructive sleep 
apnoea/hypopnoea syndrome (OSAHS), 
percentage of sleep time spent with oxygen saturations of less than 90% (TST90) 
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5.2 Arterial Stiffness 
The AIx was significantly higher in patients with OSAHS compared to control 
subjects, but no difference in PWV or aortic distensibility (at any of the three levels) 
was seen (Table 5.4).  
Several of the MRI images obtained were of insufficient quality to determine aortic 
distensibility at one or more of the three levels. This, along with one case of 
claustrophobia meant it was not possible to compare aortic distensibility in two pairs 
in the ascending aorta and in five pairs in the descending aorta and at the level of the 
diaphragm. For reasons of body habitus, PWV could only be compared in 18 of the 
20 matched pairs. 
 
Table 5.4 Arterial stiffness in patients with OSAHS and controls 
 






AoD Ascending aorta (mmHg-1 x10-3) 
(n=18) 
5.6 (1.6) 5.9 (2.4) 0.65 
AoD Descending aorta (mmHg-1 x10-3) 
(n=15) 
4.9 (1.4) 4.9 (1.4) 0.87 
AoD at level of diaphragm (mmHg-1 x10-3) 
(n=15) 
7.2 (2.2) 6.6 (2.0) 0.45 
PWV (m/s) (n=18) 7.6 (1.2) 7.4 (1.2) 0.55 
AIx (%) (n=20) 19.3 (10.9) 12.6 (10.2) 0.017 
Table 5.4 The ‘n’ value represents number of paired samples available for analysis using the 
paired t-test. The reasons for missing data are given in Section 5.2 above. Results presented 
as mean (standard deviation. Abbreviations: aortic distensibility (AoD); aortic pulse wave 
velocity (PWV); augmentation index (AIx); obstructive sleep apnoea/hypopnoea syndrome 
(OSAHS) 
 
As noted above in Section 5.1, a greater proportion of the subjects with OSAHS were 
current smokers, although this was not statistically significant. Across the group as a 
whole (n=40) no difference in AIx was seen between smokers, ex-smokers or non-
smokers (Table 5.5) 
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Results presented as mean (standard deviation) 
Abbreviation: augmentation index (AIx) 
 
5.3 Endothelial Function 
Endothelium-dependent change in AIx, a measure of vasomotor endothelial function, 
was impaired in patients with OSAHS compared to controls (p=0.02). No difference 
in endothelium-independent change in AIx was seen between the two groups (Table 
5.6). 
 
Table 5.6 Endothelial function in patients with OSAHS and controls 
 







Change in AIx (%) following 
salbutamol (endothelium-dependent 
change) 
-4.3 (3.2) -8.0 (4.9) 0.02 
Change in AIx (%) following GTN 
(endothelium-independent change) 
-15.1 (5.5) -14.1 (3.7) 0.45 
Results presented as mean (standard deviation). Abbreviations: augmentation index (AIx); 
glyceryl trinitrate (GTN); obstructive sleep apnoea/hypopnoea syndrome (OSAHS) 
 
Across the group as a whole (n=40) no difference in endothelium-dependent change 
in AIx was seen between smokers, ex-smokers or non-smokers (Table 5.7). 
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Table 5.7 The influence of smoking history on the endothelium-




















Results presented as mean (standard deviation. Abbreviation: augmentation index (AIx) 
 
5.4 Association between OSAHS severity and vascular function   
In the 20 patients with OSAHS in the case-control study, the AHI was negatively 
correlated with aortic distensibility at the level of the descending aorta (r = -0.56; 
p=0.015) and at the diaphragm (r = -0.45; p=0.049), but not at the level of the 
ascending aorta (r= -0.33; p=0.20) as shown in Figure 5.2. Fasting glucose was also 
negatively correlated with aortic distensibility in the descending aorta (r= -0.47: 
p=0.05). In a stepwise linear regression model with distensibility of the descending 
aorta as the dependent variable, and AHI and fasting glucose as independent 
variables, only AHI remained as an independent predictor (β-coefficient = -0.49; 
p=0.037). The addition of smoking status to the stepwise linear regression model did 
not alter this, with smoking status being excluded from the model (β-coefficient 
=0.12; p=0.61). There was no significant correlation between aortic distensibility at 
any of the three sites and nocturnal hypoxia; as measured by the 4% oxygen 
desaturation rate, minimum oxygen saturations or total sleep time with oxygen 
saturations below 90%. There was a non-significant correlation between aortic 
distensibility at the level of the diaphragm and the 4% oxygen desaturation rate and 







Figure 5.2 Relationship between AHI and aortic distensibility in patients 
with OSAHS 
 
Figure 5.2 Apnoea hypopnoea index (AHI) plotted against aortic distensibility as measured 
at three levels within the thoracic aorta. The broken lines represent 95% confidence intervals 
and r values represent Spearman’s rank correlation coefficients. 
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Table 5.8 Correlation coefficients for measures of nocturnal hypoxia 
and aortic distensibility (AoD) in patients with OSAHS 
 






time with O2 
saturations 
below 90% 
AoD Ascending aorta 
(mmHg-1 x10-3)  
- 0.41  
(p=0.10) 
- 0.21  
(p=0.64) 
- 0.33  
(p=0.19) 
AoD Descending aorta  
(mmHg-1 x10-3)  
- 0.39  
(p=0.14) 
- 0.14  
(p=0.62) 
- 0.38   
(p=0.15) 
AoD at level of diaphragm  
(mmHg-1 x10-3)  




- 0.48  
(p=0.07) 
Table 5.8 Values represent correlation coefficients (r). 
Abbreviations: aortic distensibility (AoD); oxygen (O2) 
 
AHI correlated non-significantly with PWV (r=0.46; p=0.055), but did not correlate 
with either AIx or endothelium-dependent change in AIx. There was no correlation 
between any measure of arterial stiffness or endothelial function and office blood 
pressure in this group of patients. Aortic distensibility at the level of the diaphragm 
(n=16) did however correlate with mean systolic blood pressure recorded during 
ABPM (r= -0.54; p=0.030). 
 
5.5 Summary of results presented in Chapter 5  
In this study of normotensive patients with OSAHS, AIx was increased and 
endothelium-dependent change in AIx was impaired when compared to well- 
matched control subjects and in the absence of overt CVD. Thus, even in the 
presence of the relatively modest nocturnal oxygen desaturation seen here, patients 
with OSAHS had evidence of increased arterial stiffness and impaired endothelial 
function. Furthermore, disease severity, as measured by the AHI, was shown to 
correlate with aortic distensibility, a measure of arterial stiffness in the descending 
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aorta and at the level of the diaphragm. These results will be discussed in detail along 
with the potential limitations of the study in Chapter 7. 
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Aortic pulse wave velocity (PWV) measured by applanation tonometry is considered 
the gold standard measurement of arterial stiffness (Laurent 2006) and as such, the 
other measurements of stiffness, namely aortic distensibility and AIx, were compared 
to this. Baseline measurements of arterial stiffness were available for 73 subjects in 
total (20 control subjects and 53 patients with OSA) and these were used for the 
analyses presented in this chapter. All 73 were free of known CVD and their baseline 
demographics and measures of arterial stiffness are shown in Table 6.1 below. 
 
Table 6.1 Demographics and baseline measures of arterial stiffness 
(n=73) 
 
Age (years) 45 (8) 
Sex 66% male 
BMI (kg/m2)* 29.8 (27.4-32.6) 
Systolic Blood pressure (mmHg) 127 (13) 
Diastolic Blood Pressure (mmHg) 76 (9) 
Mean Arterial Pressure (mmHg) 93 (10) 
PWV (m/s) (n=69) 7.6 (1.4) 
AoD Ascending aorta (mmHg-1 x10-3) (n=60) 5.3 (2.1) 
AoD Descending aorta (mmHg-1 x10-3)* (n=60) 4.8 (3.5-5.7) 
AoD at level of diaphragm (mmHg-1 x10-3) (n=65) 6.6 (2.1) 
AIx (%) ( n=73) 16.1 (10.9) 
Results presented as mean (standard deviation) unless otherwise stated  
*Median (Interquartile range) 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); augmentation 




Baseline PWV measurements were available for 69 subjects (95 %). Missing 
measurements resulted from difficulties obtaining a satisfactory pressure wave at the 
femoral pulse site due to body habitus. As reported in Chapter 3 (section 3.11.2.1), 
the intraclass correlation coefficient (ICC) for repeated PWV measurements was 0.95 
(95% CI 0.92-0.97); p<0.001. 
 
6.2 PWV compared to aortic distensibility measured using cardiac MRI 
Baseline aortic distensibility measurements were available for 60 subjects (82%) in 
the ascending and descending aorta and in 65 subjects (89%) at the level of the 
diaphragm. In two cases this was due to subjects experiencing unexpected 
claustrophobia on entering the MRI scanner. In the remainder of cases this was due 
to the quality of the MR images obtained being of insufficient quality to allow for 
distensibility calculations. As reported in Chapter 3 (Section 3.11.1.1) the ICC for 
aortic distensibility measurements across all three sites was 0.85 (95% CI 0.60-0.95); 
p<0.001. 
PWV was significantly and negatively correlated with measurements of aortic 
distensibility at each of the three measurement sites, as shown in Table 6.2 below. 
This negative correlation persisted when control subjects and patients with OSA 














Table 6.2 Correlation coefficients for comparison of PWV and aortic 
distensibility 
 
 PWV (m/s) p value 















Table 6.2 *denotes number of paired measurements available for comparison 
Values represent correlation coefficients (r). 
Abbreviations: aortic distensibility (AoD); aortic pulse wave velocity (PWV); metres per 
second (m/s) 
 
6.3 PWV compared to the augmentation index (AIx) 
Baseline AIx measurements were available in all 73 subjects at baseline. As reported 
in Chapter 3 (section 3.11.3.1), the ICC for AIx measurements was 0.96 (95%CI 
0.94-0.98; p<0.001). PWV and AIx were significantly correlated with an r value of 
0.43; p<0.001 based on 69 paired measurements (see Figure 6.1 below). The 














Figure 6.1 The relationship between PWV and AIx   
 
 
Figure 6.1 The relationship between pulse wave velocity (PWV) and the augmentation index 
(AIx). The broken lines represent 95% confidence intervals and r value represents the 
correlation coefficient. 
 
6.4 A comparison of distensibility measurements at different sites along 
the aorta 
Aortic distensibility was measured in the ascending and descending aorta (at the 
level of the right pulmonary artery) and at the level of the diaphragm. Measurements 
across all three sites showed good correlation. Distensibility in the ascending aorta 
correlated with that of the descending aorta (r= 0.74; p<0.001), and at the level of the 
diaphragm (r=0.65; p<0.001). Distensibility in the descending aorta correlated with 
that at the level of the diaphragm (r=0.68; p<0.001). 
 
6.5 Discussion of results 
In this study, three measure of arterial stiffness were made; namely aortic 
distensibility, measured directly during cardiac magnetic resonance imaging (MRI), 
pulse wave velocity (PWV) and augmentation index (AIx) both measured by 
applanation tonometry. These are measures of local aortic stiffness, regional stiffness 
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and wave reflection, respectively, providing a comprehensive assessment of arterial 
stiffness throughout the arterial tree. As this work was not the main aim of the study, 
the results are discussed here rather than in Chapter 7, the main discussion chapter. 
PWV, the gold standard measurement of arterial stiffness, is non-invasive, 
reproducible (Wilkinson 1998) and widely used. However in obese patients (Laurent 
2006) and particularly at the femoral pulse site it can be difficult to obtain pressure 
waves of sufficient quality for analysis. In determining PWV, the path length is 
usually measured externally using a tape measure and this too can be affected by 
obesity. Reproducibility in this study was high as reported above, but in four patients 
it was not possible to obtain a PWV measurement due to body habitus.  
MRI scanning is also non-invasive and as aortic distensibility can be measured 
directly, should be less influenced by issues of body habitus and as such, is 
considered free from operator bias (Oliver 2003). Measured in this way, aortic 
distensibility has previously been shown to decrease with age (Oliver 2003) and is 
lower in patients with hypertension (Resnick 1997), type II diabetes mellitus (van der 
Meer 2007), end stage renal disease (Zimmerli 2007) and more recently in moderate 
to severe OSA (Kylintireas 2012).   
Although MRI determination of aortic distensibility is a well-validated technique 
(Oliver 2003), prior to commencing this study we were not aware of any studies 
directly comparing aortic distensibility measured in this way, with the gold standard 
measurement of PWV. We found aortic distensibility at all three measurement sites 
to be significantly and negatively correlated with PWV measured by applanation 
tonometry. Since completing our study two groups have reported similar findings in 
obese subjects (Joly 2009) and a mixed group comprising patients with primary 
aldosteronism or hypertension and controls (Mark 2014). Additionally Redheuil et al 
concluded that compared to other measures of aortic function, aortic distensibility in 
the ascending aorta measured using MRI was the best marker of subclinical large 
artery stiffening in subjects under 50 years of age (Redheuil 2010). 
As reported above, the reproducibility of aortic distensibility measurements in this 
study was acceptable, but on a number of occasions it was not possible to obtain 
aortic distensibility measurements, either due to the quality of the scans or due to 
unexpected claustrophobia (which may be more likely in obese patients due to the 
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internal diameter of the MRI scanner). Additionally a number of otherwise eligible 
subjects were unable to participate in the study at all due to claustrophobia or the 
presence of implanted/embedded metallic foreign bodies. Despite the above noted 
benefits, these issues, along with the financial costs associated with MRI scanning 
are likely to currently limit the measurement of aortic distensibility to research 
studies or exceptional circumstances. 
It is not always possible, particularly in obese subjects, to obtain PWV measurements 
(Bakker 2011), with pressure waves at the femoral pulse presenting the greatest 
problem in this study. AIx is however determined, using a generalised transfer factor, 
from the radial pressure wave. The radial pulse is usually relatively superficial and 
easy to palpate, even in obese subjects and accordingly AIx measurements were 
available for all 73 subjects at baseline. Measurement of AIx is relatively 
straightforward and as it is obtained at the wrist, is easier for patients to undergo than 
a PWV measurement, making it ideal for use in large numbers of patients. 
PWV and AIx are not interchangeable terms, although AIx is in part dependent on 
PWV. PWV is a direct measure of regional aortic stiffness along the aortic and aorto-
iliac pathways, recording the speed at which the systolic pressure wave reaches the 
peripheries (Laurent 2006). AIx is a measure of arterial wave reflection and as such 
is an indirect measure of stiffness throughout the entire arterial tree (see Chapter 3, 
sections 3.11.2 and 3.11.3 for further details of PWV and AIx). A higher PWV 
results in the reflected wave arriving earlier, leading to increased AIx during early 
systole (Kelly 2001). AIx has been shown, in a large meta-analysis, to be predictive 
of cardiovascular events and all-cause mortality (Vlachopoulos 2010). In this study, 
PWV and AIx were significantly correlated overall and this remained the case when 
subjects with OSA and control subjects were examined separately. This is in keeping 
with a previous large study in healthy adults (McEniery 2005), as well as in smaller 
studies of patients with CVD and controls (Yasmin1999, Woodman 2005). This has 
not however been a universal finding, with several studies finding no association 
between PWV and AIx (Vyas 2007, Lemogoum 2004). As described above, AIx is a 
composite measure of wave reflection comprising not only arterial stiffness, but also 
the magnitude and timing of the reflected wave and additionally is influenced by 
heart rate, height and left ventricular function (Protogerou 2007). McEneiry et al 
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reported that age-related changes in AIx and PVW were non-linear with age, 
affecting the AIx more in subjects aged under 50 years with changes in PWV more 
prominent in older subjects (McEneiry 2005), suggesting the involvement of more 
than one physiological process. Subjects in this study were relatively young and 
when considered overall (n=73) or separately (i.e. subjects with OSA, subjects with 
OSAHS and control subjects), had PWV values falling within the recently published 
‘normal’ range based upon their mean ages and blood pressures (Boutouyrie 2010). 
In conclusion, in this study all three measures of arterial stiffness were reproducible, 
but unlike AIx, measurements of PWV and aortic distensibility were not always 
technically possible. Both aortic distensibility and AIx were well correlated with 














Chapter 7: Discussion of findings 
 
7.1 Summary of the key findings   
This study shows that patients with OSAHS have evidence of increased arterial 
stiffness and impaired endothelial function compared to well-matched controls, even 
in the absence of cardiovascular disease (CVD) or hypertension. The median AHI in 
this study suggested at least moderate to severe disease, but patients did not 
experience significant nocturnal hypoxia. This is important as intermittent hypoxia 
(IH) has been postulated as the most important factor in any causal link between 
OSA and CVD (Lavie 2003, Foster 2007), and this will be discussed below. 
Despite the findings of the case-control study (Chapter 5), in a larger group of 
patients with OSA (also without CVD or hypertension), 12-weeks of CPAP therapy 
in the context of this randomised placebo-controlled trial, did not lead to an 
improvement in any measure of arterial stiffness or endothelial function. Sub-group 
analysis similarly showed CPAP to have no significant effect upon arterial stiffness 
or endothelial function in subjects with excessive daytime sleepiness (EDS) or those 
with CPAP compliance of ≥4 hours per night. As was previously described in the 
early randomised controlled trials (Faccenda 2001, Pepperell 2002) and subsequently 
confirmed in large meta-analyses (Bazzano 2007, Haentjens 2007, Schein 2014), 
CPAP therapy did effect a small reduction in blood pressure. 
The implications of these results will be discussed below in the context of the other 
published work in this area, along with the limitations of this study and suggestions 
for future work. 
 
7.2 Findings of the case-control study  
 
7.2.1 OSAHS is associated with increased arterial stiffness 
Patients with OSAHS had increased arterial stiffness, as measured by the 
augmentation index (AIx), compared to well-matched control subjects. Additionally 
aortic distensibility was negatively correlated with the AHI.  
Prior to starting this study, there had been several reports of increased arterial 
stiffness in patients with OSA, as measured by ankle-brachial pulse wave velocity 
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(Nagahama 2004, Shiina 2006), aortic distensibility (Kasikcioglu 2005) and PWV 
(Drager 2005). Since then, there has been an explosion of work in this area, with a 
recent review highlighting 23 subsequent studies examining the relationship between 
OSA and a variety of measures of arterial stiffness (Phillips 2013b). Nineteen of 
these studies reported results for either AIx, aortic distensibility or PWV, all three of 
which were measured in this study. Four of the five studies measuring AIx reported a 
higher AIx in patients with OSA compared to control subjects (Phillips C 2005, 
Noda 2008, Kohler 2008a, Buchner 2012). However all of these studies included at 
least some subjects with either CVD or hypertension. The severity of OSA in these 
studies varied and this is discussed below in the context of the disease severity 
reported in the study presented in this thesis. 
Importantly, the study presented in this thesis is the first to examine the effect of 
OSAHS on AIx in subjects without known CVD or hypertension. It is difficult to 
adequately match patients with varying degrees of CVD and the exclusion of such 
patients is likely to reduce confounding. Additionally, control subjects were true 
controls recruited from the community (as opposed to being subjects who had been 
found not to have OSA after referral to a sleep clinic, as is often the case in the 
literature) without evidence of EDS and who subsequently underwent full 
polysomnography to exclude OSA. 
One previous study did not find the AIx to be raised in subjects with OSA (Yim-Yeh 
2010). In that study, obese but otherwise healthy subjects were recruited from the 
community and underwent polysomnography. Those with an AHI ≥10 were deemed 
to have OSA (irrespective of symptoms) with those with an AHI of less than 10 
forming the control group, and in this respect the study was quite different from the 
work in this thesis. In the study by Yim Yeh et al, subjects with OSA were older, had 
higher blood pressure, a greater waist-to-hip ratio, a higher HbA1c and were more 
likely to be male than the control group. However despite this, they did not find AIx 
to be increased in subjects with OSA. However, it must be noted that in the study by 
Yim Yeh et al, although the mean AHI was 23, an AHI of ≥10 was considered to 
represent OSA and at this lower level would represent very mild disease. The authors 
suggest that their findings might reflect the inclusion of females (studies in this area 
often exclude or contain very few females), the raised BMI or the exclusion of 
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subjects with known CVD. Given that our study included a similar percentage of 
female subjects and that the mean AIx was similar (19.6% vs. 16.2% in their study) it 
is tempting to speculate whether the lack of EDS in the study by Yim Yeh et al may 
be an important factor. The importance of EDS in the association between OSA and 
CVD is unclear, with evidence of increased CVD risk associated with EDS of any 
cause in older people (Newman 2000) and a recent meta-analysis suggesting that 
CPAP is ineffective in reducing blood pressure in patients with OSA in the absence 
of EDS (Bratton 2014). This issue will be addressed in detail with reference to the 
results of the randomised controlled trial in Section 7.4.4 below. 
An unintended consequence of excluding patients with CVD and hypertension was 
that subjects eligible for our study had milder disease in terms of nocturnal hypoxia, 
than often appears in publications in this area. Whilst the median AHI [32 IQR (22-
41)] in patients with OSAHS indicated moderate to severe disease, nocturnal hypoxia 
was relatively mild, with a 4 % desaturation rate of 8.1 (11.7) per hour, mean 
minimum oxygen saturations of 87.4% (4.3%) and a mean of only 1.2% (3.3%) of 
sleep time with oxygen saturations less than 90%. This level of hypoxia is relatively 
modest compared to that reported in previous studies and probably reflects the 
relative youth of subjects in our study and the exclusion of patients with a history of 
respiratory failure or CVD. Indeed with a 4% desaturation rate of 8.1, irrespective of 
symptoms, a diagnosis of OSAHS may not have been made on the basis of oximetry 
alone in many of these cases. Kohler et al found the AIx to be increased in subjects 
with minimally symptomatic OSA (i.e. in the absence of EDS) (Kohler 2008a). OSA 
was diagnosed by Kohler et al on the basis of the ODI, with a mean ODI of 23.1, 
suggesting more severe hypoxia than seen in the study presented in this thesis. 
Similarly, a higher 4% desaturation rate than seen in our study was reported by 
Phillips et al (Phillips C 2005) and in a subsequent study, sleep time with oxygen 
saturations of less than 90% was 18.3% (Buchner 2012). In the other study reporting 
an increased AIx in patients with OSA (Noda 2008), the overall mean severity of 
OSA (either in terms of AHI or nocturnal hypoxia) was not reported. 
Despite relatively modest nocturnal hypoxia, and in the absence of known CVD, 
patients with OSAHS had a higher AIx than well-matched controls in our study. The 
absolute difference in AIx between patients with OSAHS and controls was 6.7% 
120 
[19.3 (10.9) vs. 12.6 (10.2)] which is likely to be of clinical significance. AIx is a 
reproducible measurement of wave reflection, and reflects arterial stiffness 
throughout the entire arterial tree (Wilkinson 1998). In this study, measurement of 
AIx was possible in all patients, even in the presence of significant obesity. AIx has 
been shown to predict cardiovascular disease (Weber 2004) and a recent meta-
analysis reported that an absolute increase in AIx of 10% leads to a 26% increase in 
cardiovascular events and a 38% increase in all-cause mortality (Vlachopoulos 
2010). 
In this study, aortic distensibility in the descending aorta and at the level of the 
diaphragm was negatively correlated with the AHI, with a non-significant trend 
towards a correlation between aortic distensibility at the level of the diaphragm and 
measures of nocturnal hypoxia. Prior to starting this study, it had been hypothesised 
that additional effects on the structure and function of the thoracic aorta may be seen 
due to intra-thoracic pressure swings during obstructive events leading to shear stress 
(Cistulli 1997, Sampol 2003). Furthermore, two studies (Kasikcioglu 2005, 
Tanriverdi 2006) the latter of which excluded patients with CVD and hypertension, 
had reported that aortic distensibility, determined at echocardiogram, was reduced in 
patients with OSA. Tanriverdi et al also showed, as in our study, that aortic 
distensibility was negatively correlated with the severity of sleep apnoea (Tanriverdi 
2006). Serizawa et al reported an increase in the diameter of the ascending aorta in 
patients with OSA (Serizawa 2008) and subsequent work using MRI scanning in 
healthy volunteers demonstrated changes in proximal aortic diameter during 
simulated hypopnoeas (but not apnoeas) (Stöwhas 2011). In the study presented in 
this thesis, despite finding a negative correlation between aortic distensibility and the 
AHI, aortic distensibility was not lower in patients with OSA compared to well-
matched controls. Four further studies have been published examining the aortic 
distensibility in patients with OSA, all of whom included some patients with CVD or 
hypertension. Three of these studies found distensibility was lower in patients with 
OSA (Tavil 2007, Keles 2009, Kylintireas 2012), with a fourth reporting no 
independent effect of OSA upon aortic distensibility (Lee 2010). In the one other 
study to use cardiovascular magnetic resonance imaging (MRI) to directly determine 
aortic distensibility, distensibility was lower in patients with OSA and correlated 
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with the ODI, although this did not retain significance following multivariate 
analysis (Kylintireas 2012). That study differed from our study in that subjects with 
CVD or hypertension were not excluded. As has been discussed above, patients 
recruited to the study presented in this thesis, had milder OSAHS than is often 
reported in the literature, particularly with regard to levels of nocturnal hypoxia, 
which may at least in part explain this finding. Additionally, with the exception of 
the study by Keles et al, the mean ages of subjects in the studies examining aortic 
distensibility in patients with OSA and controls were higher than the patients in the 
case-control study reported in this thesis [mean age 44(7) years]. This is important as 
aortic distensibility decreases with age (van der Heijden-Spek 2000) and certainly 
when all the participants entering the randomised controlled trial were considered 
together (n=53), baseline distensibility at each of the three measured sites was 
significantly inversely correlated with age (see Chapter 4, section 4.6.6). It is 
possible that any effect of OSAHS on the aorta might be more significant in the 
presence of an already stiffened aorta. The relatively young age of the subjects in our 
study also means that they are likely, on average, to have had undiagnosed OSAHS 
for less time than older subjects included in the studies above, and therefore it is 
possible that it may be too early to detect a deleterious effect on the aorta in these 
patients. 
Unlike a number of previous studies we did not find PWV to be higher in patients 
with OSAHS (Phillips 2013b). However this has not been a universal finding, with 
two studies also reporting no difference (Korcarz 2010, Tonini 2010). With the 
exception of the study by Drager et al (Drager 2005), published before the start of 
this study, all of the subsequent studies have included at least some patients with 
CVD or hypertension. Indeed, although Drager et al showed PWV to be higher in 
subjects with severe OSA, defined as an AHI of ≥30 (but with a mean AHI of 55.7 
and almost a third of sleep time spent with oxygen saturations less than 90%), 
compared to control subjects, they did not find PWV to be higher in subjects with 
mild-moderate disease, in keeping with the findings presented in this thesis. In our 
study there was a non-significant correlation between AHI and PWV (r=0.46; 
p=0.055). Drager et al did find PWV to be correlated with the AHI and this may 
reflect the inclusion of patients with more severe OSA. However it should also be 
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noted that despite the exclusion of patients with known cardiovascular disease, 
hypertension and diabetes mellitus (as in our study), values for PWV were much 
higher, with a mean value of >10m/s compared to a mean of 7.6m/s in this study. 
Recently published ‘normal’ values for PWV (Boutouyrie 2010) suggest that the 
mean PWV measured in the work presented here falls within the normal range based 
upon the mean age and blood pressure of the group and this may further explain the 
lack of difference seen between OSAHS patients and controls. The evidence for this 
normative data comes from a group of non-smoking subjects without overt CVD, 
hypertension, diabetes mellitus or dyslipidaemia (n=1455). In that cohort however, 
patients were not screened for the presence of OSA and given the prevalence figure 
of 20% for OSA in the general population (Young 2002a), many of the ‘normal’ 
subjects would be expected to have evidence of OSA at polysomnography. Chung et 
al also found increased PWV in severe OSA, but did not find it to be increased in 
patients with mild to moderate disease (Chung 2010). Thus it would appear that mild 
to moderate OSA, in the absence of significant hypoxia and pre-existing 
cardiovascular disease, is not associated with increased PWV.  
AIx, PWV and aortic distensibility are all measures of arterial stiffness. Although 
AIx and PWV have been shown in a number of studies, as in this study (see Section 
6.3), to be positively correlated (Yasmin 1999, Woodman 2005, McEniery 2005), 
they are not interchangeable. This is important with regard to the results of the study 
presented in this thesis and when comparing studies of differing measurements of 
arterial stiffness. PWV is considered to be the gold standard measurement of arterial 
stiffness, measuring regional vessel stiffness in the aorta which leads directly on 
from the left ventricle. As such, aortic stiffness is responsible for many of the 
pathophysiological effects of arterial stiffness (Laurent 2006). Arterial stiffness as 
measured by PWV has been well studied and has been shown, in a number of 
populations, to predict cardiovascular morbidity and mortality (Blacher 1999a, 
Blacher 1999b, Willum-Hansen 2006). AIx is a measure of wave reflection 
throughout the arterial tree and therefore is an indirect measure of global arterial 
stiffness, and has been shown to predict CVD and death (Vlachopoulos 2010).  
AIx therefore, unlike PWV or aortic distensibility, is a composite measure of 
stiffness in both the elastic and more peripheral arteries and as described in Chapter 2 
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(section 2.3), stiffness in the peripheries is primarily modulated by vasomotor tone, 
which is in part influenced by endothelial function. As discussed below in section 
7.2.2, patients with OSAHS had evidence of impaired endothelial function and this 
may have contributed to the finding that arterial stiffness as measured by AIx, but not 
PWV or aortic distensibility, was increased in OSAHS patients. 
Although AIx was found to be higher in subjects with OSAHS, the mean values for 
AIx and PWV in both patients with OSAHS and controls are similar to previously 
published ‘normative’ data (McEniery 2005, McEniery 2006, Boutouyrie 2010, 
Janner 2010). In a large study of over 4000 subjects, age-related changes in AIx and 
PVW were non-linear with age, affecting the AIx more in subjects aged under 50 
years with changes in PWV more prominent in those over 50 years (McEneiry 2005). 
This non-linear relationship between age and measures of arterial stiffness has now 
been confirmed in a number of studies (Mitchell 2004, Wojciechowska 2006, Janner 
2010) with a plateau in AIx noted at around 60 years of age (Janner 2010). This has 
led to the suggestion that AIx may be a more sensitive marker of arterial ageing in 
younger subjects (McEneiry 2005, Janner 2010). The mean age of subjects in the 
case-control study was 44 years and it may be that at this relatively young age, AIx is 
a better marker of increased arterial stiffness than PWV.  
Less is known about the prognostic significance of aortic distensibility, although this 
is a direct measure of local aortic stiffness following on from the left ventricle. A 
recent large study of 2122 subjects without overt CVD (other than hypertension) 
showed aortic distensibility to predict cardiovascular morbidity and mortality over a 
mean follow-up period of 7.8 years. After adjustment for known cardiovascular risk 
factors, aortic distensibility remained a significant predictor of non-fatal 
cardiovascular events with hazard ratio of 1.45 (95% CI 1.18-1.78; p<0.0005) per 
standard deviation change in aortic distensibility (Maroules 2014). 
 
7.2.2 OSAHS is associated with impaired endothelial function  
In this study endothelium-dependent vasodilation was significantly impaired in 
patients with OSAHS, suggesting that even in patients with relatively mild disease 
and in the absence of known cardiovascular disease there is evidence of endothelial 
dysfunction. Endothelial dysfunction predicts future cardiovascular disease in a 
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variety of high risk patient groups and in healthy controls. It has been proposed as a 
key mechanism linking OSA and CVD (Kohler 2010, Hoyos 2015). Prior to starting 
this study, a number of small studies had reported endothelial dysfunction in patients 
with OSA (Kato 2000, Duchna 2000, Imadojemu 2002, Ip 2004, Oflaz 2006) and in 
a small study, endothelial function correlated with nocturnal hypoxia (Kraiczi 2001). 
Since then there has been a rapid expansion of work in this area, with a recent review 
identifying 35 studies (including this one) measuring endothelial function in adult 
patients with OSA compared to control subjects (Hoyos 2015). The overwhelming 
majority of these studies have shown, using a variety of means of assessing 
vasomotor endothelial function, that OSA is associated with impaired endothelial 
function. Only a minority of these studies have definitely excluded patients with 
CVD and hypertension and in doing so in the study presented here, the potential for 
confounding due to underlying CVD is reduced. The majority of studies to date have 
used flow mediated dilatation (FMD) to measure endothelial function. Although 
FMD is a non-invasive means of assessing endothelium-dependent vasodilation, it 
requires a highly skilled operator and expensive equipment (Stoner 2012). Changes 
in brachial artery diameter are determined using ultrasound following the reactive 
hyperaemia seen after a period of ischaemia (Lekakis 2011). Vasomotor endothelial 
function can also be assessed by measuring the effects of beta-2 agonists and GTN 
upon the AIx as used in this study (see Sections 2.4 and 3.12 for further details). 
Although a relatively novel technique prior to starting our study, this method of 
using beta-2 agonists to assess endothelium-dependent vasodilation had been shown 
to be reproducible (Wilkinson 2002B, Hayward 2002) and correlated with invasively 
measured endothelial function measured at venous occlusion plethysmography 
(Wilkinson 2002B). Blunting of the AIx response to beta-2 agonists has been shown 
in conditions known to be associated with endothelial dysfunction, including diabetes 
mellitus (Chowienczyk 1999), coronary artery disease (Hayward 2002), 
hypercholesterolaemia (Wilkinson 2002b) and peripheral vascular disease (Kals 
2006). Using the same technique, Kohler et al showed that endothelial function is 
impaired in subjects with minimally symptomatic OSA (and in many cases 
concomitant CVD or hypertension). In that same study, FMD was also impaired in 
patients with OSA (Kohler 2008a). Changes in AIx following salbutamol 
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administration reflect global endothelium-dependent vasodilation (Hayward 2002) 
and the work in this thesis shows, for the first time, an impairment of endothelial 
function measured in this way, in patients with OSAHS, but without underlying 
CVD or hypertension. 
In our study, endothelial function did not correlate with measures of OSAHS 
severity. A number of previous studies have reported a correlation between 
endothelium-dependent vasodilation and AHI and measures of nocturnal hypoxia 
(Hoyos 2015). This has not however been a universal finding with several other 
clinic-based studies finding no association (Kato 2000, Kohler 2008a). In a large 
population based study, FMD correlated with AHI and measures of nocturnal 
hypoxia, however when adjusted for BMI, the association was no longer significant 
overall, persisting only in the subset of patients with concomitant hypertension 
(Nieto 2004). Similarly, no association between FMD and severity of OSA was seen 
in a subsequent population-based study (Chami 2009). Given the population-based 
nature of these studies, the median AHI was low and it has been speculated that this, 
along with the associated lack of nocturnal hypoxia, may explain this finding (Hoyos 
2015). However, the results presented here show impairment of endothelial function 
in relatively young patients with only very mild nocturnal hypoxia. It is nonetheless 
difficult to compare clinic- and population-based studies as it may be that for any 
given AHI, subjects who present to a sleep service may differ from those who do not.  
In particular it is speculated that those who present to a sleep service are more likely 
to be experiencing EDS (Young 2002), the importance of which in the association 
between OSA and CVD in unclear and is discussed further in Section 7.4.4. They 
may also differ in other, as yet unidentified ways. 
That we found evidence of impaired endothelial function (and arterial stiffness) in a 
relatively young group of patients is perhaps not surprising, given that several studies 
have shown that the association between OSA and hypertension is greatest in 
younger patients (Bixler 2000, Grote 2000, Nieto 2000). More recently, two studies 
examining endothelial function in OSA have also concluded that the effect of OSA 
on endothelial function is greatest in younger patients (Chung 2009, Yim Yeh 2010). 
This would be in keeping with the idea that OSA may appear phenotypically 
different at different ages. As discussed in Section 1.7.2, the aetiology and clinical 
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features of OSA may be different in an older population (Launois 2007, Edwards 
2014). 
Endothelium-independent vasodilation (measured as the change in AIx following the 
administration of GTN) is primarily mediated by vascular smooth muscle and was 
not impaired in patients with OSAHS in our study. Despite an initial report to the 
contrary (Carlson 1996) and one subsequent study showing impaired endothelium-
independent vasodilation in subjects with moderate to severe OSA (Butt 2011), the 
other studies in which it has been measured, have also reported endothelium-
independent vasodilation to be unaffected in patients with OSA (Hoyos 2015).  
 
7.3 Pathophysiological implications of the main findings of the case-
control study 
Arterial stiffness and endothelial dysfunction represent pre-clinical CVD and as 
discussed in Chapter 2 (Sections 2.3 and 2.4), have been shown to predict 
cardiovascular morbidity and mortality. Thus, the finding that there is evidence of 
increased arterial stiffness and endothelial dysfunction in patients with OSAHS, in 
the absence of known CVD or hypertension has important implications, not least 
with regard to the potential for early therapeutic intervention. 
Much of the previous work in this area is potentially confounded by the inclusion of 
patients with underlying CVD. OSAHS is common, affecting 2-4 % of the 
population and OSA is commoner still with prevalence rates of 20% and as such any 
association with CVD has significant public health implications. As previously 
discussed in Chapter 2, any causal link between OSA and CVD is likely to be 
multifactorial and the pathophysiological mechanisms still remain incompletely 
understood. The acute effects of OSA include intermittent hypoxia, repeated 
arousals/sleep fragmentation and intra-thoracic pressure swings (McNicholas 2007). 
The subsequent biological consequences of which are likely to include activation of 
the sympathetic nervous system, systemic inflammation and oxidative stress. Based 
largely upon cell culture (Ryan 2005) and animal models (Fletcher 1992, Greenberg 
1999, Prabhakar 2005) prior to starting this study it was generally accepted, albeit 
with much of the evidence showing an indirect association, that intermittent hypoxia 
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(IH) was the most important mechanism underlying any link between OSA and CVD 
(Lavie 2003, Foster 2007) and this remains the case (Levy 2013).  
Animal models, although enabling IH to be studied separately from the arousals and 
intra-thoracic pressure changes seen in OSA, are not perfect models of OSA-related 
IH (Foster 2007) and in cell culture models the duration and severity of IH may be 
greater than that seen in OSA (Ryan 2005). More recent work in healthy humans 
exposed to more physiologically relevant IH over an eight hour period at night (i.e. 
IH more closely resembling that seen in OSA) demonstrated an increase in diurnal 
blood pressure and sympathetic activity after one night, with a further increase after 
two weeks of nocturnal exposure (Tamisier 2011). Additionally, healthy males 
exposed to six hours of IH (whilst awake) for four consecutive days had increased 
plasma levels of markers of oxidative stress, which returned to normal after the 
period of exposure to IH had ceased (Pialoux 2009).Using the same model Foster et 
al showed increased blood pressure and decreased nitric oxide bioavailability after 4 
days, which improved following removal of IH (Foster 2009). However, despite the 
undoubted importance of IH, patients in the study presented in this thesis had 
demonstrably stiffer arteries and impaired endothelial function in the absence of 
significant nocturnal hypoxia.  
Recent work by Jafari et al confirmed the presence of endothelial dyfunction in 
patients with OSA, but this was independent of the degree of nocturnal hypoxia 
(Jafari 2013). If the only important driver of any association between OSA and CVD 
was IH, then it might reasonably be expected that nocturnal supplemental oxygen 
might be effective in reducing CVD risk. Gottlieb et al randomised 318 patients with 
moderate to severe OSA to receive healthy lifestyle and sleep education alone or in 
combination with either CPAP therapy or supplemental oxygen therapy, with indices 
of nocturnal hypoxia similarly improved in both the CPAP and supplemental oxygen 
arms of the study (Gottlieb 2014). Despite this, and the higher reported adherence in 
subjects receiving supplemental oxygen, only the subjects receiving CPAP therapy 
experienced a (small) reduction in blood pressure after 12 weeks, confirming the 
results of a previous, smaller study (Norman 2006). The mean ESS at baseline of 
those receiving CPAP and supplemental oxygen were 8 and 9.6 respectively, 
suggesting that patients were not particularly symptomatic. The authors do not report 
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whether any of the interventions led to a symptomatic improvement. Limited sleep 
studies were performed at baseline and after 12 weeks, so the authors were not able 
to draw further conclusions regarding the importance or otherwise of intra-thoracic 
pressure swings or arousal/sleep fragmentation in their study. 
The evidence above suggests that the other acute effects of OSA, namely 
arousals/sleep fragmentation and intra-thoracic pressure swings may also play an 
important role. As discussed above (Section 7.2.1) there has been recent interest in 
the possibility of direct shear stress to the aorta caused by intra-thoracic pressure 
swings and further work is required in this area. Additionally little is known about 
the effect of intra-thoracic pressure swings on the sympathetic nervous system (see 
Section 2.13.4). 
Although previous studies had linked arousal/sleep fragmentation to increased 
sympathetic nervous system activity (Somers 1993a, Horner 1995), evidence for a 
possible link with CVD came largely from studies of sleep deprivation (Irwin 2006, 
Chaput 2007, Knutson 2007). More recently, evidence largely from observational 
studies, suggest that sleep fragmentation due to non-respiratory sleep disorders may 
be associated with hypertension (Walters 2009, Batool-Anwar 2009). In a recent 
large (n=780) population study of older individuals (mean age 68.7 years) without 
known coronary artery disease, sleep fragmentation was associated with increased 
diurnal blood pressure (Chouchou 2013). This association was independent of other 
confounders, including indices of sleep disordered breathing. Additionally the 
measured arousal index was associated with an increase in sympathetic nervous 
system activity as measured by pulse transit time and heart rate variability 
(Chouchou 2103). Similarly in a large population sample (n=1021) drawn from the 
Wisconsin Sleep Cohort, the sleep fragmentation index (defined as the number of 
awakenings and transition to stage I sleep from deeper NREM or REM sleep per 
hour of sleep) was associated with awake systolic blood pressure in subjects without 
evidence of sleep disordered breathing (AHI <1), suggesting an independent role for 
arousals in the aetiology of hypertension (Morrell 2000). There is limited evidence to 
suggest that the sympathetic nervous system may be implicated in vascular 
remodelling (Schiffrin 2002), and in a small study of healthy subjects, stimulation of 
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the sympathetic nervous system led to an acute impairment of endothelial function 
(Hijmering 2002). 
The results of the case-control study presented in this thesis are important and raise a 
number of issues which are summarised below: 
1. In the absence of known CVD or hypertension, subjects with OSAHS are at 
increased risk of CVD. This adds to the evidence base in this area, but of 
course this study cannot exclude the possibility of CVD as an epiphenomenon 
of OSA, for example due to obesity or underlying genetic factors. Subjects 
and controls were well matched for BMI and waist-to-hip ratio, but neck 
circumference in patients with OSAHS was higher raising the possibility of 
increased central obesity (see Section 7.5 for further discussion of this). 
2. Subjects with OSAHS have evidence of increased arterial stiffness and 
impaired endothelial function even in the absence of significant nocturnal 
hypoxia. On the basis of what is often indirect evidence, the dominant 
paradigm is that IH is the most important pathophysiological link between 
OSA and CVD. This study suggests that other mechanism such as intra-
thoracic pressure swings and sleep arousal/fragmentation may play an 
important role and should be given greater consideration. 
3. Given the lack of nocturnal hypoxia in these patients and despite being 
symptomatic (all had EDS), many of them would not have been diagnosed 
with OSAHS on the basis of oximetry alone. This is important as even this 
relatively young group, free from known CVD, have evidence of subclinical 
CVD, as evidenced by increased arterial stiffness and impaired endothelial 
function compared to well-matched controls. Such patients may benefit 
symptomatically from CPAP treatment. These findings underline the 
importance, particularly in young, otherwise healthy patients of being able to 
measure obstructive events and arousals that are not associated with 
significant hypoxia. 
4. The subjects in the case-control study may not traditionally have been 
considered to be at significant CV risk given their relatively young age, 
absence of cardiovascular comorbidity and lack of significant nocturnal 
hypoxia. However despite this they have been shown to have evidence of 
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arterial stiffening and endothelial function. This underlines the importance of 
looking for and addressing other modifiable cardiovascular risk factors in all 
patients with OSAHS. 
 
7.4 Results of the randomised controlled trial  
In the context of the placebo-controlled randomised trial, 12 weeks of CPAP therapy 
did not lead to a significant improvement in any measure of arterial stiffness or 
endothelial function in subjects with OSA (in the absence of known CVD or 
hypertension). A trend towards a lower AIx with CPAP therapy was seen, but this 
was non-significant. This, despite having shown in the case-control study in subjects 
with similarly mild nocturnal hypoxia (see Table 4.4) that arterial stiffness was 
increased and endothelial function was impaired in patients with OSAHS. As has 
been previously shown in a number of studies (Bazzano 2007, Haentjens 2007, 
Schein 2014), CPAP therapy did lead to a small reduction in blood pressure. No 
significant correlation was seen amongst patients who entered the randomised 
controlled trial between any measure of arterial stiffness or endothelial function and 
severity of OSA. A small, but statistically significant rise in BMI was noted between 
the first and third visits. In an attempt to reduce confounding, a cross-over design 
was employed and patients with known CVD, hypertension and diabetes mellitus 
(DM) were excluded from the study. 
 
7.4.1 CPAP therapy is not associated with a reduction in arterial 
stiffness in patients with OSA 
Prior to commencing this study, one non-randomised study had reported a reduction 
in brachial-ankle pulse wave velocity with CPAP therapy (Kitihara 2006). However, 
a recent review identified 12 subsequent intervention studies investigating the effect 
of CPAP therapy on arterial stiffness (Phillips 2013b), with further studies published 
since then (Chung 2011, Litvin 2013, Kohler 2013, Kartali 2014). Only two of these 
studies reported no effect of CPAP on arterial stiffness (Bakker 2011, Kohler 2013), 
although in a further three studies, a reduction in arterial stiffness was only seen in 
patients deemed ‘compliant’ (detail of what constituted acceptable compliance were 
only stated in one of the studies) with CPAP therapy (Phillips 2013b).  
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Importantly, there have only been three randomised controlled studies comparing 
CPAP therapy with control (Drager 2007, Kohler 2008b, Kohler 2013) and only one 
of these excluded patients with CVD and hypertension (Drager 2007). Drager et al 
randomised 24 patients with severe OSA to receive either CPAP therapy or no 
treatment for four months. PWV fell in all twelve CPAP treated patients, with a 
mean reduction of 1.1m/s with no change in PWV seen in the control group. This is a 
clinically significant reduction, with a recent meta-analysis suggesting that a 1 m/s 
reduction in PWV leads to a 14% decrease in cardiovascular events (Vlachopoulos 
2010). Similarly Kohler et al randomised 102 patients with moderate to severe 
OSAHS to receive either CPAP therapy or sham CPAP (as used in our study) and 
showed a significant reduction in the AIx from 14.5% to 9.1% (Kohler 2008b). 
Approximately a quarter of patients in that study had pre-existing treated 
hypertension and significantly more of those receiving CPAP therapy had known 
coronary artery disease than those receiving sham CPAP (7.4% vs. 0%; p=0.04). 
Evidence of EDS was not an inclusion criterion in the first of these studies (Drager 
2007), but the mean ESS in subjects receiving CPAP therapy was raised at 14/24. 
EDS was a requirement for entry into the study by Kohler et al (Kohler 2008b). 
More recently however, the same author found no change in the AIx in patients 
without evidence of EDS randomised to CPAP therapy (Kohler 2013), despite the 
previous finding by the same group that AIx was higher in subjects with minimally 
symptomatic OSA (Kohler 2008a). In the above intervention studies Kohler et al 
have shown that CPAP improved arterial stiffness in one group of patients, but not in 
the other. The two study populations differed in a number of ways, not least in the 
presence (Kohler 2008b) or absence (Kohler 2013) of EDS and in terms of reported 
CPAP compliance (4.7 hours determined as CPAP use on the last night of the study 
vs. 2.8 hours). Those treated with CPAP in the former study (Kohler 2008b) also had 
a higher baseline AHI (41.9 vs. 9.5), were younger (48.7 vs. 58.4 years) and had a 
lower baseline AIx (14.5 vs. 27.9 %) than those in the subsequent study (Kohler 
2013). Additionally there were almost twice as many subjects receiving treatment for 
hypertension in the later study than in the former. Whilst the presence or absence of 
EDS may be important in the efficacy of CPAP in effecting an improvement in 
arterial stiffness, as it appears to be for improving blood pressure, the higher CPAP 
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compliance in the former study (Kohler 2008b) may well be important. Additionally 
the subjects with EDS were younger and healthier and had more severe OSA and 
thus it could be argued that OSA (and hence its treatment with CPAP) may have 
played a more significant role in measured arterial stiffness than in the older, more 
hypertensive subjects without EDS. 
Evidence from two reviews (Doonan 2011, Phillips 2013b) and one meta-analysis 
(Vlachantoni 2012) suggests that in the majority of studies to date, CPAP therapy has 
a beneficial effect upon arterial stiffness. The fact remains however that until now 
there had only been one randomised controlled study in patients without underlying 
CVD or hypertension (Drager 2007). Indeed only one other study definitely excluded 
patients with CVD and hypertension and was a small non-randomised study (n=27) 
showing a reduction in arterial stiffness measured by the cardio-ankle vascular index 
(Kasai 2011). The possible reasons for the discrepancy between the results of the 
study resented in this thesis and previously published work will be considered below 
in section 7.4.3.  
 
7.4.2 CPAP therapy is not associated with an improvement in 
endothelial function in patients with OSA  
Before commencing this study there had been one randomised controlled trial (Ip 
2004) and several non-randomised studies showing that CPAP had a beneficial effect 
upon endothelial function. As with arterial stiffness, there has been an explosion of 
work in this area with a recent review identifying 30 (including the research 
presented in this thesis) studies reporting on the effect of CPAP therapy on 
endothelial function (Hoyos 2015). These studies have employed a number of 
different techniques for assessing endothelial function and the authors of the review 
sub-divide studies into those examining endothelial function in the micro-vasculature 
or macro-vasculature. The two are not interchangeable (see Section 2.4), but have 
both been shown to correlate to coronary artery endothelial function (Anderson 1995, 
Bonetti 2004) and will be considered together here. 
The review identified 21 non-randomised studies, 11 of which definitely excluded 
patients with CVD and hypertension. The majority of these assessed endothelial 
function by FMD and the vast majority of studies reported an improvement in 
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endothelial function following CPAP therapy, with duration of therapy between 1 
night and 26 weeks. Two studies however, only reported an improvement in 
endothelial function in patients with CPAP compliance of ≥4 hours per night (Jelic 
2008, Jelic 2010). Most of these studies comprise small numbers of patients with an 
‘n’ of between 6 and 50 patients. Interestingly the largest non-randomised study 
(n=50) is one of only two studies to find that CPAP therapy was not associated with 
an improvement in endothelial function. Shiina et al did not find any improvement in 
venous occlusion plethysmography following three months of what is described as 
‘optimal’ CPAP therapy (average compliance not stated) despite demonstrating a 
reduction in brachial-ankle pulse wave velocity over the same time period (Shiina 
2010). Similarly, in a much smaller study of 8 CPAP-compliant subjects without 
CVD, Jelic et al found no improvement in FMD after 4 weeks of CPAP therapy 
(Jelic 2009).  
As would be expected, there have been fewer randomised control studies in this area 
and because of the cross-over design, the study presented in this thesis reports 
findings for the largest number of subjects to receive CPAP therapy and is only the 
second randomised study to definitely exclude subjects with CVD or hypertension. 
The first by Ip et al showed an improvement in FMD in 14 male patients with 
moderate to severe OSA, randomised to receive CPAP therapy (average compliance 
4.3 hours per night) for four weeks (Ip 2004). In a subset of eight patients (AHI not 
stated) using CPAP for more than three months, FMD measurements were made one 
week after CPAP withdrawal, at which time endothelial function was impaired and 
similar to baseline readings. Similarly, in a subset of patients from the MOSAIC 
study, Kohler et al showed an improvement in FMD in 31 patients with minimally 
symptomatic (and rather mild) OSA randomised to receive CPAP (Kohler 2013). 
The overall median CPAP compliance in the MOSAIC study was 2.84 hours per 
night. Compliance in the subjects in whom FMD was measured is not specifically 
reported, but the authors do note that the effect upon endothelial function was greater 
in those using CPAP for four or more hours per night (Kohler 2013). Kohler et al 
have previously shown that a two-week period of CPAP withdrawal (using sham 
CPAP) leads to a deterioration in endothelial function, not seen in those randomised 
to continue with therapeutic CPAP (Kohler 2011). Three other studies, in relatively 
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small numbers of patients, have shown improvements in endothelial function with 
CPAP therapy (Cross 2008, Trzepizur 2009, Nguyen 2010). This has not been a 
universal finding however, with two studies finding no impact of CPAP therapy on 
endothelial function (Comodore 2009, Simpson 2013). These are both relatively 
small studies and in the larger of the two, patients with moderate to severe OSA were 
randomised to receive either twelve weeks of CPAP therapy or sham CPAP. Mean 
CPAP compliance was 3.5 hours per night and endothelial function was assessed by 
peripheral artery tonometry (Simpson 2013) 
Overall, the majority of previous studies suggest an improvement in endothelial 
function with CPAP therapy; however most of these have not been randomised and 
contain relatively small numbers of patients. This current study is the largest 
randomised placebo-controlled trial of the effect of CPAP on endothelial function 
and additionally patients were free of CVD and hypertension which are known 
confounders. Potential reasons for the discrepancy between these results and 
previously published work are discussed below in section 7.4.3 
 
7.4.3 Differences between the results of this study and the published 
literature 
The findings of this study could be considered to be at odds with the majority of 
published literature in this area, in that CPAP therapy did not lead to an improvement 
in arterial stiffness or endothelial function in this group of patients with OSA. There 
are a number of possible explanations for this: 
 
1. Patients in this study had milder OSA, particularly in terms of nocturnal hypoxia, 
than often appears in publications in this area. As such, it could be argued that if IH 
is the main driver of cardiovascular disease in OSA, then subjects without significant 
hypoxia would have less to gain in terms of cardiovascular benefit from CPAP 
therapy. However the results of the case-control study showing increased arterial 
stiffness and impaired endothelial function in subjects with similarly low levels of 
nocturnal hypoxia suggest that IH is not the only important mechanism linking OSA 
and CVD.  Work by Marin et al examining the mortality of untreated patients with 
OSAHS found no increase in cardiovascular morbidity and mortality in those with 
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mild to moderate disease compared to healthy controls (Marin 2005). Whilst the 
mean AHI placed patients in the moderate to severe category in this study, they were 
not particularly hypoxic, perhaps due to their relatively young age and the exclusion 
of patients with respiratory failure and CVD. There was no intention to specifically 
recruit patients without significant hypoxia, but after excluding patients with CVD, 
hypertension and diabetes mellitus (DM), those patients who remained eligible had, 
on the whole, milder disease in term of hypoxia. Given the clear association between 
CVD and OSA this is an unsurprising consequence of excluding those with CVD or 
hypertension.  
BMI is known to be a predictor of oxygen desaturation in OSA (Peppard 2009), but 
little is known about the differences between patients with OSA who desaturate and 
those who do not. A recent study compared patients with severe OSA (defined as 
AHI >30) with and without nocturnal hypoxia (lack of hypoxia was arbitrarily 
defined as minimum oxygen saturation >88% and >80% of sleep time with oxygen 
saturations of >96%) (Palma 2014). They found subjects without hypoxia to have a 
lower BMI and waist circumference than those who did, consistent with the findings 
of Peppard et al. Apnoea duration was shorter in those without hypoxia and heart rate 
variability analysis suggested a lower sympathetic tone in those without hypoxia, 
compared to patients with hypoxia (Palma 2014). There are likely to be 
pathophysiological differences between patients with and without nocturnal hypoxia 
and further work in this area is required. 
 
2. In an attempt to reduce confounding, subjects with CVD, hypertension and DM 
were excluded and a crossover design was employed. Confounding has been a 
significant issue in previous studies examining the effect of CPAP on arterial 
stiffness with only two studies definitely excluding patients with overt CVD and 
hypertension (Drager 2007, Kasai 2011) and no previous studies using a cross over 
design (Ryan 2013). Only one other randomised controlled study of the effect of 
CPAP on endothelial function excluded patients with CVD and hypertension (Ip 
2004). Arterial stiffness and endothelial dysfunction are early or sub-clinical markers 
of CVD (Celermajer 1992, Reddy 1994, Laurent 2006, Lane 2006) and as such, the 
inclusion of subjects with known CVD is difficult to adequately control for.   
136 
 
3. Compliance with CPAP therapy was relatively low at three hours per night in this 
study and this has to be an important consideration. CPAP (and sham CPAP) 
compliance was very accurately measured with time clock data downloaded at the 
end of each limb giving figures for the amount of time spent ‘at pressure’ (i.e. not 
just with the CPAP machine switched on) every night giving an average nightly 
usage over each 12 week period. This CPAP usage was associated with a reduction 
in ESS overall [7(4-11) vs. 10(5-13); p<0.001] and so clearly had a symptomatic 
benefit but may have been insufficient to lead to a change in arterial stiffness and 
endothelial function. A figure of four hours per night on 70% of nights is often 
quoted as representing adequate compliance (Sawyer 2011), but it is clear that a 
significant proportion of subjects in research studies are non-compliant by this 
standard (Weaver 2008) and compliance out-with research studies is likely to be 
lower. Thus, the very accurately measured compliance reported here is likely to 
represent ‘real-life’ compliance and is similar to compliance in previous studies in 
which CPAP therapy led to a reduction in blood pressure (Faccenda 2001) and 
improvements in cognitive function at this centre (Engleman 1994). Mortality in a 
large series of patients with OSA was reduced in subjects who used CPAP for 
between one and six hours per night (mean use 3.9 hours) compared to those with 
lower usage (Campos-Rodriguez 2005). Several previous non-randomised studies 
have however shown that arterial stiffness and endothelial function did not change in 
subjects deemed to have insufficient compliance with CPAP (Jelic 2008, Jelic 2010, 
Phillips 2013b). The two randomised controlled studies showing a beneficial impact 
of CPAP therapy on arterial stiffness report average CPAP compliance as 6.6 and 4.7 
hours per night respectively (Drager 2007, Kohler 2008b). The third randomised 
controlled study reported lower compliance at 2.8 hours per night and showed no 
effect of CPAP therapy on arterial stiffness, but did show an improvement in 
endothelial function at that level of compliance (Kohler 2013). In the other 
randomised studies showing an improvement in endothelial function with CPAP 
therapy, all reported CPAP compliance of greater than four hours per night. The two 
randomised studies reporting no effect of CPAP on endothelial function reported 
CPAP compliance of 3.5 and 5.5 hours per night. In our study, sub-group analysis of 
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those with nightly CPAP compliance of ≥4 hours did not show any improvement in 
either arterial stiffness or endothelial function, but obviously this was in a smaller 
number of patients and the study was not powered for this. 
Overall compliance was lower than was ideal and whilst this may well represent real 
life CPAP usage in patients with this degree of OSA, may limit the generalizability 
of these findings amongst patients with greater compliance. Equally, it could be 
argued that studies reporting on any benefit derived from especially good CPAP 
compliance are of limited generalizability to the average patient with OSA who may 
never achieve such high levels of CPAP compliance (Simpson 2013). 
 
4. In the only previous randomised control trial examining the effect of CPAP 
therapy on arterial stiffness to exclude subjects with CVD or hypertension (Drager 
2007), baseline PWV was much higher than in this study, suggesting that patients 
were certainly at higher risk of CVD. Indeed recently published ‘normal’ values 
suggest that the mean PWV measured in our study falls within the normal range 
based on the mean age and blood pressure of the group (Boutouyrie 2010), which 
could have resulted in a ceiling effect. Also it is important to note that the results of 
the study by Drager et al are based upon only 12 patients who were randomised to 
receive CPAP therapy. 
 
7.4.4 Is EDS important in the development of CVD in OSA? 
Despite finding that subjects with OSAHS had increased arterial stiffness and 
impaired endothelial function compared to control subjects, there was no 
improvement in either of these measures following CPAP therapy in patients with 
OSA. A non-significant trend towards a lower AIx with CPAP was however seen in 
subjects with EDS [16.5 (11.4)% vs. 18.2 (11.2)%; p=0.058]. The only difference 
between the subjects with OSAHS in the case-control study and the patients with 
OSA in the randomised controlled study (see Table 5.1) was that the presence of 
EDS was mandatory for the former and not for the latter. Those in the case-control 
study all reported EDS and had a median ESS of 16 and whilst the median ESS in the 
randomised controlled study was 13, nineteen of the subjects had an ESS of <11.  
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Although a number of studies have demonstrated a relationship between the severity 
of EDS and severity of OSA (Gottlieb 1999, Koutsourelakis 2008, Mediano 2007), 
there is wide inter-individual variation in the susceptibility to EDS (Young 2002a) 
and the reasons for this are not clear. In population based studies however, most 
subjects with an elevated AHI will not report EDS (Kapur 2005). These findings may 
in part reflect the subjective nature of the ESS, commonly used to define EDS and 
the often multifactorial nature of EDS. In a large study of patients with OSA (defined 
as an RDI >5) and controls, Koutsourelakis et al reported that although the RDI 
accounted for 17% of the variability in the ESS, a history of depression and diabetes 
accounted for a further 11% and 7% respectively of the variability in ESS 
(Koutsourelakis 2008).  
The initial observational studies showing increased cardiovascular risk in patients 
with OSA not treated with CPAP seem to consist predominantly (but certainly not 
exclusively) of patients with EDS (Marti 2002, Marin 2005, Doherty 2005), although 
only one reports ESS results (Doherty 2005). In a more recent randomised controlled 
trial examining the effect of CPAP in patients without EDS, CPAP treatment did not 
reduce the incidence of hypertension or cardiovascular events after a median of four 
years of follow up (Barbe 2012). The authors do however report that this study may 
have been underpowered and in post hoc analysis of patients using CPAP for ≥4 
hours per night, the risk of hypertension or a cardiovascular event was lower 
(p=0.04). Recently published work suggests that calculated cardiovascular risk in 
OSA patients without EDS is not reduced by six months of CPAP therapy (Craig 
2012). As will be outlined in section 7.4.5 below, there are a number of studies 
showing that CPAP is effective in reducing blood pressure in OSA, however several 
studies and a recent meta-analysis show no effect overall in patients without EDS. In 
another meta-analysis, Montesi et al have shown that the expected blood pressure 
reduction with CPAP therapy increases with every five point increase in the baseline 
ESS (Montesi 2012), suggesting that EDS is important.  
The question as to whether the presence of EDS matters is important, not least 
because 20% of the population have evidence of OSA in the absence of EDS, 
compared to a prevalence of 2-4% for OSAHS. Kohler et al have previously shown 
increased arterial stiffness and impaired endothelial function (using the same 
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measures as in this study) in subjects without EDS, although a proportion of patients 
also had CVD (Kohler 2008a). As in our study, the inclusion criteria for patients 
entering randomised controlled trials examining the effect of CPAP on arterial 
stiffness and endothelial function are often based solely on the AHI. With regard to 
arterial stiffness, there has been one randomised controlled trial recruiting only 
patients with EDS (Kohler 2008b) and one specifically recruiting subjects without 
EDS (Kohler 2013); the former reported an improvement in arterial stiffness with 
CPAP therapy whereas the latter did not. In the eight previously published 
randomised controlled studies of the effect of CPAP on endothelial function, the 
presence of EDS was mandated in three (Cross 2008, Nguyen 2010, Kohler 2011) 
and the absence of EDS mandated in another (Kohler 2013). In the two studies 
reporting no improvement in endothelial function, EDS was not an inclusion 
criterion (Comondore 2009, Simpson 2013). 
An underlying mechanism for any association between EDS and CVD in OSA has 
not been elucidated and certainly is beyond the scope of this study. EDS is generally 
felt to be a marker for arousals and subsequent sleep fragmentation in OSA (Young 
2002a, Robinson 2006) and has been shown in a small study to be associated with 
increased sympathetic nervous system activity (SNA) (Donadio 2007). EDS is not 
exclusive to OSA and has been reported in a number of cardiovascular diseases 
(Choi 2006), although it is possible that this relates to the known prevalence of 
undiagnosed OSA in the general population. In an older population, EDS has also 
been shown to be an independent predictor of cardiovascular morbidity and 
mortality, but again undiagnosed OSA was not excluded in these subjects (Newman 
2000). In a study of 86 patients with severe OSA, daytime sleepiness (as measured 
by the ESS) was related to daytime measures of cardiac function (namely the stroke 
index and cardiac index) after controlling for the RDI and degree of nocturnal 
hypoxia (Choi 2006). The authors suggest that the presence of EDS may not just be a 
marker of OSA severity but may reflect underlying cardiovascular dysfunction.   
In our study, sub-group analysis of patients with and without EDS did not show 
CPAP to have an effect on arterial stiffness or endothelial function in either group, 
although a non-significant trend towards a reduction in AIx with CPAP in those with 
EDS was seen. These findings may of course be due to the smaller numbers of 
140 
patients with EDS, as the study was not powered for this analysis. This study 
therefore does not help to answer the question as to the importance of EDS when 
considering the association between OSA and CVD and further work is required in 
this area. 
 
7.4.5 CPAP therapy is associated with a reduction in blood pressure in 
patients with OSA 
CPAP therapy led to a small reduction in office systolic blood pressure [126 (12) vs. 
129 (14) mmHg; p=0.03]. There was no difference in ambulatory blood pressures 
between the two limbs of the study and the reason for this is unclear but may reflect 
the lack of a complete ambulatory blood pressure data set. Complete ambulatory 
blood pressure measurements were available for only 33 of the 43 subjects who 
completed the study (see section 4.6.5), increasing the likelihood of type II statistical 
error. The effect of CPAP therapy on blood pressure per se was not the main aim of 
this thesis, and the results will only be discussed briefly here. OSA is an independent 
risk factor for hypertension (Stradling 2001, McNicholas 2007) and CPAP has been 
shown in numerous studies to reduce blood pressure in patients with OSA (Faccenda 
2001, Pepperell 2002). In a meta-analysis, the overall reduction in blood pressure 
with CPAP therapy is around 2-3mmHg (Bazzano 2007, Haentjens 2007, Schein 
2014), with greater reductions in patients with more severe OSA, higher BMI and 
hypertension at baseline (Bazzano 2007). In this study only a small reduction in 
systolic blood pressure was seen and this may reflect the fact that, as discussed above 
(section 7.4.3), patients had relatively mild OSA and all were normotensive. 
However, even at this level of systolic blood pressure reduction, the findings of a 
large meta-analysis suggest a 10% reduction in stroke mortality and a 7% reduction 
in other vascular disease could be expected (Lewington 2002). An area of uncertainty 
in this area has been whether CPAP therapy has a blood pressure lowering effect in 
patients without EDS. Several randomised controlled trials have now shown no 
beneficial effect of CPAP therapy on blood pressure in patients without EDS (Barbe 
2001, Robinson 2006, Barbe 2012, Craig 2012). A recently published meta-analysis 
of over 1000 patients without EDS reported the same conclusion, with the caveat that 
exploratory analyses suggested there may be a small reduction in diastolic blood 
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pressure in patients with CPAP compliance of ≥4 hours per night (Bratton 2014). 
Patients in our study had a mean ESS of 13; however 44% of subjects had an ESS 
≤10 and hence did not have EDS. Sub-group analysis of patients with and without 
EDS demonstrated no effect of CPAP therapy on any measure of blood pressure 
(office or ambulatory) after 12 weeks. This may of course be due to the smaller 
numbers in each group and the study was not powered for this. 
 
7.4.6 Increase in BMI over the study period 
Interestingly, there was a small, but significant increase in BMI between the first and 
third visits in this study [29.9 (27.3-31.6) kg/m2 vs. 30.1 (27.4-33.3) kg/m2; 
p<0.001].  Theoretically one might imagine that if CPAP treatment led to a reduction 
in ESS (as in this study), then patients would have more energy and hence if 
anything should lose weight. Initial small non-randomised studies suggested a 
reduction in weight (Loube 1997) and visceral fat (Chin 1999) following CPAP 
therapy. However as part of the recent APPLE (Apnea Positive Pressure Long-term 
Efficacy) study, 812 patients randomised to receive CPAP therapy or sham CPAP 
had body weight measurements at baseline and after 6 months (Quan 2013). This 
also showed that those in the CPAP arm of the study had a small, but statistically 
significant increase in weight, with a small reduction in weight seen in the sham arm 
of the study. Additionally, weight gain was greater in those with better CPAP 
compliance. A very recent meta-analysis attempts to address the issue of the effect of 
CPAP upon body weight and identified 25 randomised controlled studies involving 
CPAP therapy that reported BMI results before and after intervention (Drager 2014). 
In keeping with the results presented here, this confirmed a small but significant 
increase in BMI following a minimum of four weeks CPAP therapy.   
Of course, weight gain is not always due to an increase in adiposity and may reflect 
an increase in muscle mass associated with increased activity. In the study presented 
in this thesis and in the APPLE study there is no quantification of body composition. 
However a previous study, employing imaging techniques to determine body 
composition, showed that eight months of CPAP was associated with an increase in 
lean body mass (Münzer 2010). There are a number of possible mechanisms for this 
weight gain, further elucidation of which are certainly beyond the scope of this study. 
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The potential mechanisms may include reductions in the work of breathing and 
sympathetic nervous system activity at night with effective CPAP therapy, leading to 
a reduction in energy expenditure and subsequent weight gain (Quan 2013, Drager 
2014).  Additionally, inflammatory cytokines due to untreated OSA may promote 
anorexia which is reversed by CPAP (Quan 2013). Under normal conditions during 
slow wave sleep, growth hormone is released and cortisol release is inhibited (Van 
Cauter 2008). When sleep is fragmented by OSA the relative amounts of growth 
hormone and cortisol release may be affected, potentially leading to a catabolic state, 
which if reversed by CPAP may lead to weight gain. Additionally the role of CPAP 
in reversing the effects of OSA on leptin is unclear (Drager 2014). From a practical 
point of view, the increase in weight after commencing CPAP therapy should prompt 
physicians treating patients with OSA to emphasise the need for active attempts at 
weight reduction. 
 
7.5 Limitations of the study  
This study has a number of limitations, two of which have already been discussed 
above, namely the relatively mild degree of nocturnal hypoxia in patients with OSA 
and compliance with CPAP therapy (see section 7.4.3).  
Subjects with OSAHS and controls were well-matched in all respects except for neck 
circumference, which given the known association between neck circumference and 
OSA (Davies 1990, Davies 1992) is perhaps unsurprising. There have been a number 
of recent studies suggesting an association between neck circumference and 
increased cardiovascular risk (Preis 2010, Zhou 2013). It is unclear whether this is an 
independent association or relates to the relationships of neck circumference to 
central obesity (Onat 2009) and OSA (Davies 1990, Davies 1992). Body mass index 
(BMI) measurements do not provide information about the distribution of fat 
deposition in the body. Thus, it could be argued that a higher neck circumference in 
the OSAHS patients is indicative of increased central or upper body obesity, known 
to be more associated with CVD than other patterns of fat distribution (Jensen 2008). 
Against this would be the fact that another measure of central obesity, the waist-to 
hip ratio, was not significantly different between the two groups in our study. 
Although not statistically significant, a greater number of subjects with OSAHS were 
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current smokers than in the control group. Proportions of ex-smokers were similar 
within each group. Smoking has long been established as a risk factor for CVD and 
has been shown to be associated with increased arterial stiffness (Mahmud 2003, Li 
2006) and impaired endothelial function (Celermajer 1993). Acute changes in arterial 
stiffness (Mahmud 2003) and endothelial function (Lekakis 1997, Karatzi 2007) are 
also reported after cigarette smoking. To avoid confounding from the acute effects of 
cigarette smoking, subjects were asked not to smoke for at least 10 hours prior to 
attending for vascular assessment. Across the group as a whole (20 subjects with 
OSAHS and 20 control subjects) no difference between any measure of arterial 
stiffness or endothelial function was noted between smokers, ex-smokers and never 
smokers. Subjects were not however matched for smoking history and thus cigarette 
smoking remains a potential confounder in the case-control study. 
In contrast to the arterial stiffness and endothelial function data obtained using pulse 
wave analysis (AIx data), it was not possible to obtain full data sets for PWV and 
aortic distensibility. With regards to PWV this was related to body habitus and the 
consequent difficulties in obtaining a reliable trace at the femoral or carotid pulse site 
in two of the 20 subjects with OSAHS. The difficulties of obtaining adequate traces 
at these sites have been recognised by others (Bakker 2011). Due to movement or 
other artefact, it was not always possible to determine aortic distensibility from the 
MRI scans and this, along with one case of unexpected claustrophobia, meant a 
direct comparison was only available for 15 of the 20 pairs. A consequence of 
missing data is the increased likelihood of a type II statistical error. As described in 
section 3.2.2, the case-control study was not formally powered and as such may have 
been underpowered, raising the possibility of type I statistical error. 
A potential criticism of our study is the methodology used to assess endothelial 
function. Vasomotor endothelial function was assessed using the relatively novel 
technique of measuring the effects of salbutamol and GTN on the AIx. As discussed 
above in section 7.2.2, this has been shown to be a reproducible technique that 
correlates with invasively obtained measurements of endothelial function (Wilkinson 
2002B, Hayward 2002). Additionally impairment of the AIx response to inhaled 
salbutamol has been described in numerous conditions associated with endothelial 
dysfunction (Lekakis 2011). There have been concerns regarding the use of this 
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technique to assess endothelial function in this situation (Ryan 2013, Hoyos 2015). 
These are based upon two studies published around the time that this study was being 
conducted (Donald 2006, Westhoff 2007). The first reported that the reproducibility 
of this technique was lower than that of FMD (coefficient of variation 11.5 vs 7.1 %) 
in 16 adults who were assessed on consecutive days and had AIx measurements 
before and after sub-lingual GTN and inhaled salbutamol (Donald 2007). A potential 
criticism of that study is the timing of the administration of salbutamol only 23 
minutes after the administration of GTN. It has previously been shown that the 
effects of GTN on the AIx persist for 25 minutes (Greig 2005), hence the 30 minute 
interval used in our study. The second study examines the effect of inhaled 
salbutamol on the reflection index (not augmentation index) measured by a 
photoplethysmographic device attached to the index finger in a subset of subjects and 
the authors concluded that this automated pulse wave analysis procedure cannot be 
used to assess endothelial function (Westhoff 2007). Although the technique referred 
to utilises the same principle as used in this study, it cannot be viewed as the same 
technique. Indeed, Donald et al also measured the change in reflection index 
following salbutamol in their study and found it to be much less reproducible than 
either FMD or changes in AIx following salbutamol (Donald 2007). FMD has been 
the most widely studied means of assessing endothelial function to date and at 
present represents the gold standard measurement. However it is an expensive 
technique, requiring a great deal of operator expertise. The use of arterial tonometry 
to determine the effects of salbutamol on AIx, whist undoubtedly requiring a degree 
of operator skill, is suitable in even the most obese subjects and is well tolerated by 
subjects. This makes it a useful technique in cross-over studies such as this one, in 
which subjects undergo numerous assessments and is recognised as a valid method 
of assessing endothelial function in the most recent position paper from the European 
Society of Cardiology Working Group on Peripheral Circulation (Lekakis 2011). 
Notwithstanding the above however, the use of this means of assessing endothelial 
function has not been as widespread as might have been predicted when this study 
was designed and conducted. Indeed the above noted position paper (Lekakais 2011) 
comments on its relative novelty as a technique. Kohler et al used the same method 
(alongside the more commonly used FMD technique) of assessing endothelial 
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function in patients with minimally symptomatic OSA patients, published whilst this 
study was underway (Kohler 2008a). However no subsequently published study in 
the field of OSA has employed this technique, with the majority favouring FMD for 
the assessment of endothelial function (Hoyos 2015). Therefore despite the 
advantages described above, I could not recommend its use as the sole means of 
assessing endothelial function in future studies in this area and given the prominence 
of the use of FMD, this would seem a logical alternative option. 
The power calculation for this study was based upon pilot data comparing aortic 
distensibility in patients with OSA and healthy controls. On this basis and for a 
crossover design it was calculated that a sample size of 40 was required (see Chapter 
3, section 3.14) and indeed 43 patients completed the study. This may however mean 
that the study is underpowered with regard to the other measures of arterial stiffness 
and endothelial function and along with the incomplete data set may have increased 
the likelihood of type II statistical error. 
As discussed in Chapter 3, there has been much debate around the ideal placebo for 
trials involving CPAP (Karlawish 2001, Brown 2011). For the reasons outlined in 
section 3.7.2, sham CPAP (i.e. CPAP set to deliver sub-therapeutic pressure) was 
chosen as the placebo. Sham CPAP replicates some of the experience surrounding 
the provision of a CPAP machine and the wearing of a CPAP mask at night but has 
previously been shown to have little (Rodway 2010) or no (Jenkinson 1999, Farre 
1999) effect on respiratory events during sleep. In CPAP naïve patients, such as 
those in our study, the use of sham CPAP should assist with the blinding of patients 
and researchers, along with reducing the impact of any placebo effect associated with 
the use of therapeutic CPAP. Several studies have shown that CPAP use does not 
differ from sham CPAP use (Brown 2011) and this approach has been used 
successfully in previous trials at this centre (Smith 2007, Cross 2008). In this study 
however, CPAP compliance was significantly higher than compliance with sham 
CPAP, which could suggest that subjects were not completely blinded. If this were 
the case, then perhaps one might imagine that sham CPAP use would be lower in 
those patients who entered the CPAP limb first and thus had experience of the 
benefits of therapeutic CPAP. This proved not to be the case however, with sham 
CPAP use unaffected by the order in which patients received CPAP and sham CPAP. 
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The ESS fell more with CPAP than sham CPAP and a lack of perceived symptomatic 
benefit may have led to lower sham CPAP use. Whilst acknowledging that there is 
no perfect placebo for CPAP, sham CPAP is probably the most rigorous placebo and 
is currently felt to represent the placebo of choice (Rodway 2010, Brown 2011). 
Although the study did not include a formal washout period, the vascular 
assessments were made 12 weeks after crossover making the persistence of carry 
over effects unlikely. Indeed, recent work by Kohler et al demonstrated a rapid 
recurrence of OSA (within two days) of switching from therapeutic to sham CPAP. 
Two weeks after switching from CPAP to sham CPAP they also showed an increase 
in blood pressure and an impairment of endothelial function compared to subjects 
who continued on therapeutic CPAP (Kohler 2011). 
It could be argued that in order to effect a change in vascular function patients would 
need to be treated with CPAP therapy for longer than 12 weeks. Whilst this may be 
the case, many of the previous studies showing improvements in blood pressure 
(Faccenda 2001, Pepperell 2002) and vascular function (Ip 2004, Cross 2008, Kohler 
2008b) with CPAP therapy were conducted over a four to 12 week period. Similarly, 
anti-hypertensive therapy has previously been shown to have a beneficial effect on 
aortic distensibility after 12 weeks of treatment (Honda 1999) and it was on this basis 
that the 12-week duration was chosen. Indeed, there have only been two randomised 
controlled trials of the effect of CPAP therapy on arterial stiffness or endothelial 
function that have been conducted over longer time periods with treatment durations 
of four (Drager 2007) and six months (Kohler 2013). Notwithstanding the above, 
OSA is a chronic disease and for that reason a longer treatment duration, particularly 
in relatively young patients without evidence of CVD, may be desirable. In a placebo 
controlled study such as this one this would however also prolong the period that 
patients received the placebo intervention (in this case sham CPAP). This presents an 
important ethical challenge particularly given the known efficacy of CPAP in the 
treatment of OSA (McDaid 2009) and the longer term use of sham CPAP may be 
difficult to justify. Additionally with 12 weeks in each arm of the study, subjects are 
already being asked to maintain their interest and willingness to participate for six 
months. It is not clear whether extending the study duration would lead to an increase 
in the drop-out rate. 
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7.6 Conclusions  
This study extends previous observations by showing that even relatively young, 
normotensive patients with OSAHS, free of overt CVD have evidence of increased 
arterial stiffness and impaired endothelial function. OSAHS is common and 
prevalence rates are likely to increase with increasing obesity rates and as such, any 
association between OSAHS and CVD has significant public health implications. 
Early detection of those at increased cardiovascular risk may enable timely 
therapeutic intervention and risk reduction.  
Importantly in this study, patients had evidence of increased arterial stiffness and 
impaired endothelial function, despite a lack of significant nocturnal hypoxia. 
Intermittent hypoxia (IH) has generally been considered to represent the most 
important mechanism underlying any link between OSA and CVD; however these 
findings would suggest that other mechanisms may also play an important role. Less 
is known about the other acute effects of OSA, namely arousals/sleep fragmentation 
and intra-thoracic pressure changes with regard to an association between OSA and 
CVD, and further work is needed in this area. A better understanding of the 
underlying pathophysiological mechanisms may help to identify patients at risk of 
CVD and potentially lead to new treatment strategies for OSA. 
Despite the finding that patients with OSAHS had increased arterial stiffness and 
impaired endothelial function in the case-control study, CPAP therapy did not lead to 
a significant improvement in either of these measures in a larger group of patients 
with OSA in the randomised controlled trial. There are a number of possible reasons 
for this. Firstly, in subjects with relatively mild OSA and in the absence of 
underlying CVD, CPAP therapy may be ineffective in improving vascular structure 
and function. Patients in this study were assessed after 12 weeks and it is possible, 
particularly in those with milder disease, that any improvement would require a 
longer period of treatment. 
It is possible that the lack of effect seen relates to the relatively low CPAP 
compliance in this study. As described above, a number of studies have only shown 
improvements in vascular structure and function in subjects with (variably defined) 
good compliance with CPAP therapy. CPAP compliance in this study was very 
accurately measured and at three hours per night was sufficient to lower the ESS and 
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effect a small reduction in diurnal systolic blood pressure. In patients such as those 
studied here, this probably reflects ‘real life’ CPAP compliance.  
This study again raises the question about the importance of EDS in the link between 
OSA and CVD.  Patients in the case-control all had EDS as compared to only a 
proportion of those in the randomised controlled trial. This may provide an 
explanation for the lack of improvement in vascular function in patients with OSA, 
despite finding that patients with OSAHS had increased arterial stiffness and 
impaired endothelial function at baseline. Although CPAP has been shown in many 
studies to reduce blood pressure in OSA, this does not seem to occur in patients 
without EDS and the reasons for this are as yet unclear. 
In considering the findings of this study from a clinical perspective, it is important to 
remember that the cohort of patients studied here (in both the case-control study and 
the RCT) represent a very specific sub-population of patients with OSA overall.  
OSA is known to be an independent risk factor for hypertension, co-existing in up to 
40% of patients (Phillips B 2005, Parati 2013) and although not established as an 
independent risk factor for CVD, there is a clear association between OSA and CVD. 
In an attempt to reduce confounding in this study, patients with known CVD, 
hypertension or DM were deliberately excluded. As such, the finding that CPAP did 
not improve arterial stiffness or endothelial function in this sub-population does not 
exclude a beneficial effect of CPAP therapy upon vascular function in patients with 
pre-existing CVD or indeed in those with more significant nocturnal hypoxia. 
Subjects in this study did not have evidence of significant nocturnal hypoxia, indeed 
the 4% desaturation rate was low at 9.3 (12.3) per hour and the percentage of sleep 
time with oxygen saturations of less than 90% was also low at 4.4 (13.2)%. 
The findings of this study, coupled with the finding from the case-control study that 
patients with OSAHS have evidence of increased arterial stiffness and impaired 
endothelial function, clearly emphasises the need to carefully consider and address 
other modifiable cardiovascular risk factors in all patients with OSA. This should be 
in addition to any consideration of CPAP provision. 
CPAP is clearly an effective treatment for the symptoms of OSA, but on the basis of 
previous evidence and the work contained within this thesis, the case has not yet 
been made for the use of CPAP therapy in OSA solely to reduce cardiovascular risk. 
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In order to answer the question of whether CPAP treatment is effective in improving 
vascular structure and function and subsequent cardiovascular morbidity and 
mortality, large prospective randomised studies are ideally required with long term 
follow up. Given the already proven benefits of CPAP in terms of symptom control 
however, this would be ethically challenging and this approach may only be possible 
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Effect of Continuous Positive Airway Pressure 
(CPAP) on Aortic Distensibility in Patients with 




INFORMATION SHEET FOR POTENTIAL SUBJECTS 
 
 
You are invited to participate in a study being conducted within the Department of 
Sleep Medicine at the Royal Infirmary of Edinburgh. Before you decide whether to 
take part in the study it is important that you understand the objectives of this 
research and what it will involve. Please take time to read the information below 
carefully and discuss it with friends, relatives or your GP if you wish. Please do not 
hesitate to ask us if there is anything you do not understand or if you would like any 
further information. 
 
It is entirely up to you as to whether you wish to participate in this study. If you 
decide to do so you will be given a copy of this information sheet to keep and will be 
asked to sign a written consent form. If you decide not to participate or if you wish to 
withdraw at any time during the study you are entirely free to do so and this will not 
in any way affect the standard of care that you receive. 
 
The aim of this study is to look at the effect that treatment of Obstructive Sleep 
Apnoea/Hypopnoea Syndrome (OSAHS) with Continuous Positive Airway Pressure 
(CPAP) has on the stiffness of the body’s main blood vessel, the aorta.  
 
OSAHS can cause high blood pressure and this is associated with an increase in 
cardiovascular risk (i.e. heart attacks and strokes). The degree of stiffness of the aorta 
may be important in this increased risk. We aim to look at whether this degree of 
stiffness is altered by treatment with CPAP. It is not known exactly what leads to this 
aortic stiffening in OSAHS, it may be related to dips in the oxygen levels overnight 
due to breathing pauses (apnoeas), or it may be related to factors associated with 
daytime sleepiness. By looking at different groups of patients within the Department 
of Sleep this may become clearer. 
 
In the study you will receive two different types of CPAP treatment. CPAP machines 
can be set to provide air at different pressures. You will receive one such pressure for 
three months, and a different pressure for the second three month period. This will 
better enable us to detect any changes attributable to CPAP treatment. You will be 
randomised to determine which of these two forms of CPAP you receive first. 
During the study neither you nor the principal researcher will know in which order 
you receive the two forms of treatment. Prior to being randomised you will have an 
overnight sleep study to ascertain your suitability for inclusion.  
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We would also check some routine blood tests, including your cholesterol and 
glucose level, along with a 24-hour blood pressure monitoring (this is applied in the 
hospital but then can be worn at home or at work whilst going about your normal 
daily activities). 
 
We will look at the stiffness of the aorta using Magnetic Resonance Imaging (MRI). 
This is a non-invasive imaging technique that does not involve ionising radiation. 
Some people are not able to have such a scan if they have certain implants or foreign 
bodies inside them. You will be asked specifically about this prior to entry into this 
study, but if you think you might fall into this category then please let us know.  
 
We will also perform what is known as pulse wave analysis at the same visit. This 
again is a non-invasive technique and looks at blood flow at the wrist, neck and 
groin. In order to look at the response of the blood vessels, measurements will be 
repeated following administration of Glyceryl Trinitrate (better known as GTN, a 
commonly used medicine for angina) by a spray under the tongue, and Salbutamol, 
(a commonly used medicine for asthma) taken via an inhaler. 
 
These measurements (MRI and pulse wave analysis) will be taken before treatment is 
commenced, and then repeated after each three month period of treatment (i.e. three 
times in total) 
 
Any information collected about you during the course of the study will be kept 
strictly confidential. Any information that leaves the hospital will have all identifying 
details removed such that you could not be recognised from it. We will inform your 
General Practitioner of your participation in this study. If during the course of your 
participation in the study we find any unexpected results, for example on the blood 
tests or MRI scan, we will of course discuss these with you fully and inform your 
GP. It may be something simple that can be dealt with by your GP, if not we will 
refer you on to the relevant hospital department. 
 
Any travel expenses incurred by you during your participation in the study will be 
reimbursed. 
 
Though it is not expected, if taking part in this research harms you, there are no 
special compensation arrangements. If you are harmed due to negligence, then you 
may have grounds for legal action but you may have to pay for it. Regardless of this, 
if you wish to complain, or have any concerns about any aspect of the way in which 
you have been approached or treated during the course of this study then the normal 
National Health Service complaints mechanism is available to you. 
A group called Consumers for Ethics in Research (CERES) publish a leaflet entitled 
‘Medical Research and You’. This leaflet gives information about medical research 
and addresses some of the questions you may have. A copy can be obtained from 
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Background: Obstructive sleep apnoea–hypopnoea syndrome (OSAHS) is associated with increased car- 
diovascular morbidity and mortality. Our study examined arterial stiffness and endothelial function in 
subjects with OSAHS with no known cardiovascular disease compared to well-matched controls. 
Methods : Twent y subjects with OSAHS (defined as apnoea–hypopnoea index [AHI] P15 and Epworth 
Sleepiness Scale score P11) without cardiovascular disease and 20 well-matched controls underwent 
a compreh ensive evaluation of arterial stiffness and endothelial function. Arterial stiffness was measured 
by applanation tonometry and cardiovascular magnetic resonance imaging (MRI) and endothelial func- 
tion assessed by measuring vascular reactivity after administration of glyceryl trinitrate and salbutamol. 
Results: Subjects with OSAHS had increased arterial stiffness (augmentation index 19.3 [10.9] vs. 12.6 
(10.2)%; p = 0.017) and impaired endothelial function (change in augment ation index following salbuta- 
mol !4.3 (3.2) vs. !8.0 (4.9)%; p = 0.02) compared to controls. Aortic distensi bility, a measure of arterial 
stiffne ss, was negatively correlated with the AHI. 
Conclusions: Our findings suggest that even in the absence of known cardiovascular disease, subjects with 
OSAHS have increased arterial stiffne ss and impaired endothelial function and are at increased risk for 
cardiovascular disease. 
! 2013 Elsevier B.V. All rights reserved. 
1. Introduction 
Obstructive sleep apnoea is caused by repetitive obstructi on of 
the upper airway during sleep and when it leads to excessive day- 
time somnolence is called obstructi ve sleep apnoea–hypopnoea 
syndrome (OSAHS). OSAHS affects 2% to 4% of the middle-aged 
population [1] with a further 20% having frequent apnoeas and 
hypopnoeas in the absence of excessive daytime somnolence [2].
Obstructive sleep apnoea is an independen t risk factor for 
hypertension [3] and also has been associated with increased car- 
diovascular morbidit y and mortality [4–8].
The mechanism s for these associations are not completely 
understood , but each obstructive event is associated with transient 
increases in blood pressure [9], arterial stiffness [10], and sympa- 
thetic activity [11] that may contribute to endothelial dysfunction. 
Prior to beginning our study, previous studies in small numbers of 
patients suggested that subjects with obstructi ve sleep apnoea had 
increased arterial stiffness [12] and evidence of endotheli al dys- 
function [13,14].
The aim of our study was to comprehensive ly examine both 
arterial stiffness and endothelial function in subjects with OSAHS, 
without overt cardiovascu lar disease (CVD) or diabetes mellitus 
(DM) compare d to well-match ed controls. It was our hypothesis 
that OSAHS leads to increased arterial stiffness and endotheli al 
dysfunct ion independen t of pre-existing CVD. 
2. Methods 
2.1. Subjects 
Twenty subjects with OSAHS (defined as apnoea-hyp opnoea 
index [AHI] P15 on overnight polysomnograp hy (PSG) and an 
Epworth Sleepiness Scale score P11) with no history of CVD or 
DM were recruited through the Department of Sleep Medicine. 
Exclusion criteria were: previous continuous positive airway 
pressure , respiratory failure, medications affecting blood pressure, 
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sleepiness when driving, professional driving, contraindica tions to 
magnetic resonance imaging (MRI), and intercurrent illness. 
Twenty control subjects with no history of OSAHS, CVD, or DM 
were recruited via advertisement (within the hospital and on the 
hospital and university intranet) and a local general practitioner 
practice. Control subjects were required to have an AHI 610 on 
PSG and an Excessive Sleepiness Scale score <11 and also were sub- 
ject to the exclusion criteria. We were able to match 20 subjects 
with OSAHS for age (within 5 years), sex, and body mass index 
(within 10%) on a one-to-one basis with the control subjects 
(Table 1).
To exclude a history of CVD, a detailed medical history was ta- 
ken from all subjects and their medical records examined. Subjects 
with a raised clinic blood pressure also were excluded and all sub- 
jects underwent a fasting blood glucose measurement to exclude 
DM.
A 16-channel in-patient PSG (Compumedics Ltd., Abbotsford, 
Victoria, Australia) was performed in all subjects. Sleep was scored 
using standard Rechtschaff en and Kales criteria [15]. Apnoea was 
defined as a reduction in airflow of P90% from baseline for at least 
10 s and hypopno ea as a reduction in airflow of P30% for at least 
10 s with an oxygen desatura tion of P4% from baseline or a
P50% reduction in airflow for at least 10 s with a P3% oxygen 
desaturation or associate d arousal [16].
Subjects were recruited between March 2007 and February 
2009. Our study was approved by Lothian Local Research Ethics 
Committee (ref. 06/S1102/5 4) and written informed consent ob- 
tained from all subjects. 
2.2. Study design 
All vascular studies were conducted at the same time of day and 
subjects and controls had fasted overnight and abstained from 
smoking, alcohol, and caffeine for at least 10 h prior to the vascular 
studies.
2.3. Assessment of arterial stiffness and endothelia l function by 
applanation tonometry 
All studies were carried out by a single operator (AJ) in accor- 
dance with the Expert Consensus Document on Arterial Stiffness 
[17]. Measurements were recorded supine in a temperature -con- 
trolled room after at least 30 min of rest. Resting blood pressure 
and heart rate were recorded in duplicate using an automated 
sphygmomano meter (Omron 705IT, Milton Keynes, UK) and the 
mean used for analysis. 
2.3.1. Pulse wave analysis 
Radial artery pressure waveforms were continuously measured 
by tonometer (Colin Corp., Komaki City, Japan) and the Sphygmo -
Cor! system (version 7, AtCor Medical, Sydney, Australia). A vali- 
dated mathematical transfer function was applied to the mean of 
approximat ely 10 waveforms to derive an aortic pressure wave- 
form [18]. From this, the augmentation index (AIx), a measure of 
central-pr essure augmentati on, was determined . AIx is a measure 
of stiffness throughout the arterial tree and is calculated as the dif- 
ference between the first and second systolic peaks, expressed as a
percentage of the pulse pressure. AIx is affected by heart rate and 
was corrected to a heart rate of 75 beats per minute, as previously 
described [19]. Readings with >10% variability in pulse height or in 
the diastolic portion of the waveform were excluded. Repeated 
measure ments of AIx were taken at baseline, with the mean value 
used for analysis. 
Endotheli al function was assessed by measuring endothelium -
depende nt change in AIx following inhaled salbutamol and endo- 
thelium-i ndependent change in AIx following sublingual glyceryl 
trinitrate (GTN) [20,21].
After baseline recordings, 500 lg of GTN tablet was given sub- 
lingually for 3 min and then removed. AIx was then recorded 
every minute for 10 min and then every 5 min for a further 
15 min. Previous studies demonstrated that the haemodynam ic 
effects of GTN can persist for up to 25 min [22] and therefore, 
400 lg of inhaled salbutam ol via a spacer device was given 
30 min after the GTN. AIx was then recorded every minute for 
10 min and then every 5 min for a further 10 min. The greatest 
change in AIx following the administration of each drug was used 
for analysis [20].
2.3.2. Pulse wave velocity 
Pulse wave velocity (PWV) increases with arterial stiffness and 
records the time taken by the systolic pressure wave to reach the 
peripher ies. Carotid–femoral (aortic) PWV was measured by a
micromano meter (Millar Instruments, Houston, TX, USA) and the 
Sphygmo Cor ! system by sequential acquisition of carotid and fem- 
oral pressure waveforms gated to the R wave of a simultaneou sly 
recorded electrocar diogram. The SphygmoCor ! system applied 
the intersecting tangent algorithm to determine the onset of the 
forward wave and the difference in transit time between the caro- 
tid and the femoral locations was used to calculate the PWV. Read- 
ings that met quality control standards were accepted for analysis 
[23]. We aimed to repeat each recording three times and the mean 
PWV was used for analysis. 
Table 1
Baseline characteristics. 
Subjects with OSAHS (n = 20) Control subjects (n = 20) p Value 
Age (y) 44 (7) 44 (7) 0.94 
Sex 13 men 13 men 
BMI (kg/m2)* 29.7 (27.4–32.7) 29.4 (27.4–33.5) 0.20 
Neck circumference (cm)* 40.5 (38.1–41.9) 39.0 (36.6–41.5) 0.02 
Waist to hip ratio 0.94 (0.07) 0.93 (0.08) 0.54 
Systolic blood pressure (mmHg) 127 (14) 124 (11) 0.33 
Diastolic blood pressure (mmHg) 76 (10) 75 (9) 0.75 
MAP (mmHg) 93 (11) 91 (9) 0.42 
Fasting glucose (mmol/L) 4.9 (0.5) 4.9 (0.3) 0.68 
Total cholesterol (mmol/L) 5.5 (1.0) 5.6 (0.9) 0.79 
Current smokers 30% 5% 0.13 
Ex-smokers 35% 40% 1.00 
Apnoea/hypopnoea index * 32 (22–41) 4 (3–6) Part of selection criteria 
Epworth Sleepiness Scale score * 16 (14–18) 4 (2–8) Part of selection criteria 
Mean (standard deviation) unless indicated. 
BMI, body mass index; MAP, mean arterial blood pressure; OSAHS, obstructive sleep apnoea–hypopnoea syndrome. 
* Median (interquartile range).
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2.4. Assessment of aortic distensibility 
Aortic distensibility was measure d using cardiovascu lar MRI. 
Studies were performed on a 1.5-Tesla MRI scanner (Philips Med- 
ical Systems, Best, The Netherlands). Sagittal oblique images of 
the aorta in the supine position were used to define planes orthog- 
onal to the aortic axis for electrocar diogram-gated, steady-state, 
free precession cine imaging with full R–R coverage in the ascend- 
ing and descending aorta at the level of the right pulmona ry artery 
and at the level of the diaphragm. Noninvasive blood pressure 
recordings were taken in the scanner immediatel y before and after 
each image was acquired (S/5™ monitor, Datex-Ohmed a, Helsinki, 
Finland), with the mean used to calculate the pulse pressure. Image 
analysis was performed by a single operator (MC) using an auto- 
mated algorithm (EasyVision, Philips Medical Systems). Aortic dis- 
tensibility was calculated as (Amax ! Amin)/(Amin " Pulse pressure )
where Amax and Amin were the maximum and minimum aortic 
areas during the cardiac cycle. 
2.5. Data analysis 
Data are expressed as mean (standard deviation) unless stated. 
Statistical analyses were performed using SPSS version 17 (SPSS,
Chicago, IL, USA). Differences between groups were analysed using 
paired t tests or Wilcoxon signed rank tests. Differences in categor- 
ical data were analysed using McNemar test. Differenc es in vascu- 
lar parameters between different smoking categories were 
examined using a one-way analysis of variance. Spearman rank 
correlation coefficient was used to determine correlations between 
vascular paramete rs and AHI. A p value of <0.05 was considered 
statistically significant. A stepwise linear regression analysis was 
performed with variables entered into the model if the initial sig- 
nificance of their correlation with the dependent variable was 
60.05.
3. Results 
Baseline characteri stics for the subjects with OSAHS and 
matched controls were similar with the exception of neck circum- 
ference (Table 1). There were more current smokers in the subject 
group, but this was not statistically significant; the numbers of ex- 
smokers were similar in each group. Cigarette pack-year history 
(among current and ex-smokers) was similar in subjects with 
OSAHS and controls (14.6 [14.5] vs. 11.4 [4.71] years; p = 0.47).
The median AHI among subjects with OSAHS was 32, suggesting 
at least moderate disease; however, the mean minimum oxygen 
saturation was relatively high at 87.4 (4.3)% and the mean percent- 
age of sleep time with oxygen saturatio ns below 90% was low at 
1.2 (3.3)%.
AIx was higher in subjects with OSAHS than in controls (19.3
[10.9] vs. 12.6 [10.2]%; p = 0.017).
We were able to measure PWV in 18 of the matched pairs 
(missing measurements due to patient body habitus) and this 
was similar in subjects with OSAHS and controls (7.6 [1.2] vs. 7.4 
[1.2] m s!1; p = 0.55). There was no differenc e in aortic distensibil- 
ity between the subjects with OSAHS and controls in the ascendin g
aorta (5.6 [1.6] vs. 5.9 [2.4] mmHg !1 " 10!3; p = 0.65), or descend- 
ing aorta (4.9 [1.4] vs. 4.9 [1.4] mmHg !1 " 10!3; p = 0.87) or at the 
level of the diaphragm (7.2 [2.2] vs. 6.6 [2.0] mmHg !1 " 10!3;
p = 0.45). For technical reasons and one case of claustrophobia ,
we were unable to compare aortic distensib ility in two pairs in 
the ascendin g aorta and in five pairs in the descending aorta and 
at the level of the diaphragm .
Endothelium -dependent changes in AIx, a measure of endothe- 
lial function, was impaired in subjects with OSAHS compared to 
controls (p = 0.02). There was no differenc e in endothelium-ind e- 
pendent change in AIx between the two groups (Table 2).
A greater proportion of the subjects with OSAHS were smokers; 
however , this was not statistical ly significant. Across the group 
(n = 40) no differenc e in AIx or endothelium -dependent change in 
AIx was seen between current smokers, ex-smokers, or 
nonsmok ers. 
In subjects with OSAHS, AHI was negatively correlated with aor- 
tic distensibilit y in the descending aorta and at the level of the dia- 
phragm (r = !0.56; p = 0.015 and r = !0.45; p = 0.049, respectively )
(Fig. 1). Fasting glucose also was negatively correlate d with aortic 
distensib ility in the descending aorta (r = !0.47; p = 0.05). In a lin- 
ear regression model with aortic distensibilit y in the descending 
aorta as the depende nt variable and AHI and fasting glucose as 
independen t variables, only AHI remained as an independen t
predictor .
A nonsignificant correlation between AHI and PWV was seen 
(r = 0.46; p = 0.055). AHI did not correlate with AIx or endotheli al 
function in this group of subjects. 
4. Discussion 
In our study of subjects without overt CVD, we have shown that 
subjects with OSAHS have increased AIx and impaired endotheli al 
function compared to well-matched controls. 
We also have shown that disease severity, as measured by AHI 
correlate s with aortic distensib ility, a measure of arterial stiffness. 
Obstruct ive sleep apnoea is associated with increased cardiovascu -
lar morbidity and mortality [4–8], and numerous mechanism s are 
proposed including alteration s in arterial stiffness and endotheli al 
function.
Alx has previousl y been shown to be higher in patients with 
obstructi ve sleep apnoea than in control subjects [24–26], but 
these studies have all included patients with CVD. Our study ex- 
tends previous observations by demonstrat ing that even young 
normotens ive subjects with relatively mild OSAHS who are free 
of CVD have a higher AIx than well-matched controls (19.3
[10.9] vs. 12.6 [10.2]%; p = 0.017). AIx is a composite measure of 
central arterial stiffness and peripheral wave reflection and pre- 
dicts cardiovascular events, with a recent meta-analysis suggest- 
ing that an absolute increase in AIx of 10% leads to a 26% increase 
in cardiovascu lar events and a 38% increase in all-cause mortality 
[27].
We did not find PWV to be significantly higher in subjects with 
OSAHS in our study. Several other studies have reported a higher 
PWV in patients with obstructive sleep apnoea when compare d
to control subjects [28]. However, in keeping with our findings
Drager et al. [12]. did not demonstrat e a differenc e in PWV in the 
absence of CVD between control subjects and those with mild- 
to-mode rate disease. They found the AHI to be highly correlate d
with PWV (r = 0.61, p < 0.0001) [12]; in our study a trend towards 
a correlation between AHI and PWV was noted in subjects with 
Table 2
Endothelium-dependent and endothelium-ind ependent changes in augmenta tion 
index in subjects with OSAHS and controls. 
Subjects with 





Change in AIx (%)
following salbutamol 
!4.3 (3.2) !8.0 (4.9) 0.02 
Change in AIx (%)
following GTN 
!15.1 (5.5) !14.1 (3.7) 0.45 
Mean (standard deviation).
AIx, augmentation index; GTN, glyceryl trinitrate; OSAHS, obstructive sleep 
apnoea–hypopnoea syndrome. 
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OSAHS. It should be noted that in the aforementione d study, PWV 
was significantly higher than our data and recently published nor- 
mal values suggest that the PWV measured in our study fall within 
the normal range based on the mean age and blood pressure of the 
group [29]. This finding may explain why, despite demonstrat ing a
difference in AIx between patients with OSAHS and control sub- 
jects, we did not detect a difference in PWV between the two 
groups.
It has been hypothes ized that additional effects on the structure 
and the function of the thoracic aorta may be seen due to 
intrathoraci c pressure swings during obstructi ve events leading 
to shear stress, and recent work in healthy volunteers 
demonstrat ed changes in proximal aortic diameter during 
simulated hypopnoeic (but not apnoeic) events [30]. Similarly ,
aortic diameter has been shown to be greater in patients with sleep 
apnoea in a study that included patients with CVD [31]. Like 
Keles et al. [32] we found the AHI to be correlate d with aortic 
distensibilit y despite the milder degree of obstructive sleep apnoea 
in our patients. However, we did not find a difference in aortic 
distensibilit y between subjects with OSAHS and well-matched 
controls. The few studies that have previousl y examined this 
hypothes is have produced conflicting results [32–34] and further 
work is required in this area. 
Endotheli al function was impaired in OSAHS subjects compared 
with control subjects. The magnitude of the difference that we 
have reported is similar to the findings of Kohler et al. [25] who
used the same method of assessing endothelial function in subjects 
with minimally symptom atic obstructive sleep apnoea, a propor- 
tion of whom also had CVD. Several studies have previousl y re- 
ported impaired endothelial function as measured by flow-
mediated dilatation in patients with obstructive sleep apnoea 
[13,14,35 –38]. However, many of these studies involved small 
numbers of patients or included patients with CVD. In the largest 
of these studies [13,37], subjects had more severe obstructi ve sleep 
apnoea than in our study. The results of our study add to current 
knowled ge, suggestin g that endothelial function is impaired even 
in patients with less severe OSAHS in the absence of known CVD. 
The mechanisms through which obstructive sleep apnoea leads 
to increased arterial stiffness and endothelial dysfunction are likely 
to be multifactorial. Obstructive sleep apnoea is associated with 
oxygen desaturation , sleep fragmentation and intrathoracic pres- 
sure swings with individual events associated with transient in- 
creases in blood pressure [9], arterial stiffness [10], and 
sympathetic activity [11]. Intermittent hypoxia has been proposed 
as a key mechanism and has been shown to lead to oxidative stress 
and systemic inflammation [39]. Obstructive sleep apnoea is an 
independen t risk factor for hyperten sion [3], which may in turn 
lead to vessel damage. 
In our study of normotensive patients with relatively modest 
nocturna l oxygen desaturation, arterial stiffness was increased 
and endothelial function was impaired when compared to well- 
matched control subjects. The AHI correlated with aortic distensi- 
bility, but in our patient group no correlation was seen between 
minimum oxygen saturation, percentage of sleep time with oxygen 
saturatio ns below 90%, or blood pressure and aortic distensib ility. 
This is only a small study but these results suggest that other as- 
pects of obstructive sleep apnoea, such as sleep fragmentation ,
intrathor acic pressure swings and activation of the systemic ner- 
vous system also may be important in the development of in- 
creased arterial stiffness and endothelial dysfunction .
Identifying subjects with OSAHS without CVD or DM was diffi-
cult and meant that overall our subjects had milder disease than of- 
ten appears in publications in this area, which may have contributed 
to the fact that we showed AIx but not PWV or aortic distensib ility to 
be higher in patients with OSAHS than in the control group. 
Our OSAHS and control groups were well matched in all re- 
spects except for the greater neck circumference seen in OSAHS 
subjects. Recent work suggests that neck circumferen ce is associ- 
ated with cardiovascu lar risk [40]. It remains unclear if this is an 
independen t association or if it is due to the already known asso- 
ciation of neck circumferen ce with OSAHS. 
Finally, it should be emphasised that this is a relatively small 
study and we were not able to obtain complete data sets for 
PWV and aortic distensibilit y, which may have increased the pos- 
sibility of type II statistical error. 
In conclusion, these findings suggest that even in our cohort of 
normotensi ve subjects with relatively mild OSAHS and no history 
of CVD, there is evidence of increased arterial stiffness and impair- 
ment of endothelial function. 
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Fig. 1. Relationship between apnoea–hypopnoea index (AHI) and aortic distensi- 
bility. AHI plotted against aortic distensibility as measured at three levels within 
the thoracic aorta. The broken lines represent 95% confidence intervals. 
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a b s t r a c t
Background: Obstructive sleep apnea (OSA) is associated with increased cardiovascular morbidity and
mortality which may be mediated by increased arterial stiffness and endothelial dysfunction. Continuous
positive airway pressure (CPAP) therapy improves excessive daytime somnolence (EDS), but its effect on
vascular function in patients without preexisting cardiovascular disease (CVD) is unclear.
Methods: Fifty-three patients with OSA defined as an apnea–hypopnea index (AHI) of P15 and without
CVD were recruited into a double-blind, randomized, placebo-controlled, crossover trial of 12 weeks of
CPAP therapy, of whom 43 participants completed the study protocol. Arterial stiffness was assessed
by measuring the augmentation index (AIx) and pulse wave velocity (PWV) by applanation tonometry
and cardiovascular magnetic resonance imaging to determine aortic distensibility. Endothelial function
was assessed by measuring vascular reactivity after administration of salbutamol and glyceryl trinitrate.
Results: CPAP therapy lowered systolic blood pressure (SBP) (126 mmHg [standard deviation {SD}, 12] vs
129 mmHg [SD, 14]; P = .03), with a trend towards reduced AIx (15.5 [SD, 11.9] vs 16.6 [SD, 11.7]%;
P = .08) but did not modify endothelial function. When subjects with (n = 24) and without (n = 19) EDS
were separately examined, no effect of CPAP therapy on vascular function was seen.
Conclusions: In patients without overt CVD, CPAP therapy had a nonsignificant effect on AIx and did not
modify endothelial function.
! 2013 Elsevier B.V. All rights reserved.
1. Introduction
Obstructive sleep apnea (OSA) is common and is caused by
repetitive obstruction of the upper airway during sleep. When
OSA leads to excessive daytime somnolence (EDS) it is termed
obstructive sleep apnea–hypopnea syndrome (OSAHS), affecting
2–4% of the middle-aged population with an even greater propor-
tion having evidence of OSA without EDS [1].
OSA is associated with increased cardiovascular morbidity and
mortality [2,3] and is an independent risk factor for hypertension
[4]. Many mechanisms linking OSA and cardiovascular disease
(CVD) have been proposed, with individual obstructive events
associated with transient increases in blood pressure (BP) [5],
arterial stiffness [6], and sympathetic activity [7]; all of which,
along with systemic inflammation [8] and intrathoracic pressure
swings, may contribute to endothelial dysfunction. We previously
showed [9] that subjects with OSAHS in the absence of known
CVD had evidence of increased arterial stiffness and impaired
endothelial function when compared to well-matched control
subjects.
Observational studies suggest that cardiovascular morbidity
and mortality is lower in patients treated with continuous positive
airway pressure (CPAP) therapy [2,10,11]. Randomized controlled
trials (RCTs) have shown that CPAP therapy lowers BP [12,13],
and it also has been shown to improve endothelial function in
small studies [14,15]; however, many of these studies did not
exclude patients with CVD [12,13,15]. To our knowledge, the
effects of CPAP therapy on arterial stiffness had not yet been
investigated prior to beginning our trial.
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The aim of our double-blind, randomized, placebo-controlled,
crossover trial was to examine the effects of CPAP therapy on arte-
rial stiffness and endothelial function in subjects with OSA in the
absence of overt CVD or diabetes mellitus (DM).
2. Methods
2.1. Subjects
Fifty-three subjects with OSA (apnea–hypopnea index [AHI] of
P15 on polysomnography), with no history of CVD or DM, were re-
cruited through the Department of Sleep Medicine, Royal Infirmary
of Edinburgh (Fig. 1). Exclusion criteria were previous CPAP ther-
apy, respiratory failure, medications affecting BP, sleepiness when
driving, professional driving, contraindications to magnetic reso-
nance imaging, and intercurrent illness. EDS was defined as a score
of P11 on the Epworth Sleepiness Scale (ESS). A detailed medical
history was taken and medical records were examined to exclude
a history of CVD or hypertension. A fasting venous glucose sample
was taken to exclude DM.
Sixteen channel, inpatient, overnight polysomnography (Com-
pumedics Ltd., Abbotsford, Australia) was performed in all sub-
jects with sleep scored using standard Rechtschaffen and Kales
criteria [16], and apnea and hypopneas were defined per the
2007 American Academy of Sleep Medicine standard criteria
[17].
Subjects were recruited between March 2007 and August 2008.
Sample size was determined using pilot data to provide a 90%
chance of detecting a 10% difference in mean aortic distensibility
(AoD) at a significance level of 5% (n = 40). Therefore, we aimed
to recruit 60 subjects to allow for the occurrence of dropouts.
The study was approved by Lothian Local Research Ethics Commit-
tee (ref. 06/S1102/54) and written informed consent was obtained
from all subjects.
2.2. Study design
Our double-blind, randomized, placebo-controlled, crossover
trial examined the effects of CPAP therapy on arterial stiffness
and endothelial function in subjects with OSA. The study is regis-
tered with the International Standard Randomized Controlled Trial
Number Register (ISRCTN48783995).
Subjects underwent vascular assessments at baseline and were
randomized to receive either CPAP therapy (S8 Autoset™, Res-
Med, Abingdon, UK) or sham CPAP for 12 weeks before crossing
into the second arm of the study for a further 12 weeks. Sham
CPAP was achieved by setting the CPAP flow to the lowest possi-
ble setting and adding a flow-restricting connector and extra
holes to the circuit, allowing air to escape [13,15]. Randomization
was performed by a single researcher (MV) who was not involved
in the measurement of vascular outcomes, using a computer gen-
erated balanced block. Both the subjects and the researchers who
assessed vascular outcomes (AJ and MC) were blinded to treat-
ment allocation. Optimum CPAP pressures were determined at
overnight inpatient CPAP titration (Spirit™, ResMed, Abingdon,
UK). CPAP usage was determined using time-clock data, which
measured time spent at the prescribed pressure throughout the
entire study period.
Vascular assessments were repeated after each arm of the study
and were conducted at the same time of day, with subjects having
fasted overnight and abstained from cigarettes, alcohol, and caf-
feine use for at least 10 h prior to beginning the study. Resting
BP and heart rate were recorded in duplicate using an automated
sphygmomanometer (Omron 705IT, Milton Keynes, UK) with the
mean used for analysis.
2.3. Assessment of arterial stiffness and endothelial function by
applanation tonometry
All studies were performed in the supine position in a temper-
ature-controlled room after at least 30 min of rest and in accor-
dance with the Expert Consensus Document on Arterial Stiffness
[18] by a single operator (AJ).
2.3.1. Pulse wave analysis
Radial artery pressure waveforms were continuously measured
by tonometer (CBM 7000, Colin Corp., Komaki City, Japan) and the
SphygmoCor! system (version7, AtCor Medical, Sydney, Australia),
which applied a validated transfer function to the mean of approx-
imately 10 waveforms, giving an aortic pressure waveform. From
this mean, the augmentation index (AIx) corrected to a heart rate
of 75 beats per minute as previously described [9], was deter-
mined. AIx is a measure of stiffness throughout the arterial tree
and represents the difference between the first and second systolic
peaks, expressed as a percentage of the pulse pressure. Repeated
measurements of AIx were taken at baseline and the mean value
was used for analysis. Readings with >10% variability in pulse
height or in the diastolic portion of the waveform were excluded.
Noninvasive assessment of endothelial function was performed
by measuring endothelium-dependent change in AIx following the
administration of salbutamol and endothelium-independent
change in AIx following glyceryl trinitrate [19]. As previously de-
scribed [9], after baseline recordings 500 lg of glyceryl trinitrate
tablet was given sublingually for 3 min and then was removed.
AIx was then recorded every minute for 10 min and then every
5 min for a further 15 min. A dose of 400 lg of inhaled salbutamol
via a spacer device was subsequently administered, with record-
ings of AIx every minute for 10 min and then every 5 min for a fur-
ther 10 min. The greatest change in AIx following the
administration of each drug was used for analysis [19].
2.3.2. Pulse wave velocity
Pulse wave velocity (PWV) increases with arterial stiffness and
measures the speed at which the systolic pressure wave reaches
the peripheries. Carotid-femoral (aortic) PWV was measured as
previously described [9] using a micromanometer (Millar Instru-
ments, Houston, TX) and the SphygmoCor! system by sequential
acquisition of carotid and femoral pressure waveforms gated to
the R-wave of a simultaneously recorded electrocardiogram. Only
those readings that met quality-control standards [20] were ac-
cepted for analysis. We aimed to repeat each recording three times,
with the mean PWV used for analysis.
2.4. Assessment of aortic distensibility (AoD)
Cardiovascular magnetic resonance imaging (1.5 Tesla, Philips
Medical Systems, Best, Netherlands) was used to determine AoD.
Sagittal oblique images of the aorta in the supine position were
used to define planes orthogonal to the aortic axis for electrocar-
diogram-gated steady-state free precession cine imaging with full
R–R coverage in the ascending and descending aorta at the level
of the right pulmonary artery and at the level of the diaphragm.
BP measurements (S/5™ monitor, Datex-Ohmeda, Helsinki, Fin-
land) were taken in the scanner immediately before and after each
image was acquired, and the mean was used to determine the
pulse pressure. Image analysis was performed using an automated
algorithm (EasyVision, Philips Medical Systems) by a single opera-
tor (MC) who was blinded to treatment allocation, with AoD calcu-
lated as (Amax ! Amin)/(Amin " pulse pressure) in which Amax and
Amin were the maximum and minimum aortic areas during the car-
diac cycle.
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2.5. Data analysis
Statistical analyses were performed using SPSS version 17
(SPSS, Chicago, IL) and all data are expressed as mean (standard
deviation [SD]) unless otherwise stated. Differences between treat-
ment arms were analyzed using paired t tests or Wilcoxon signed
rank tests. Repeated measures analysis of variance was used to
look for evidence of an order effect. The unpaired t test, Mann–
Whitney U test, and v2 test were used to analyze baseline differ-
ences between those who dropped out of the study and those
who completed the follow-up, as well as between subjects with
and without EDS. A P value of <.05 was considered statistically
significant.
3. Results
3.1. Baseline characteristics and vascular measurements
Fifty-three subjects with OSA underwent baseline vascular
assessments, of whom 10 did not complete the RCT (Fig. 1); base-
line data for these subjects did not significantly differ from the 43
patients who completed the study. Baseline characteristics for
those completing the study are shown in Table 1. The median
AHI was 31, suggesting moderate disease severity; however, the
mean minimum oxygen saturations were relatively high and the
mean percentage of sleep time spent with oxygen saturations be-
low 90% was low (Table 1), which suggests that these patients
did not experience significant nocturnal intermittent hypoxia.
Baseline arterial stiffness and endothelial function are shown in
Table 2.
3.2. CPAP usage
There was a difference in CPAP use (P = !001) between the two
limbs of the study, with subjects using CPAP for 3.0 h per night
(range, 0–8.1 h) and sham CPAP for 2.0 h per night (range,
0–5.8 h). ESS scores were lower on CPAP therapy than on sham
(median, 7 [interquartile range {IQR}, 4–11] vs median, 10 [IQR,
5–13]; P < .001).
3.3. Vascular outcomes
Systolic blood pressure (SBP) was lower on CPAP therapy than
on sham (126 [SD, 12] vs 129 [SD, 14] mmHg; P = .03) (Table 3).
Fig. 1. Study profile. Abbreviation: CPAP, continuous positive airway pressure.
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No significant treatment order effects were seen for any of the
measured vascular variables.
3.3.1. Arterial stiffness
There was a nonsignificant trend (P = .08) toward a lower AIx on
CPAP therapy than on sham CPAP. No differences in PWV or AoD
were seen (Table 3). For reasons of body habitus, we were unable
to measure AIx in one subject and PWV in three subjects. For
technical reasons and one case of claustrophobia, we were unable
to measure AoD in the ascending aorta in six subjects; in the
descending aorta in five subjects; and at the level of the diaphragm
in four subjects.
3.3.2. Endothelial function
CPAP therapy did not affect endothelial function, and no differ-
ence in endothelium-dependent or endothelium-independent
change in AIx observed (Table 3).
3.4. Subgroup analysis
Of the 43 subjects who completed our study, 24 had EDS and 19
did not. Nonsleepy subjects were older than those with EDS
(50 years [SD, 9 years] vs 43 years [SD, 7 years]; P = .005), but base-
line BP and body mass index were not statistically different. Sub-
group analysis of subjects with and without EDS showed no
difference in any of the measured vascular variables following
CPAP therapy in either group.
A post hoc analysis of subjects who used CPAP therapy for at
least 4 h per night (n = 17) did not reveal any significant differences
in any of the measured vascular variables between the CPAP ther-
apy and sham limbs.
4. Discussion
In a rigorous, double-blind, randomized, placebo-controlled,
crossover trial, CPAP therapy lowered SBP with a trend towards a
reduction in AIx after 12 weeks. However, CPAP therapy had no ef-
fect on PWV, AoD, or endothelial function in this group of subjects
without CVD after 12 weeks.
OSA is associated with increased cardiovascular morbidity and
mortality [2,3], and numerous mechanisms are proposed. Using
the same measures, we previously showed [9] that subjects with
OSA and EDS had increased AIx and impaired endothelial function
compared to well-matched control subjects in the absence of CVD.
In keeping with previous findings, CPAP therapy led to a reduction
in BP [21]. A trend towards a reduction in AIx was seen, but it was
not statistically significant. AIx is a measure of central arterial stiff-
ness and peripheral wave reflection, with increased AIx associated
with increased cardiovascular events and all-cause mortality [22].
Two studies have previously reported a reduction in AIx following
CPAP therapy [23,24]; however, one of those studies was nonran-
domized [24], and both studies included patients with CVD.
Carotid-femoral (aortic) PWV is the gold standard measurement
of arterial stiffness [18] and is an independent predictor of cardio-
vascular outcome [25]. CPAP therapy did not lead to a reduction in
PWV in our study, in contrast to the work by Drager et al. [26] who
Table 1
Baseline characteristics of subjects who completed the study (N = 43).
Parameter
Age (y) 46 (9)
Sex 28 men
BMI (kg/m2)* 29!9 (27.3–31.6)
Neck circumference (cm)* 40 (37–41.5)
Waist to hip ratio 0!95 (0.07)
Systolic blood pressure (mmHg) 128 (13)
Diastolic blood pressure (mmHg) 76 (9)
MAP (mmHg) 93 (10)
Fasting glucose (mmol/L) 4!9 (0.4)
Total cholesterol (mmol/L) 5!3 (1.0)
Current smokers 23%
Ex-smokers 23%
Cigarette pack/y history (among smokers and ex-smokers) 11.4 (8.0)
Apnea–hypopnea index* 31 (20–41)
4% O2 desaturation rate/h 9.3 (12.3)
Minimum O2 saturation (%) 86.1 (5.1)
TST90 (%) 4.4 (13.2)
Epworth Sleepiness Scale score* 13 (6–15)
Abbreviations: y, year; BMI, body mass index; MAP, mean arterial pressure; O2,
oxygen; h, hour; TST90, percentage of sleep time spent with oxygen saturations of
less than 90%.
Mean (standard deviation) unless otherwise indicated.
* Median (interquartile range).
Table 2
Baseline vascular function in subjects who completed the study (N = 43).
Vascular parameter
Augmentation index (%) (N = 43) 17!1 (11.6)
Femoral PWV (meters/s) (n = 40) 7.6 (1.5)
AoD-ascending aorta (mmHg"1 # 10"3) (n = 35) 5.0 (1.9)
AoD-descending aorta (mmHg"1 # 10"3) (n = 35)* 4.8 (3.3–5.4)
AoD at level of diaphragm (mmHg"1 # 10"3) (n = 42) 6.5 (1.9)




Change in AIx (%) following GTN (N = 43) (endothelium-
independent)
"14.0 (4.6)
Abbreviations: PWV, pulse wave velocity; s, second; AoD, aortic distensibility; AIx,
augmentation index; GTN, glyceryl trinitrate.
Mean (standard deviation) unless otherwise indicated.
* Median (interquartile range).
Table 3
Vascular function following CPAP and sham CPAP treatment periods (N = 43).
CPAP Sham CPAP P value
Systolic blood pressure (mmHg) 126 (12) 129 (14) .03
Diastolic blood pressure (mmHg) 77 (8) 77 (8) .90
MAP (mmHg) 94 (8) 94 (9) .29
Augmentation index (%) (n = 42) 15.5 (11.9) 16.6 (11.7) .08
Femoral PWV (meters/s) (n = 40) 7.5 (1.2) 7.6 (1.4) .29
AoD-ascending aorta (mmHg"1 # 10"3) (n = 37) 4.9 (1.7) 5.1 (1.9) .44
AoD-descending aorta (mmHg"1 # 10"3) (n = 38)* 4.6 (3.9–5.7) 4.5 (3.7–5.1) .22
AoD at level of diaphragm (mmHg"1 # 10"3) (n = 39) 6.8 (1.9) 6.9 (2.3) .80
Change in AIx (%) following salbutamol (n = 42)* (endothelium-dependent) "5 ("8 to "3) "4 ("6.8 to "2.5) .50
Change in AIx (%) following GTN (n = 42) (endothelium-independent) "14.1 (5.1) "15.3 (4.6) .13
Abbreviations: CPAP, continuous positive airway pressure; MAP, mean arterial pressure; PWV, pulse wave velocity; s, second; AoD, aortic distensibility; Aix, augmentation
Index, GTN, glyceryl trinitrate.
Mean (standard deviation) unless otherwise indicated.
* Median (interquartile range).
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showed a significant reduction in PWV following CPAP therapy in a
smaller, randomized, parallel trial of patients with severe OSA in
the absence of CVD. However, it should be noted that baseline
PWV in CPAP-treated patients in that study was higher at 10.4
(SD, 1.0) meters per second, compared to 7.6 (SD, 1.5) meters per
second in our study. A reduction in PWV has been reported follow-
ing CPAP therapy in several nonrandomized studies, some of which
included subjects with CVD [24,27].
OSA may exert additional direct effects on the thoracic aorta,
due to swings in intrathoracic pressure and subsequent shear
stress during obstructive events. We and others have previously
shown the AHI to be correlated with AoD [9,28], and recently pub-
lished work showed that AoD was lower in subjects with OSA com-
pared to matched control subjects [29]. Despite this, we did not
find CPAP therapy to have any effect on AoD after 12 weeks of
treatment, and to our knowledge our study is only the second
study to examine this association. In a small nonrandomized study
on OSAHS, subjects who were compliant with CPAP therapy (mean
use, 6.3 [SD, 2.1] h/night) had an improvement in AoD at 6-month
follow-up [28].
In our study CPAP therapy did not lead to an improvement in
endothelial function after 12 weeks. Several smaller studies dem-
onstrated an improvement in endothelial function following CPAP
therapy, but those studies were in subjects with more severe OSA
[14,15,30–32]. Some of the studies also included patients with CVD
[15,30] and many were nonrandomized [30–32].
We previously showed that a subgroup of 20 subjects with OSA
and EDS had increased arterial stiffness and impaired endothelial
function compared to well-matched control subjects [9]. Aside
from a higher ESS score (16 [IQR, 14–18] vs 13 [IQR, 6–15]), those
patients did not significantly differ in baseline demographics, OSA
severity, or vascular function compared to the group who com-
pleted the RCT. However, despite this, no treatment effect on vas-
cular function was seen with CPAP therapy, and this may have
been related to the inclusion of patients without EDS in this trial.
Studies have shown that, although CPAP therapy lowers BP in pa-
tients with OSA [21], there may be little effect in those without
symptoms of EDS [33,34]. While overall we have shown that CPAP
therapy lowers SBP with a trend towards a reduction in arterial
stiffness, a subgroup analysis of sleepy and nonsleepy subjects
did not show CPAP therapy to affect BP, arterial stiffness, or endo-
thelial function in either group. This finding may be due to the
small numbers in each group, and therefore the effectiveness of
CPAP therapy in modifying vascular function in nonsleepy subjects
remains unclear. Thus further work is required in this area.
Identifying patients with OSA but without CVD or DM was dif-
ficult, and this led to an overall milder spectrum of disease than of-
ten is reported in the literature. Given the increasing evidence for
the role of intermittent hypoxia in the pathogenesis of CVD in OSA
[35], it is tempting to attribute the lack of any treatment effect to
the absence of significant hypoxia in these patients. However, as
discussed above, we previously showed a subset of patients with
a similarly mild degree of nocturnal hypoxia to have increased
arterial stiffness and impaired endothelial function, suggesting
that although important, intermittent hypoxia is not the only fac-
tor affecting the cardiovascular system in OSA. Other factors
including EDS and recurrent arousals also may play a role.
A limitation of our study is that mean CPAP use was 3 h at pres-
sure per night. This compliance is disappointing, but it is similar to
the compliance of 3.3 h reported in a previous study [12] of 68 pa-
tients that demonstrated a reduction in BP with CPAP therapy and
in other consecutive series of new CPAP therapy users in this cen-
ter [36]. Thus we believe that this CPAP use reflects clinical practice
in patients with this degree of OSA, but this may of course limit the
generalizability of these results among patients with greater com-
pliance. Post hoc analysis of those using CPAP therapy for more
than 4 h did not demonstrate any change in vascular function;
however, the smaller number of subjects involved made it impos-
sible to form a definitive conclusion regarding this, and indeed the
study was not powered to do so. There is no ideal placebo for CPAP
therapy but the most rigorous arguably is sham CPAP, which was
used in our study [37]. It could be argued that an improvement
in vascular function requires longer than 12 weeks of therapy;
however, many of the previous studies that showed an improve-
ment in BP [12,13] or vascular function [14,15,23,30,31] with CPAP
therapy were conducted over a 4- to 12-week period. Equally, anti-
hypertensive therapy has been shown to improve AoD after
12 weeks of treatment [38].
5. Conclusions
In this group of subjects with relatively mild OSA in the absence
of CVD or DM and in the context of a rigorous, double-blind, ran-
domized, placebo-controlled crossover trial, we found that CPAP
therapy lowered BP but had a nonsignificant effect on arterial stiff-
ness, as measured by AIx, and did not modify endothelial function.
Although it is clear that CPAP therapy is an effective treatment for
EDS, more evidence is required, especially in patients with less
severe OSA who do not have evidence of CVD, to determine its
cardiovascular benefits.
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